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ABSTRACT
Previous investigations have characterized both the genomic and 
antigenic variations in equine infectious anemia virus (EIAV) surface 
glycoproteins that arise during replication of the virus. DNA sequence 
analyses have defined regions of conserved and variable sequences localized in 
the EIAV envelope glycoproteins. These studies indicate that EIAV 
persistence and periodicity of clinical disease result from the relatively rapid 
evolution of antigenic variants which allows the virus to temporarily circumvent 
the host immune response.
The primary objective of this work is the complete characterization of 
the immunogenic components of the EIAV env-encoded surface unit (SU) and 
transmembrane (TM) glycoproteins. These surface glycoproteins have been 
purified by reverse-phase HPLC and directly sequenced to determine cellular 
processing events in the generation of these critical immunogens. Synthetic 
peptides have been synthesized and employed in immune binding assays to 
correlate equine immune reactivity to various neutralizing, nonneutralizing, 
conserved and variable epitopes of the SU and TM proteins. Sera from both 
experimentally and naturally EIAV infected animals were utilized in these 
studies. The relationship between amino acid sequence variations and the 
observed differences in protein antigenicity has been evaluated. In addition, 
selected peptides were employed to follow the evolution of glycoprotein-
x
specific humoral responses during the course of virulent and avirulent EIAV 
chronic infections. Lastly, protein conformational models based on a battery of 
predictive algorithms have been developed to aid in the elucidation of 
structural motifs which may contribute to protein immunogenicity.
The results of these studies provide a detailed map of EIAV surface 
glycoproteins immunogenic properties and localize key antigenic determinants 
in natural and experimental EIAV persistent infections. Immunodominant 
conserved regions have been identified which may prove useful as antigens for 
diagnostic testing and potential subunit vaccine candidates have been 
elucidated. These studies demonstrate the relevance of EIAV as an animal 
model system for developing and evaluating lentivirus vaccine strategies, 
including that of the human immunodeficiency virus (HIV).
CHAPTER 1 
INTRODUCTION
In recent years there has been an explosion in public interest and 
scientific endeavor into uncovering the mechanisms of lentivirus infectivity and 
pathogenicity in hopes of developing effective vaccine and therapeutic 
protocols. Identification of HIV in 1983 as the causative agent of AIDS 
shattered the belief that infectious disease was no longer a threat in the 
developed world (Gallo and Montagnier, 1988). Today HIV infection is a 
major cause of morbidity and mortality, in fact, it has become the leading 
cause of death in the United States for hemophiliacs and intravenous drug 
users (Heyward and Curran, 1988). Hence, it is crucial that lentivirus animal 
models be developed and utilized to study the mechanisms of virus replication 
and pathogenesis, and for evaluating the efficacy of vaccine protocols.
The lentivirus subfamily of retroviruses cause an array of chronic 
degenerative diseases despite the presence of virus-specific immune responses. 
The lentiviruses have developed a number of strategies to maintain a persistent 
infection and to escape from host immune defenses. Many of these persistence 
strategies have been correlated to specific and often unique structural 
properties of the lentivirus proteins.
Equine infectious anemia virus (EIAV) is unique among the lentivirus 
infections in that the infected animal routinely brings virus replication under
1
immunologic control. Thus a detailed study of the antigenicity of EIAV 
antigens and their interaction with the host immune system during the course 
of a persistent infection can provide important information on the immune 
status to be achieved by candidate vaccines.
Retroviridae.
Retroviruses are characteristically recognized by their morphology, the 
structure of their RNA genomes, and the presence of RNA-dependent DNA 
polymerase (reverse transcriptase). The family retroviridae has been 
traditionally divided into three subfamilies, oncovirinae which were originally 
isolated as tumor-inducing agents, spumaviridae which were isolated as agents 
that cause vacuolation ("foaming") of cells in culture, and lentivirinae which 
were so named because of their relatively slow pathogenic process (Latin 
lentus > slow). Established taxonomic characteristics are listed in Table 1.
The retrovirus genome consists of two molecules of positive-sense, 
single-stranded RNA which are typically identical (diploid) and range from 7 
to 10 kb in length. The order of the genes encoding structural proteins is 
invariably S'-gag-pol-env-y (Montelaro, et al., 1986).
This large group of viruses has been associated with a variety of 
diseases, including rapid and long-latency malignancies, wasting and 
neurological disorders, immunodeficiencies, as well as lifelong viremia in the 
absence of any clinical manifestations (Coffin, 1990). Retroviruses are unusual
Table L Taxonomic characteristics common to retroviruses/1
Morphology
Spherical enveloped virions (80 to 120 nm in 
diameter); variable surface projections (8 nm); 
icosahedral or cubic capsid containing a 
ribonucleoprotein complex.
Physiochemical properties
Density 1.16 to 1.18 g/ml in sucrose, 1.16 to 
1.21 g/ml in cesium chloride; sensitive to lipid 
solvents, detergents, and heat inactivation; 
highly resistant to UV and X-ray iiradiation.
Nucleic acid
About 1% by weight; linear single-stranded 
positive-sense RNA (60 to 70 S) composed of 
two identical subunits (30 to 35 S).
Protein^
About 60% by weight; gag-encoded internal 
structural proteins (3 to 5); poZ-encoded 
reverse transcriptase, protease, and integrase 
(2 to 3); e/iv-encoded envelope structural 
proteins (1 to 2).
Lipid
About 35% by weight; derived from the 
infected cell's membrane.
Carbohydrate
About 4% by weight; associated 
predominantly with env proteins.
a. From Teich (1982), and Bharat Parekh, Ph.D. 
dissertation, Louisiana State University, 1983.
b. The numbers in parentheses indicate the number of 
corresponding polypeptides.
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parasites in that they interact with their host cell in a revealing and often 
unprecedented way: by converting their single-stranded RNA genome into 
double-stranded DNA, by stably integrating themselves into the chromosomes 
of the host, by rapidly altering their genomes by mutation and recombination 
events, and by entrusting gene expression to host transcription and translation 
machinery (Varmus, 1988). This reversal of genetic information flow from 
RNA to DNA has been termed "reverse transcription" and is mediated by the 
pol gene product, reverse transcriptase. Integration of the double-stranded 
"provirus" DNA is accomplished by another pol-encoded enzyme, integrase.
The oncovirinae were first realized as agents isolated from naturally 
occurring tumors that were capable of inducing similar tumors in appropriate 
hosts (Bishop and Varmus, 1985). Oncogenic retroviruses are broadly divided 
into two groups: 1) those which carry a viral oncogene (v-onc) which rapidly 
induces tumors in animals and cell transformation in culture, and 2) those 
which lack a viral oncogene, do not transform cells in culture, but are still 
capable of inducing tumors after a long latency (Varmus, 1988). Detailed 
analyses of viral oncogenes and their cellular counterparts (c-one, also known 
as proto-oncogenes) have provided valuable insights into the molecular 
mechanisms of oncogenesis, growth control, and signal transduction.
With the exception of Rous Sarcoma Virus (RSV), essentially all 
oncogene-containing retroviruses are replication defective and incapable of 
replication in the absence of a corresponding nondefective, nontransforming
"helper" virus (Coffin, 1990). Although the replication-competent viruses lack 
oncogenes and are unable to transform cells in culture, they are responsible for 
inducing a variety of malignancies by the promotion of proto-oncogenes. 
Despite the array of tumor inducing mechanisms, many oncoviruses have little 
or no effect on the host cell, other than to render it efficient at producing virus 
at a low level. (Teich, et al., 1985). Representative members of the 
onvcovirinae subfamily include the avian and murine leukosis and sarcoma 
viruses, bovine and feline leukemia virus, mouse mammary tumor virus, and 
Mason-Pfizer monkey virus.
The spumavirinae are ubiquitous in nonhuman primates, bovines and 
felines where they induce persistent infections without apparent clinical 
disease. Isolation of human foamy viruses has only been reported from 
primary cultures of tissues of various human diseases (Rethwilm, et al., 1990). 
Additional reports have indicated a low seropositivity in populations of East 
Africa and pacific islands, but no disease correlation could be made (Hooks 
and Detrick-Hooks, 1981; Weiss, 1988). Representative members of this 
subfamily include the human spumaretrovirus (HSRV), simian foamy virus 
(SFV), and bovine syncytial virus (BSV),
Lentivirinae are a diverse group of exogenous, nononcogenic 
retroviruses responsible for a variety of neurological and immunological 
diseases. Lentiviruses are best known as agents of slow disease syndromes 
which begin insidiously after prolonged periods of subclinical infection and
progress slowly to the degeneration of multiple organs and frequently death 
(Gartner, et al., 1986; Gendelman, et al., 1989; Montelaro, et al., 1986). 
Lentiviruses persist indefinitely in their hosts and replicate at variable rates 
during the course of the lifelong infection reflecting the latent and productive 
stages of the disease (Narayan and Clements, 1990). Although other organs 
are affected, the primary target is cells of the macrophage/monocyte lineage. 
Unlike the oncoviruses which have a strong requirement for dividing cells, the 
lentiviruses efficiently replicate in nondividing, end-stage cells. In fact, it 
appears that cellular factors, including maturation, play a role in the activation 
of lentiviral gene expression and shift from latency to productive replication 
(Gendelman, et al., 198S).
Disease in lentivirus infected hosts may be primary (caused by the 
lentivirus itself) or secondary (caused by opportunistic pathogens) due to the 
loss of immune functions. In nature, disease in lentivirus-infected ungulates is 
primarily a consequence of the infecting lentivirus, whereas disease in humans, 
macaques, and cats is generally caused by opportunistic organisms as a result 
of the loss of helper T-lymphocyte function in the host (Narayan and Clements, 
1990) (Figure 1). Acute EIAV is typically marked by hemolytic anemia, 
anorexia, bone marrow depression, fever, ataxia and immune-complex disease 
manifested as glomerulonephritis (Montelaro, et al., 1984; McClure, et al.,
1982). EIAV replicates mainly in macrophages in the spleen, lymph node and 
liver (Figure 1) and is associated with hyperplasia of lymphocytes and
FIGURE 1. FATE OF LENTIVIRUSES PRODUCED BY 
MACROPHAGES IN DIFFERENT HOST SPECIES AND THEIR 
ROLE IN THE INDUCTION OF DISEASE.
Cell-free virus propagated in equine macrophages combine with virus- 
induced antibodies to produce an immune-complex disease manifested as 
glomerulonephritis. Anemia, ataxia, and lymphadenopathy of the liver and 
bone marrow are included in the disease syndrome.
Although ruminant macrophages are poorly permissive for virus 
replication, they present viral antigens to lymphocytes. Clinical disease is due 
to active-chronic inflammation in the involved tissue or organ. Lesions are 
characterized by infiltration of lymphocytes and macrophages.
The influence of infected primate macrophages on disease induction is 
variable in that primate macrophages vaiy in the production of lentivirus 
antigens. Similar responses observed with the equidae and ruminants are 
seen; in addition, primate infections are accompanied by fusion of the antigen- 
presenting macrophage and the T4 lymphocyte resulting in lysis of the helper 
T-cell population, subsequent infections by opportunistic pathogens and 
immunosuppression.
L V/MO indicates the interaction between the infected macrophage and 
the T lymphocyte.
From Narayan and Clements, 1990.
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macrophages in these organs. In addition, interstitial mononuclear infiltrates 
have been observed in nonlymphoid tissues such as the kidney, adrenal glands, 
brain and heart (Pedersen, 1989). These hyperplastic and infiltrative lesions 
tend to disappear as the horse progresses into the chronic stage of infection 
(Pedersen, 1989).
In lentivirus infected ruminants, histological alterations are seen in the 
lung, brain, spinal cord, lymph nodes, spleen, joints, and areas of glandular 
tissue of mammary glands (Figure 1). These inflammatory lesions have been 
shown to be caused by the productive replication of virus (Narayan and 
Clements, 1990). In addition, previous studies have indicated that the 
interaction of the infected macrophage with T-cell lymphocytes induces the 
synthesis of interferon which can enhance the expression of la  antigen and 
abnormal proliferation of lymphoid cells (Narayan, et al., 1985). In primates, 
the macrophage tropism has been demonstrated in human and macaques 
tissues infected with HIV (Koenig, et al., 1986) and has been associated to the 
histological lesions observed in the lung, brain, and lymph node (Salahuddin, et 
al., 1986) (Figure 1).
The lentivirus subfamily is linked by similarities in genetic organization, 
nucleotide sequence homology in the gag and pol genes, molecular mechanisms 
of replication, biological interactions with their hosts, and group-specific major 
antigen cross-reactivity (Putney and Montelaro, 1990). Virus transmission is 
horizontal and accomplished by the exchange of various body fluids including
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blood and blood products, respiratory and inflammatory exudates, and 
secretions such as milk and semen. Infected fluid transfers are mediated by 
insect vectors, colostrum, hypodermic needles, sexual promiscuity, and crowded 
husbandly conditions. The infectious carrier status of the host is facilitated by 
the continuous presence of the viral genome in monocyte-macrophages and 
possibly lymphocytes (Narayan and Clements, 1990). A blood transfer from 
persistently EIAV-infected horses affected by man or blood-feeding vectors is 
the major mode of EIAV transmission (Issel, et al., 1988). The predominant 
arthropod vectors of EIAV are insects of the Diptera order including deer flies 
(Chrysops spp.), and horse flies (Tabanus and Hybomitra spp.) (Hawkins, et al., 
1976; Foil, et al., 1984).
Current lentivirus classification includes the human immunodeficiency 
viruses (HIV-1 and -2) (Barr-Sinoussi, et al., 1983; Clavel, et al, 1986); the 
simian immunodeficiency viruses of Asian macaques (SIVmac) (Benveniste, et 
al., 1986) and several African species including the African green monkey 
(SIV agJ (Franchini, et al., 1987) the sooty mangabey (SIVsm) (Fultz, et al.,
1986), and the mandril (SIVmnd) (Tsujimoto, et al., 1988); the recently isolated 
immunodeficiency viruses of feline (FIV) (Pedersen, et al., 1987) and bovine 
(BIV) (Braun, et al., 1988); the visna-related South African Ovine Maedi Visna 
virus (SA-OMW ) (Querat, et al., 1990); and the prototype animal lentiviruses 
Maide-visna virus (Cutlip and Laird, 1976) and progressive pneumonia virus 
(PPV) (Kennedy, et al., 1968) of sheep, caprine arthritis-encephalitis virus
11
(CAEV) of goats (Narayan, et al., 1980), and equine infectious anemia virus 
(EIAV) of horses (Charman, et al., 1976). There is no doubt this subfamily 
will continue to increase in number as more sensitive virus isolation and 
diagnostic techniques are developed.
Virion Structure.
Although a common morphological theme link the retroviruses, some of 
the earliest studies using electron microscopy revealed some differences in 
detail. These differences led to the classification of four morphological groups 
(A to D), a classification that is still utilized to a limited extent today (Teich, 
1982). Lentiviruses bud like C-type particles in that the first visible virion 
forms are crescent-shaped and are localized at the site of budding from the 
host cell membrane. During the course of budding, a central core is not 
apparent; budding and assembly seem to occur simultaneously (Gelderblom, et 
al., 1987). In contrast to the icosahedral symmetry noted with the cores of 
type C and type B oncoviruses, lentiviruses characteristically exhibit an oblong 
or cone-shaped core. This cone-shaped inner core particle appears to be 
formed after the virus is released from the cell.
Overall the virus particle appears to be 100 nm in diameter with a 
helical ribonucleoprotein complex contained within the oblong core all of 
which is encased in a lipid envelope (Figure 2). The oblong core contains 2 
copies of the single-stranded RNA genome which is associated with 5-10
FIGURE 2. LENTIVIRUS MODEL
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gp90
A schematic model depicting the structural organization of lentiviruses 
in general, and EIAV in particular. The acidic protein, p9, probably associates 
with the core shell.
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copies of the po/-encoded reverse transcriptase. The gag gene encodes the 
internal structural proteins including the matrix (MA) protein which lines the 
lipid bilayer, the major capsid shell protein (CA) which represents the 
principal group-specific antigen, and the basic nucleocapsid (NC) protein which 
associates with the RNA genome. Each virion is composed of several 
thousand copies of the gag-encoded proteins (Parekh, et al., 1980; Montelaro, 
et al., 1989).
As diagrammed in Figure 2, the outer surface of the virion particle is 
covered by a single protein structure composed of two e/zv-encoded protein 
subunits, the surface unit (SU) and the transmembrane (TM) protein. Each 
virion particle contains several hundred of the e/zv-encoded protein products, 
probably arranged in a symmetrical pattern in the lipid bilayer as trimers 
(Montelaro, et al., 1989). An overview of the lentivirus structural proteins is 
presented in Table 2 using the standardized retrovirus nomenclature system 
reported by Leis, et al. (1988).
Gag-encoded proteins.
The gag gene encodes the structural proteins necessary for the assembly 
of the virus particle and the encapsidation of the viral genome. The gag 
products alone can form virus particles which can be infectious if introduced 
into the cell by artificial means (Dickson, et al., 1985). Gag proteins are 
expressed as a polyprotein precursor which accumulate beneath the plasma
14
TABLE 2. LENTTVIRUS PROTEIN NOMENCLATURE*
YIRUS HI TM MA CA E l EE
HIV-1 gpl20 gp41 pl7 p24 P7 p66 pl2
HIV-2 gpllO gp32 pl5 p24 pl3 ND ND
SIV gpllO gp41 pl6 p28 p8 ND ND
EIAV gp90 gp45 pl5 p26 p l l p60 ND
CAEV gpl35 pl9 p28 pl6 ND ND
Visna gpl35 pl6 p27 pl4 ND ND
a) Adapted from Leis, et al., 1988. SU - surface protein; TM - 
transmembrane protein; MA - matrix protein; CA - capsid protein; NC - 
nucleocapsid protein; RT - reverse transcriptase; PR - protease; ND - not 
determined.
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membrane and is then proteolytically processed by the po/-encoded protease 
(PR) to yield the core proteins found in the mature virion (Bolognesi, et al., 
1978). The polyprotein precursor is translated from the full length genomic 
RNA in the order of 5’-MA-CA-NC-3\ These structural proteins comprise the 
predominant protein components of the lentivirus particle; up to 90% of virus 
proteins are gag encoded (Putney and Montelaro, 1990).
In EIAV, the presumed gag initiation codon occurs 124 bases 
downstream from the primer binding site in the LTR. From this initiator, the 
gag gene extends for 1458 bases and could code for a polypeptide of 486 
residues which has been designated PrSS8®* (Stephens, et al., 1986). Four 
prominent structural proteins (p26, pl5, p l l ,  p9) have been identified in 
EIAV and have been documented as distinct proteolytic cleavage products of 
the PrSS®** precursor (Parekh, et al., 1980; Henderson, et al., 1987).
Henderson, et al. (1987) analyzed each core protein for its N- and C- terminal 
amino acids, and was able to confirm the order of the proteins in the precursor 
as 5’-pl5-p26-*-pl l-p9-3\ where the * represents a pentapeptide separating the 
capsid and nucleocapsid proteins.
QA  protein. The CA proteins have a Mr between 24,000 and 28,000 
daltons, represent the major internal protein of the virion, may be modified by 
phosphorylation as in HIV p24, and induce group-specific antibodies during 
infection (Putney and Montelaro, 1990). The major core shell proteins of the 
lentiviruses display notable sequence homology such that monoclonal
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antibodies raised against HIV-1 p24 cross-react with the CA proteins of HTV-2 
and SIV (Clavel, et al., 1986); and serological cross-reactivity has been 
demonstrated in EIAV, visna, and HTV (Henderson, et al., 1987; Montelaro, 
unpublished results).
Although CA antibodies have not been shown to be protective of 
infection, it has been demonstrated that HIV p24 antibodies are an indicator 
of disease progression (Ranki, et al., 1987). A pronounced decrease in 
detectable gag antibody levels closely preceding the development of acquired 
immunodeficiency syndrome (AIDS) has been documented (Polk, et al., 1987). 
This loss of antibody was found to coincide with the appearance of serum 
antigenemia. An analogous study was performed with rhesus macaques which 
were experimentally infected with different isolates of SIV/Delta that varied in 
pathogenicity (Zhang, et al., 1988). Again the humoral immune response and 
its relationship to virus-specific antigenemia was examined. It was observed in 
immunodeficient monkeys that as gag antibody levels decreased, there was a 
concomitant increase in SIV antigenemia, and this reciprocal shift was 
predictive of disease progression. Monkeys with encephalitis had little, if any 
detectable antibody, and progressive, often severe antigenemia (Zhang, et al.,
1988). Several hypotheses have been put forth to explain these observations. 
Lange, et al. (1987) proposed that a) the loss of p24 antibody could be due to 
the formation of immune complexes which prevent antibody detection by 
current serological assays and/or b) there is an actual reduction in gag
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antibody which allows the virus to replicate unimpaired, thus advancing disease 
progression. Finally, it was speculated that the lack of detectable antibody in 
macaques with CNS involvement may be due to antibody interaction with the 
virus and the subsequent entry of the virus-antibody complex into the CNS 
(Zhang, et al., 1988).
The three-dimensional structure of the CA proteins of several 
nonenveloped RNA viruses are now known, including the picornavirus VP2 
core protein (Rossman, 1988). Each of the various shell proteins exhibited a 
similar structural motif consisting of an eight-stranded antiparallel fJ-barrel 
with exposed loops connecting the individual strands (Rossman, 1988; Argos, 
1989). A homology search between the picornavirus VP capsid sequences and 
lentivirus gag polyprotein sequences revealed a relevant homology between the 
SIV p24 CA protein and the picornavirus (foot and mouth disease virus) VP2 
coat protein (Argos, 1989). Given the homology of the lentivirus CA proteins, 
it was deduced that the structure of HIV p24 could be an eight-stranded 21- 
barrel fold, and regions most likely to be exposed were subsequently inferred 
by analogy with the characteristic "PUFF region of VP2 folds (Argos, 1989).
protein. Lentivirus nucleocapsid proteins package the viral RNA in 
a highly condensed form as a 60-70S dimer (Coffin, 1984). There is 
experimental evidence suggesting that the NC plays a catalytic role in the 
dimerization of the RNA genome at the dimer linker structure located 300-400 
nucleotides from the 5' end (Darlix, et al., 1982; Prats, et al., 1988). Additional
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studies indicate the NC directs the annealing of the replication tRNA primer 
to the primer binding site of the viral RNA, possibly by unwinding these RNA 
structures (Prats, et al., 1988). NC proteins are small, very basic, and can be 
divided into three domains: a basic amino terminus domain followed by a 
conserved cysteine-histidine box (CysX2CysX4HisX4Cys) characteristic of 
retrovirus (and other) nucleic add-binding proteins (Meric and Goff, 1989), 
and a carboxyl domain rich in proline and basic residues (Prats, et al., 1988). 
Spedfic point mutations that altered the conserved cys-his motif were found to 
block retrovirus replication and to inhibit packaging of the genomic RNA 
(Meric and Goff, 1989).
MA protein. The matrix protein which lines the lipid bilayer is at the 
amino-terminus of the precursor polypeptide and undergoes a two-step 
modification involving proteolytic removal of the initiator methionine followed 
by the covalent attachment of myristic add (n-tetradecanoic acid) to the newly 
formed N-terminal glycine residue (Schultz and Oroszlan, 1983). Myristic acid 
addition occurs through an amide bond to an N-terminal glydne residue, 
rendering the protein refractory to amino add sequencing (Grand, 1989). In 
agreement with this observation, amino add analysis of EIAV pl5  does not 
demonstrate an initiator methionine (Henderson, et al., 1987) and N-terminal 
sequence analysis has been reported to be blocked (Henderson, et al., 1987; 
Ball, et al., 1988). However, when EIAV-infected cells are incubated in the 
presence of [3H]myristate, Pr55 does not incorporate significant radioactivity.
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Additionally, direct analysis by chemical means established that EIAV pl5, like 
avian retroviral MA proteins, does not contain myristic acid (Henderson, et al.,
1987) and seems to incorporate a different fatty acid.
Many RNA and DNA virus proteins are covalently modified by fatty 
acylation during or after translation (Grand, 1989). This attachment of long 
chain fatty acids appears to be important for targeting the modified proteins to 
the plasma membrane and orienting the proteins on the membrane to optimize 
their function (Rhee and Hunter, 1987). It has been shown that myristylation 
is essential for assembly or budding or both of Moloney MuLV (Rein, et al.,
1986). Finally, mutation analyses of HIV gag which abolished the myristylation 
of the precursor proteins prevented virus particle release (Gottlinger, et al.,
1989).
Pol-encoded protease and virus assembly.
Virus assembly takes place primarily at the plasma membrane of the 
host cell (Bolognesi, et al., 1978). Both the gag and the gag-pol polyprotein 
products migrate to the membrane and aggregate forming the primary capsid 
structure. Assembly involves specific interactions with the 3 principal domains 
of the gag precursor protein: the C-terminal NC protein interacts with the 
genome, the central CA protein associates with other precursor molecules, and 
the N-terminal MA protein interacts with the cell membrane and envelope 
glycoproteins (Bolognesi, et al., 1978) Thus, polyprotein precursors initiate
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particle assembly and only undergo proteolytic cleavage during or shortly after 
the nascent viral particles bud from the plasma membrane (Coffin, 1990; 
Yoshinaka and Luftig, 1977). Pol-encoded protease is one of the enzymes 
expressed from the virus genome and active in precursor processing in the final 
stage of virus particle assembly. Particle maturation which involves a 
morphological conversion is induced by the protease activity and is required 
for virus infectivity (Katoh, et al., 1989).
The protease monomer is synthesized as part of the gag-pol fusion 
polyprotein which results from an infrequent ribosomal frameshift (Jacks and 
Varmus, 1985). There is evidence suggesting that the protease can 
autocatalytically release itself from the gag-pol product (Crawford and Goff, 
1985). On the basis of the observed conservation of a characteristic Asp-Thr- 
Gly active site sequence and sensitivity to specific protease inhibitors 
(pepstatin), it was proposed that the retrovirus protease enzymes were 
members of the pepsin-like aspartyl protease family (Katoh, et al., 1989).
The ciystal structure of the HIV protease has been determined and 
revealed 2 monomer components related by a twofold axis of symmetry in 
which each monomer contributes one Asp-Thr-Gly sequence to the symmetric 
active site (Navia, et al., 1989). Based on the homology with aspartyl 
proteases, it can be assumed that only a dimer of HIV protease would be 
catalytic (Navia, et al., 1989). It was concluded that once the nascent virions 
budded, the autoproteolytic protease would diffuse within the closed
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environment of the virus particle and initiate a cascade of proteolytic events. 
The rapid cleavage of structural and enzymatic proteins would result in the 
rapid self-assembly of mature virus particles which are required to realize full 
infectivity (Navia, et al., 1989).
Env-encoded glycoproteins.
Translation of the env polyprotein product is different from that of the 
gag and pol products whose translation takes place on free polyribosomes using 
the full length genomic RNA. The mRNA from which env products are 
translated is a spliced subgenomic molecule which produces a precursor 
polyprotein that is subsequently processed to yield the N-terminal SU and C- 
terminal TM molecules. The envelope polyprotein, like other cell-surface 
proteins, is synthesized on polyribosomes closely associated with the rough 
endoplasmic reticulum (Varmus, 1988). To direct this process, it is assumed 
that all primary env protein products contain a leader sequence at their amino- 
terminus. The length of the hydrophobic domain of the viral signal sequence 
seems to be critical since mutations in this region of the RSV env product 
reduced the signal peptide efficiency by 50-95% (Willis, et al., 1983). As with 
cellular proteins, the leader sequence is responsible for directing the host 
system in the synthesis of the nascent protein and its translocation into the 
lumen of the rough endoplasmic reticulum (Wickner and Lodish, 1985). After 
translation is complete, the precursor env protein remains anchored to the
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endoplasmic reticulum membrane by the hydrophobic membrane-spanning 
domain (approximately 20 amino acids) near the precursor carboxyl-terminus; 
deletion of this hydrophobic sequence results in the polyprotein being exported 
and released from the cell in a soluble form (Perez, et al., 1987). The 
biosynthesis and intracellular transport of these mutated proteins could not be 
distinguished from that of the full length product indicating that protein signals 
for biosynthesis and intracellular transport of the envelope protein complex 
must reside in the extracellular domain (Perez, et al., 1987). Additional 
intracellular transport studies have indicated that the RSV envelope product 
oligomerizes into what appears to be a trimer structure prior to transport from 
the rough endoplasmic reticulum (Einfeld, et al., 1989).
The first addition of N-linked carbohydrate components to the 
envelope proteins occurs during or shortly after translation in the lumen of the 
endoplasmic reticulum. Additional modification of the carbohydrate (trimming 
of the high-mannose core, addition of other carbohydrate moieties) takes place 
in the Golgi apparatus, as does cleavage of the precursor envelope 
glycoprotein into the SU and TM constituents which remain associated with 
one another (Dickson, et al., 1985). This posttranslational cleavage reaction 
utilizes a cellular enzyme which is currently thought to be trypsin or trypsin­
like; cleavage is made on the carboxyl side of the terminal arginine in the 
conserved cleavage site (Lys/Arg - X - Lys/Arg - Arg) (Freed and Risser,
1987). Failure of this cleavage to occur results in noninfectious virions even
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though provirus replication, RNA processing, protein expression and virus 
assembly are not altered (McCune, et al., 1988). This suggests that release of 
the hydrophobic fusion domain at the N-terminus of the TM protein is 
necessary for the full expression of virus infectivity. Finally, the mature env 
glycoprotein complexes are transported to the host plasma membrane where 
virus budding ensures their presentation on the outer surface of the mature 
virion (Coffin, 1990). Export to the cell surface is mediated by the host cell 
secretoiy pathway (Hunter, 1988).
Possible roles fif 1M carbohydrate component. Although the majority of 
N-linked glycosylation sites occur in the SU component, the number and 
distribution is quite variable between different retroviruses. However, within a 
given virus group, conserved N-linked glycosylation sites can be observed 
(Willey, et al., 1988) and consequently may reflect a role in the structure- 
function of the glycoprotein. It has been suggested that oligosaccharides play a 
role in transport by stabilizing protein folding which in turn may be required 
for efficient transport (Willey, et al., 1988). It is likely that glycosylation 
stabilizes the glycoprotein by protecting the protein from proteolytic enzymes. 
This masking of susceptible residues may also reduce the immunogenicity of 
the protein, presumably by preventing immunoreactive cells from interacting 
with peptide antigenic determinants (Elder, et al., 1986). Data presented by 
Huso, et al. (1988) suggested that the carbohydrate molecules on the SU 
glycoprotein in CAEV is not only important for protection from proteases, but
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also important for protecting the virus from rapid neutralization by antibodies. 
Finally, recent experiments have disclosed that several retroviral env proteins 
are also modified by O-linked glycosylation (Pinter and Honnen, 1988).
Common surface glycoprotein characteristics. The surface glycoprotein 
complex can be divided into 3 common domains (cytoplasmic, transmembrane, 
extracellular) across the retrovirus family. In addition, there is an overall 
similarity in the location of key apolar regions along the peptide backbone of 
the envelope molecule: a) at the amino-terminus of the SU protein there is a 
short stretch of hydrophobic amino acids which directs the nascent env protein 
into the host transport system; b) near the carboxyl-terminus of the TM 
protein there is a longer stretch of hydrophobic residues that halts the 
translocation process, anchors the molecule in the membrane and orients the 
glycoprotein complex into the common domains with the N-terminus 
extracellular; c) a third apolar region occurs at the N-terminus of the TM 
protein and C-terminal to the conserved cleavage site which is involved in the 
process of membrane fusion during virus entry (Perez, et al., 1987; Hunter, et 
al, 1983).
Critical functional ef lli£ eon glycoproteins. The SU protein plays a 
critical role in virus infectivity by binding to a surface receptor on the target 
cell. In this way, the SU component defines the host range of the virus. 
However, there are very few cell-surface receptors which have been 
unequivocally identified to interact with retrovirus SU proteins. The best
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characterized receptor is that of HTV and SIV which is the CD4 antigen found 
predominantly (although not exclusively) on a subset of lymphocytes known as 
helper T-cells (Maddon, et al., 1986).
The principal humoral immune response during persistent lentivirus 
infections is directed against the env-encoded glycoproteins, yet these proteins 
are highly variable. Distinct regions of conserved and variable sequences have 
been delineated in HIV (Starcich, et al., 1986) and EIAV (Payne, et al., 1987). 
Overall, the env gene from different HIV isolates varies between 15-20% 
(Hahn, et al., 1986). Up to 25% of visna virus isolates from infected sheep 
have antigenically distinct envelope glycoproteins (Stanley, et al., 1986). 
Variation of the antigenic character of the surface glycoproteins provides a 
means of circumventing the current immune status and is one mechanism of 
lentivirus persistence.
Notably, neutralizing antibodies are directed against the exposed 
envelope surface glycoproteins. Glycoprotein-specific neutralizing antibodies 
have been demonstrated in sera from EIAV and visna virus infected animals, 
and in the serum of humans infected with HIV (Pedersen, 1989).
The genome.
The single-stranded RNA genome is unique in several aspects, 
including: 1) there are 2 identical copies (diploid), 2) synthesis and 
processing are accomplished by the host cell mRNA-processing machinery and
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thus, each viral RNA molecule contains typical eukaryotic mRNA 
modifications, 3) a specific cellular tRNA is associated by basepairing to the 
S’ end and primes minus strand DNA replication, and 4) each molecule is 
terminally redundant, containing the identical sequence at the S’ end, adjacent 
to the cap structure, and at the 3’ end immediately before the poly(A) tract 
(Varmus, 1983; Coffin, 1990).
Key differences which distinguish the lentivirus genome from that of the 
mammalian and avian oncogenic retroviruses include the overlapping gag and 
pol genes, the larger coding region of the env gene, and the presence of several 
short open reading frames (ORFs) in the pol-env intergenic region and 
overlapping the 3’ end of env (Figure 3) (Davis, et al., 1987). These short 
O R Fs have been reported to encode trans-acting proteins which act as either 
positive or negative regulators of viral gene expression and are frequently 
expressed by double splicing events (Peterlin and Luciw, 1988). This complex 
transcription pattern is a common feature of lentivirus gene expression and 
may contribute to the intricate aspects of the lentivirus life cycle, including 
restricted replication and latency, and intermittent high levels of cytopathic 
replication (Peterlin, et al.t 1988b).
Once the viral core is uncoated in the cytoplasm, the virion-associated 
reverse transcriptase initially produces hybrid RNA/DNA molecules which are 
converted to double-stranded DNA entities and translocated into the nucleus. 
Following integration of the double-stranded DNA copy of the viral genome
FIGURE 3. LENTIVIRUS GENOMIC ORGANIZATION
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Lentivirus genomes are characterized by overlapping gag and pot genes, 
large env coding region, and additional short open reading frames between pol 
and env and near the 3’ terminus of env. HIV-1 additional O RFs include vif 
(virion infectivity factor), vpr (viral protein R), tat (trans-activator of 
transcription), rev (regulator of expression of virion proteins), vpu (viral protein 
U), and nef (negative factor). The HIV-2 and SIV genomes also enode vif (vip 
or virion infectivity protein in SIV), vpr, tat, rev, and nef, but do not code for 
vpu. HTV-2 and SIV also encode for viral protein X (vpr) (Peterlin and Luciw,
1988).










into the chromosomal DNA of the host, virus expression becomes dependent 
on the replication machinery of the host cell (Peterlin and Luciw, 1988).
Recent studies comparing EIAV RNA and DNA synthesis during 
persistent and cytopathic infections in vitro disclosed that during the persistent 
infection of fetal equine kidney (FEK) cells, 70% of the total EIAV proviral 
DNA was not integrated and equally divided between linear and circular forms 
(Rasty, et al., 1990). In these persistently infected cells, there were 2 major 
transcripts, the 8.2 kilobase (kb) full length genomic mRNA encoding the gag 
and pol proteins and a 3.5 kb single-spliced mRNA encoding the env 
glycoproteins. In contrast, the cytopathic infection of fetal donkey dermal 
(FDD) cells exhibited high levels of provirus integration ranging from 65% to 
greater than 90% of the total proviral DNA (Rasty, et al., 1990). In addition 
to the 2 major mRNA transcripts previously observed in FEK cells, a small, 
low-abundance 1.5 kb transcript was detected. Finally, in persistently infected 
cells, the 8.2 and 3.5 kb transcripts were in approximately equal concentrations, 
while in cytopathic infections, the env-encoding 3.5 kb transcript comprised 
nearly 75% of the total viral mRNA indicating that the envelope proteins may 
be involved in cytopathology (Rasty, et al., 1990). Finally, EIAV appears to 
have a relatively simpler transcription pattern than visna and HIV with only 
the S2 short ORF product absolutely required for trans-activation of the EIAV 
LTR (Dom and Derse, 1988; Davis and Clements, 1989).
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Lentivirus persistence mechanisms.
The nature of the lentivirus life cycle has several obvious advantages for 
viral persistence. As described above, the SU protein can interact with a host 
cell-surface receptor and enter the cytoplasm by a fusogenic event; reverse 
transcription provides a DNA copy of the genome which is stably integrated 
into the host chromosome; transcription is mediated by host cell RNA 
polymerase II; viral mRNA is processed by host cell enzymatic systems; and 
translation of viral transcripts is by host translation machineiy (Peterlin and 
Luciw, 1988). Thus, the life cycle of a lentivirus imposes on the normal 
functions of the host cell. In this way, integrated proviral DNA can only be 
eliminated by death of the cell and disruption of viral replication could disrupt 
vital replicative events in the host cell.
The provirus can be expressed immediately or remain latent for years 
such that infection of replicating bone marrow cells or progenitor immune cells 
could result in mature immune cells which can be induced by unknown factors 
to productively replicate virus (Montelaro, et al., 1989). Once virus expression 
is induced, the infection spreads to uninfected cells by free virus or by cell to 
cell transfer. The fusogenic properties of the TM glycoprotein facilitates 
fusion of the infected and uninfected cells and the transfer of virus which goes 
unnoticed by host immune surveillance (Montelaro, et al., 1989).
Despite this array of survival strategies, the viral genome is only 
temporarily safe in a productive, cytolytic infection. To persist in the host, the
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virus must replicate and disperse to other target cells giving the host an 
opportunity to immunologically respond to the free virus. Lentiviruses have 
developed several strategies to avoid neutralization by the host immune 
system:
A) Lentivirus infections are characterized by low levels of neutralizing 
antibodies. Obviously, epitopes responsible for inducing neutralizing antibodies 
are not recognized by or are hidden from the host immunosurveillance. Thus, 
the host fails to produce antibodies effective in neutralizing the virus while a 
multitude of nonneutralizing antibodies are produced. These virus-binding, 
nonneutralizing antibodies may actually aid the targeting of infectious virus to 
uninfected immune cells. Jolly, et al. (1989) examined the effect of an array of 
nonneutralizing antibodies on visna virus infectivity. The results of this study 
indicate that antibody binding can specifically enhance the binding, 
internalization and uncoating of the virus in macrophages (Jolly, et a l 1989).
B) Neutralizing antibodies that are produced by certain lentivirus 
infected animals are of relatively low titer and require extended incubation 
times with the virus to accomplish inactivation. Thus, the infecting virus can 
replicate and spread from cell to cell before neutralization ensues (Montelaro, 
et al., 1989).
C) Extensive lentivirus replication can ultimately result in 
immunosuppression of the host. Immunosuppression can be mediated by the 
TM protein, by depletion of infected immune cells or by affecting the
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production of cytokines. Although immunosuppression occurs at various 
degrees in all lentivirus infections, it is the outstanding marker of acute HIV 
and SIV infections.
D) Genetic variation during virus replication gives rise to altered 
structural and antigenic properties of the viral proteins. This evolution of 
antigenic variants provides an unmistakable strategy of avoiding host immune 
responses; virus infection is promoted even in the presence of fully competent 
immune cells. Alterations are primarily located in the env gene, with 
negligible variations observed in the gag and pol sequences (Payne, et al.,
1987). Antigenic variants arising from env variation during persistent infections 
has been documented in visna virus, EIAV, HIV and CAEV by neutralization 
assays and/or monoclonal binding assays (Narayan, et al., 1978; Montelaro, et 
al., 1984; McGuire, et al., 1988).
Together, these mechanisms present a formidable challenge to the 
natural protective systems of the host and to the development of an effective 
lentivirus vaccine. Of the persistence strategies, the greatest obstacle to 
overcome in developing a broadly protective vaccine is the extensive genomic 
and antigenic variation. Killed and avirulent virus vaccines as well as subunit 
vaccines would have to achieve a broad spectrum of specificity to 
accommodate the vast number of emerging serologically distinct mutants.
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Persistent EIAV infections.
There are 3 characteristic stages of disease exhibited by naturally and 
experimentally EIAV infected horses (Kono and Yamamoto, 1970). The first 
stage, acute EIA, is generally associated with the first exposure to virus and 
characteristic clinical symptoms (fever and hemorrhages) which appear to 
correlate with virus expression and host cell lysis. Horses that recover from 
the acute attack remain asymptomatic for weeks to months followed by 
recurring cycles of viremia and illness. This cyclic recrudescence of disease 
known as chronic EIA is associated with the classical symptoms (edema, 
anorexia, leukopenia, etc.) which demarcate EIAV infections. The frequency 
and severity of these disease cycles decline with time after which cycling stops 
and either chronic wasting disease sets in or the animal remains clinically 
normal; most EIAV infected horses progress to an inapparent stage which 
lacks detectable levels of plasma viremia (Montelaro, et al., 1989; Narayan and 
Clements, 1989). However, these animals harbor latent virus as evidenced by 
the efficient transmission of infection which accompanies the experimental 
transfer of whole blood to naive ponies and the onset of a new cycle of disease 
when the horse is placed under stress or administered immunosuppressive 
drugs (Kono, et al., 1976). The ability to induce productive virus expression 
and clinical disease in these inapparent carriers by stressing or suppressing the 
immune response indicates an active immunological management of EIAV 
virus replication was present prior to intervention. Immunological
34
management of virus expression is further supported by the observation of 
Periy, et al. (1988) that horses with combined immunodeficiency, i.e. lacking 
both B- and T-lymphocytes, are not capable of controlling EIAV replication 
and display a persistent viremia following experimental infection; normal 
horses infected in parallel were effective at clearing detectable plasma viremia.
The recurrent nature of EIAV and the failure of all classical vaccination 
protocols can be attributed to the sequential appearance of antigenically 
distinct viral isolates which arise during the course of a persistent EIAV 
infection and temporarily escape the established humoral and cellular immune 
responses. Biochemical and immunological evidence of antigenic variation 
have been documented (Salinovich, et al., 1986; Payne, et al., 1984, 1987b) and 
have demonstrated that a distinct population of EIAV predominates during 
each clinical episode in a single infected pony. From these results, a sequence 
of events can be proposed which accounts for the emergence of EIAV variants 
during a persistent infection (Figure 4). Following the initial infection and 
viremia, the horse mounts an apparently effective immune response which 
clears most of the virus. However, there can be a minor population of mutant 
viruses, either present in the original inoculum or evolved during the 
replication of the initial viremia. The animal appears clinically normal until 
one or more of these variant viruses replicate and establish another episode of 
viremia and disease. The horse mounts another immune response to clear the 
new variant virus since the initial response was not effective (Montelaro, et al.,
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FIGURE 4. MODEL OF CHRONIC EIAV INFECTION.
Shown is a schematic representation of the recrudescent viral strains 
and the corresponding variant-specific immune response during a chronic 
infection of EIAV. The infecting virus replicates in equine macrophages 
generating a plasma viremia and the characteristic clinical symptoms of 
chronic EIA. Detectable levels of viremia are eliminated by a seemingly 
competent immune response of the infected animal, the infection becomes 
inapparent and the horse appears clinically normal. However, mutant viral 
strains emerge relatively rapidly which reestablish viremia in the infected 
horse and clinical manifestations of the chronic infection. A second 
immunological response follows the appearance of this antigenically distinct 
virus and the cycle repeats itself.
CHRONIC EIA
i m m u n e  r e s p o n s e  i m m u n e  r e s p o n s e
t o  v i ru s  2v i r u s  2t o  v i r u s  1v i r u s  1
T I M E
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1986).
The model depicted in Figure 4 was shown to be accurate by 
comparison of the neutralization properties of serial serum samples with 
sequentially recovered viral isolates (Salinovich, et al., 1986). The results of 
these experiments revealed that each viral isolate was neutralized by serum 
samples taken after its corresponding febrile episode, but none of the isolates 
were neutralized by serum samples acquired before the febrile episode of 
origin (Salinovich, et al.t 1986). Thus, the horse was able to mount an effective 
immune response, including neutralizing antibodies, to each antigenically 
distinct isolate as it evolved, but the existing immune status was unable to 
prevent the emergence of new variants and the consequential viremia and 
disease. After the virus goes through a number of mutations, it becomes 
relatively quiescent in macrophages suggesting that host immunity, although 
not completely effective in eliminating the infection, is capable of controlling 
virus expression and associated disease. This data distinguishes EIAV from 
visna and HIV which require 1-2 years for the emergence of variant virus 
whose expression is never immunologically controlled (Clements, et al., 1980; 
Pederson, 1989), and from CAEV persistent infections in which significant 
levels of neutralizing antibody are not detected (Narayan, et aL, 1982).
A crucial question regarding lentivirus variation is the number of 
variants that can occur in nature. This question was addressed by comparing 9 
EIAV isolates recovered during distinct clinical episodes in 2 ponies
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experimentally infected with the same virus utilizing peptide and 
oligonucleotide mapping procedures (Payne, et al., 1987b). Each virus isolate 
was determined to be antigenically distinct, hence a large number of variants 
seem possible (Payne, et al., 1987b). Nucleotide sequencing of HIV isolates 
has revealed a similar pattern of variation (Hahn, et aL, 1986) and amino acid 
divergence in HIV env glycoproteins has been reported to be as high as 21% 
(Alizon, et al., 1986). Variation in the EIAV env glycoproteins is not as 
pronounced as that of HIV. Pairs of EIAV viral isolates have been reported 
to differ by 3% to 9% in the envelope amino acid sequence (Payne, et al.,
1987) with the majority of the alterations localized in the SU protein. Further 
analysis revealed a hypervariable segment in the variable domain of gp90 
which displayed an amino acid divergence between 2 isolates between 3% and 
20% (Payne, et al., 1987). These data suggest there is a large but finite 
number of variant strains that arise during the course of an EIAV persistent 
infection.
The clinical profiles portrayed in Figure 5 demonstrate that the time 
required for the evolution of antigenically distinct variants is variable but rapid 
in the EIAV system. The shortest time observed between febrile episodes 
(and corresponding variant virus) was about 15 days (P3.2-1 to P3.2-2). As 
mentioned above, the generation of variants in other lentivirus infections is 
considerably slower. The clinical profiles also demonstrate that each pony 
brings virus replication and clinical symptoms under immunological control
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FIGURE 5. CLINICAL HISTORY OF 2 PONIES USED IN 
PARALLEL INFECTIONS OF EIAV.
Clinical histories of 2 experimentally infected Shetland ponies depicting 
febrile episodes (rectal temperature above 39 C) from which variant virus 
isolates were recovered. Identical virulent virus inocula of host-adapted EIAV 
(passage 2) was utilized. Each viral isolate recovered at each febrile episode 
was antigenically distinct.
Pony 3 (top panel) exhibited classical chronic EIA and died after 4 
febrile episodes on day 180.
The bottom panel indicates that pony 2 experienced chronic EIA with a 5 
month period of inapparent infection between febrile episode 3 (P3.2-3) and 4 
(P3.2-4).
"P3" indicates third virus passage. This is followed by the pony number 
(P3.3 and P32). The last numbers represent the sequential viral isolates 
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within 1 year post infection. Thus, EIAV presents a unique model to study the 
evolution of virus structure and the dynamic interaction between the evolving 
lentivirus antigens and the host immune response.
Shown in Figure 6 (top panel) is a schematic of the kinetics of humoral 
immune responses to EIAV antigens during chronic EIA induced by 
experimental infections. Protein-specific antibodies were detected by Western 
blot and ELISA immunoassays (Rwambo, et al., 1990). The first EIAV 
antibodies detected are directed against the major surface glycoprotein gp90 at 
7 to 10 days post inoculation. Levels of gp90-specific antibody continue to rise 
over the next few months, regardless of the number of febrile episodes.
Notably, early gp90 antibodies are nonneutralizing and frequently fail to 
neutralize even the homologous EIAV strain in current in vitro neutralization 
assays (Figure 6, bottom panel) (Rwambo, et al., 1990). Thus, it appears that 
neutralization by antibody binding is not the major mechanism of clearing the 
initial viremia. However, neutralizing antibodies to EIAV are detected later in 
infection, are type specific, and appear at approximately the same time as 
detectable antibodies to gp45, i.e. 3-4 weeks post infection (Figure 6) 
(Montelaro, et al., 1990). The gp90-specific antibody titer eventually plateaus, 
but remains the predominant antibody response through the course of the 
infection. TM-specific antibodies rise slowly and stabilize at levels significantly 
lower than those observed for gp90. Detectable p26-specific antibodies are 
first observed 10-14 days post infection and reach a plateau veiy rapidly.
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Top panel schematically summarizes antigen-specific antibody 
responses as determined by ELISA and immunoblot assays.
Bottom panel illustrates the broadening of neutralizing antibodies 
following several clinical episodes.
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Finally, only minor antibody levels are detected against the pl5, p l l ,  and p9 
viral components (Montelaro, et al., 1990).
In general, the scope of neutralizing antibodies increases with each 
clinical episode although the total antibody titer remains essentially unchanged 
(Rwambo, et al., 1990). Even sera from ponies that display a single febrile 
incident contain more broadly neutralizing antibodies several months post 
infection compared to earlier time points (Montelaro, et al., 1989).
Antibody neutralization.
Several mechanisms of virus neutralization by antibody binding have 
been elucidated, including: 1) antibodies that crosslink virus particles resulting 
in an alteration of protein conformation; 2) antibodies that block virus 
attachment by directly binding to the SU binding domain; 3) antibodies that 
block virus attachment by binding determinants adjacent to the binding domain 
(steric hindrance); and 4) antibodies which prevent virus penetration by 
binding to the fusion domain (Putney and Montelaro, 1990).
Visna virus has been reported to be neutralized by 2 different 
mechanisms depending on the cell type (Narayan and dem ents, 1990). 
Neutralization of fibroblast infection is mediated by prevention of viral 
attachment whereas neutralization in macrophages involves a post-binding 
event. The phagocytized virions are uncoated but RNA transcription does not 
occur. HIV neutralizing antibodies have been detected in most AIDS patients,
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but the mechanism of neutralization is still unknown (Putney and Montelaro,
1990).
Immunological management of EIAV. The obvious question now is 
how does the infected horse achieve immunological control of EIAV 
expression. One possibility is that in response to the sequential production of 
variants, the immune system accumulates sufficient type-specific responses 
which are able to control any new variant that emerges. This possibility is not 
likely. There are numerous variants that exist in nature; 30 EIAV isolates 
recovered from experimentally infected ponies were antigenically distinct 
(Montelaro, et al., 1990). Additionally, attenuated EIAV whole virus vaccines 
were effective in protecting vaccinated animals from infection by homologous 
virus challenges, but with heterologous EIAV strains, only disease was 
prevented (Issel, et al., 1990). Thus, it is probable that a sufficient array of 
type-specific responses cannot be achieved easily.
Another possible mechanism of achieving immunological management 
of EIAV replication is the "gradual strengthening of immune responses against 
antigenic determinants that are conserved but immunorecessive" (Montelaro, et 
al., 1990). These weak immunogens would not induce strong immune 
responses during the first viremic episode, but because these antigenic sites are 
conserved, they will be repeatedly presented to the immune system during 
sequential episodes of viremia and during periods of low virus replication.
This type of exposure could enhance anamnestic reactions resulting in strong
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responses to a relatively weak antigenic determinant.
The fact that there is a natural animal model system which successfully 
manages a lentivirus disease should inspire the quest for more knowledge on 
how this management is achieved and how it can be applied to an AIDS 
vaccine.
Research Objectives.
The goals of this study were to assess the complete spectrum of 
antigenic properties exhibited by conserved and variable domains of the 
surface glycoproteins of EIAV, gp90 and gp45; to localize neutralizing and 
nonneutralizing monoclonal antibody epitopes; and to evaluate the immune 
responses to discrete regions of the env glycoproteins in both naturally and 
experimentally infected horses. Ultimately, the objective was to map critical 
regions of the EIAV surface glycoproteins which elicit a strong humoral 
immune response during a persistent EIAV infection in order to provide a 
critical foundation for developing effective EIAV vaccine strategies and 
sensitive diagnostic assays.
Towards these goals:
1. A practical purification technique was developed for the 
purification of the surface glycoproteins from purified virus by HPLC 
methodology. Isolated glycoproteins were subjected to direct amino acid 
sequencing providing constructive information concerning the processing of
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these vital molecules. In addition, purified env products proved useful in a 
variety of immunoassays.
2. A battery of predictive computer algorithms were employed to 
evaluate potentially pertinent antigenic sites. A detailed structural model for 
retrovirus SU proteins was developed and the previously reported TM 
structural model was expanded.
3. A panel of peptides representing the primary sequence of gp90 
and key regions of gp45 were chemically synthesized, purified and 
characterized. These peptide sequences were also evaluated by computer 
algorithms for potential secondary structure.
4. Several peptide immunoassays were analyzed for efficacy in 
detecting glycoprotein-specific antibody with minimal nonspecific protein 
binding. From these studies, a novel enzyme-linked immunoassay was 
developed for evaluation of equine immune reactivity to the chemically 
synthesized peptides.
5. To dissect equine humoral immune responses during a persistent 
EIAV infection, the synthetic peptides were reacted against a panel of equine 
immune sera from natural and experimental EIAV infections and serial sera 
from experimentally infected ponies.
6. Envelope-specific monoclonal antibodies were reacted against the 
panel of peptides to localize mouse epitopes to minimal sequences.
7. Serological and structural data were analyzed and compared in
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an effort to establish a structure-function relationship.
The results of these studies provide a detailed map of EIAV surface 
glycoprotein antigenic properties and indicate particular peptides as candidates 




A list of chemicals employed in this study and their sources of supply is 
enumerated below.
acetic acid - J.T. Baker; ammonium bicarbonate - Mallinckrodt; 
ammonium persulfate - BRL; 2,2’-azinobis(s-ethylbenzthiazoline sulfonic 
add) - Sigma; bovine serum albumin, fraction V - Sigma; chloramine-T - 
Sigma; 4-chloro-l-napthol - Sigma; ritric acid - Fisher Scientific; coomassie 
brilliant blue R250 - Bio-Rad; 3, 3’-diphenyloxacarbocyanine iodide - 
Molecular Probes; N-ethylmorpholine - Sigma; Freund’s complete and 
incomplete adjuvant - Sigma; glass fiber sheets - Whatman Inc.; 
glutaraldehyde - Sigma; glycerol - EM Sdence; glydne - Bio-Rad; guinidine 
hydrochloride - Sigma; 2-mercaptoethanol - Sigma; 3-mercaptoproprionic acid
- Sigma; methanol - J.T. Baker; nitrocellulose membranes (0.45 um) - 
Millipore; Nonidet P-40 - Particle Data Laboratory; Sephadex G-25 - Sigma; 
sodium chloride - Mallinckrodt; sodium iodide - Sigma; [I125]-sodium iodide - 
ICN; sodium metabisulfate - Sigma; monobasic and dibasic sodium phosphate
- Sigma; Tween 20 (polyoxyethylene-sorbitan monolaurate) - Sigma; urea - 
Bio-Rad.
HPLC solvents were HPLC grade and obtained from Mallinckrodt,
48
49
Fisher Scientific, and J.T. Baker Chemical Company. Trifluoroacetic acid was 
purchased from either Pierce or Aldrich Chemical Company. All reagents and 
solvents used in the gas phase protein sequencer were acquired from Applied 
Biosystems. Reagents for SDS-PAGE (sodium dodecyl sulfate, aciylamide, 
N,N’-methylene bisacrylamide) were electrophoresis grade and obtained from 
Bio-Rad. Organic solvents used in peptide synthesis were generally obtained 
from Fisher Scientific while specific resins and activating chemicals were 
purchased from the manufacturer of the synthesizer employed.
Low molecular weight standards included phosphoiylase a - Sigma; 
bovine serum albumin - Calbiochem; ovalbumin - Worthington Biochemical; 
carbonic anhydra.se - Sigma; trypsin inhibitor - Aldrich Chemical Company; 
and alpha-lactalbumin - Sigma, and were prepared in 0.05 M phosphate buffer, 
pH 7.4, at a concentration of 1 mg/ml.
The sources of additional chemicals and reagents which are not listed 
above are included in the specific protocols given below.
Virus propagation and purification.
The cell-adapted Wyoming strain of EIAV (prototype) (Malmquist et 
al., 1973) was propagated in primary fetal equine kidney (FEK) cells 
maintained at 37 C in Eagle’s minimal essential medium (MEM) supplemented 
with 5 to 10% fetal bovine serum, 10 mM sodium bicarbonate, 25 mM HEPES 
buffer, 100 Units of penicillin G per ml, and 100 ug streptomycin sulfate per
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ml (Amborski, et al., 1979). The supernatant media from persistently infected 
cultures were harvested every 3 to 4 days, clarified by centrifugation at 8,000 
rpm for 30 min in a Sorvall GSA rotor, and concentrated 10- to 40-fold using a 
Pellicon membrane filter cassette system (Millipore Corp., Bedford, Mass.). 
Virus was recovered from the concentrated medium by centrifugation through 
an underlayered cushion of 10% sucrose and resuspended in 0.01 M sodium 
phosphate buffer, pH 7.2 (Montelaro, et al. 1982).
Further purification of the pelleted virus was accomplished by 
sedimentation to its equilibrium density of 1.8 mg/ml on a 30 ml 25-90% 
glycerol gradient in a Beckman SW-28 rotor at 28,000 rpm for 4 hr. The 
visualized virus band was extracted with a Pasteur pipette, diluted in 0.01 M 
sodium phosphate buffer, and pelleted for 1.5 hr at 28,000 rpm. Pelleted virus 
was resuspended in a small volume of 0.01 M phosphate buffer, pH 7.2, 
aliquoted, and stored at -70 C. Virus protein recoveiy was determined by the 
Lowry protein assay (Lowiy, et al., 1951), and the quality of the gradient 
purified virus was evaluated by SDS-PAGE.
Utilizing the above protocol, about 10 mg of EIAV protein could be 
acquired from 10 roller bottles of infected FEK cells as opposed to 1 mg when 
equine dermal cells were used for virus propagation (Montelaro, et al., 1982).
In addition, the use of glycerol instead of sucrose gradients was found to be an 
important factor in preventing the shedding of virus glycoproteins.
Equine immune sera.
Serum was collected from experimentally infected ponies and naturally 
infected horses under the direction of Dr. Charles Issel, Department of 
Veterinary Microbiology and Parasitology, Louisiana State University. This 
panel of immune sera is listed in Table 3. Sera from experimentally infected 
ponies were collected at specific times post infection whereas naturally infected 
horses were selected by positive antibody reactivity in the agar gel 
immunodiffusion (AGID) assay (Pittman-Moore, Washington Crossing, NJ.).
Additional panels of experimentally infected horses which were closely 
monitored to evaluate the kinetics of the disease response are indicated in 
Table 4. Daily temperatures and weekly bleeds were acquired. As indicated 
in table 4, 3 of the horses were infected with the avirulent, prototype lab strain 
(horse numbers 78, 712, 714), and 3 were infected with the virulent, 6493 
variant which was derived from prototype virus (horse numbers 71, 74, 76).
Sera collected on the indicated days post infection (dpi) were evaluated in 
peptide immunoassays (below) against a selected panel of chemically 
synthesized peptides.
Monoclonal antibodies to gp90 and gp45.
The production and characterization of a limited panel of monoclonal 
antibodies (MAbs) to the surface glycoproteins of prototype EIAV has been 










EIAV IMMOME SERUM PAMBL
HORSE ID
71-3rd passage EIAV
72-in vitro variant EIAV 
78-Prototype EIAV 
















Reference 6 Ann T. Paint Within 1 yr. 2/25/88
Positive 7 Princess unknown 8/7/84
Sera 8 Lady Unknown 11/10/76
9 Hozanna's Girl Unknown 9/29/76
10 45 Gelding within l yr. 2/25/88
Florida 11 Toby 5/84 2/29/88
Samples 12 Classy 4/79 2/29/88
13 Sugarcane 12/75 2/29/88
14 Misty 11/74 2/29/88
15 Black Jack 11/86 2/29/88
LSD 16 Just Plain Jo 1983 2/25/88
Horses 17 Moore Bar Miss 1981 2/25/88
18 Miss Super Flame 1982 2/25/88
19 Sabrina Bell 1986 2/25/88
20 Betsy's Lead 1986 2/25/88
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TABLE 4. EQUINE SERIAL SERUM PANEL
Horse 74 - Infected 10/27/87 with Horse 76 - Infected 10/27/87 with
Virulent Strain 6493 Virulent Strain 6493
8 49 dpi- 8 49
10 55 10 55
14 62 14 65
17 70 17 77
21 77 21 84
24 84 24 91
35 91 28 105
38 119 35 119
42 140 42 140
45 143 45 155
Horse 712 - Infected 10/27/87 Horse 71 - Infected 10/27/87 with
with Prototype Virulent Strain 6493














Horse 78 - Infected 10/27/87 Horse 714 - Infected 11/24/87
with Prototype with Prototype












Department of Veterinary Microbiology and Parasitology, Louisiana State 
University. Monoclonal antibodies (6 directed against gp90, 2 against gp45) 
were utilized for epitope mapping, and are listed on Table 5.
Concentration and purification of glycoprotein specific monoclonal antibodies.
Glycoprotein specific monoclonal antibodies contained in ascites and/or 
tissue culture supernatant fluids were concentrated by ammonium sulfate 
precipitation and purified by conventional or HPLC chromatography. Salt 
fractionation was chosen since it offers the advantage of a quick concentration 
step with partial purification and minimal protein loss (Harlow and Lane,
1988). Initially, conventional protein A-sepharose chromatography was utilized 
for subsequent purification, but was found to be time consuming. Thus, HPLC 
ion exchange chromatography was implemented.
Ammonium sulfate precipitation. Tissue culture supernatants containing 
identical antibody were pooled and the total volume was noted. While stirring 
gently, dry ammonium sulfate was slowly added until a final salt concentration 
of 45%. The solution was stirred overnight at 4 C followed by centrifugation 
at 6,000 rpm for 15 min. The pelleted precipitate was solubilized in 10 - 15 ml 
of 0.1 M phosphate buffer, pH 8.0, and dialyzed against the same buffer. 
Dialysis buffer was changed a minimum of 3 times over a  period of 24 hr to 
effect the removal of ammonium ions before the dialysate was subjected to 
further purification.
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86 IgGt virus (D)c gp90 -
71 glycoprotein* gp90 -
87 IgGt virus (D) gp90 -
98 U f i i virus (D) gp90 + (64)
115 IgGt virus (D) gp90 -I- (128)
128 IgA virus (I) gp90 + (128)
105 IgG2b virus (D) gp45 -
90 IgGj virus (D) gp45 -
a) Table was extracted from Hussain, et al., 1987.
b) Reciprocal of highest dilution of ascites fluids that inhibited CPE
of 100 TCIDjq of EIAV in fetal donkey dermal cell cultures.
c) Mouse immunized with disrupted (D) or intact (I) virus.
d) Mouse immunized with virus glycoproteins isolated by lentil-lectin affinity 
chromatography (Montelaro, et al., 1983).
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Ascites fluid was diluted four-fold with cold 0.1 M phosphate buffer, 
pH 8.0, and clarified for 15 min at 5000 rpm prior to the addition of dry 
ammonium sulfate. As with the cell culture supernatants, ammonium sulfate 
was added to a final concentration of 45% and mixed gently overnight at 4 C 
followed by centrifugation, solubilization, and dialysis.
Separation of mouse IgG bv Protein A-Sepharose affinity 
chromatography. The Protein A-Sepharose CL-4B (SPA-Sepharose,
Pharmacia) matrix was swollen in 0.1 M phosphate buffer, pH 8.0, for a 
minimum of 30 min and packed in a glass column. Prior to antibody 
absorption, the column was sequentially equilibrated in 0.1 M citrate buffer, 
pH 6.0, 4.5, and 3.0. The equilibration process was then reversed, starting with 
citrate buffer, pH 3.0, and ending with phosphate buffer, pH 8.0. The dialyzed 
sample was applied and allowed to absorb slowly into the column followed by 
a phosphate buffer rinse. Phosphate buffer was added until the A2g0 nm of the 
effluent reached baseline and remained steady which was usually 5 times the 
volume of the applied sample. Antibody elution was prompted by the addition 
of the pH 6.0, followed by pH 4.5 citrate buffer. Remaining bound antibody 
was removed from the column by a final wash of citrate buffer, pH 3.0.
Antibody elution was monitored by UV absorption at 280 nm with an 
Altex Model 153 fixed wavelength detector and chart recorder. Absorbance 
peaks were collected at each pH and immediately neutralized to pH 7.0 by the 
addition of 0.1 M Tris, 0.15 M N ad , pH 8.6. The proteins were then dialyzed
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against 0.05 M phosphate, 0.15 M NaCl, pH 7.0, and reverse dialyzed in a bed 
of dry sucrose to reduce the volume.
The different binding affinity of SPA-Sepharose and elution pH for the 
diverse subclasses of mouse IgG has been described in detail (Ey, et al., 1978). 
Buffers of pH 6.0 and 4.5 were chosen for elution because the glycoprotein 
specific monoclonal antibodies employed were of the IgGx subclass with the 
exception of monoclonal antibody 128 (IgA) and monoclonal antibody 105 
(IgG2b) (see Table 5). The pH 8.0 eluate was collected and evaluated for 
antibody activity given that mouse IgG molecules bind protein A with a 
relatively low affinity when compared to human and other mammalian 
immunoglobulins (Langone, JJ ., 1978).
Purified monoclonal antibodies were aliquoted, assayed for immune 
reactivity, and stored at -70 C. The SPA-Sepharose column was washed with 
phosphate buffer, pH 8.0, and stored at 4 C.
Ion exchange chromatography. In addition to protein A affinity 
chromatography, selected ammonium sulfate precipitated antibodies were 
purified by absorption and elution on a diethylaminoethyl (DEAE) anion 
exchange column. Protein separation was accomplished by altering the ionic 
strength (charge) and/or pH of the column buffer creating a competition 
between the sample ions and mobile phase counterions for the charged 
support.
The pH of the starting antibody solution was raised above its isoelectric
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point (pi) by dialyzing against 0.02 M Tris buffer, pH 8.5. Since antibodies 
cany a net negative charge at pH 8.5, they will attach to the weakly basic 
anion exchange matrix, and elute when the pH of the column buffer 
approaches their pi (Pharmacia handbook, 1974). Elution of bound protein 
can also be facilitated by increasing the ionic strength of the column buffer. 
Hence, a protocol in which the pH of the eluting buffer was gradually lowered 
while the ionic strength was concurrently increased was employed.
A Waters single-pump, 600E Gradient Module HPLC system was used 
with a DEAE-5PW semipreparative column (Waters, 21.5 mm x 15 cm). The 
alkaline antibody solution was pumped onto the column and washed with the 
starting buffer (0.02 M Tris, pH 8.5) for 5 min at a flow rate of 5 ml/min. A 
shallow, linear gradient to 0.02 M Tris, 03  M NaCl, pH 7.0, was applied to 
effect MAb dissociation from the DEAE-matrix and protein separation.
Fractions correlating to UV absorbance peaks (280 nm) were collected, 
dialyzed against 0.05 M phosphate, 0.15 M NaG, pH 7.0, and reverse dialyzed 
in a bed of diy sucrose. Analogous to the SPA-Sepharose samples, the HPLC 
purified monoclonal antibodies were aliquoted, checked for reactivity, and 
stored at -70 C.
Sodium dodecyl sulfate polyaciylamide-gel electrophoresis (SDS-PAGE).
SDS-PAGE was performed according to Montelaro, et al. (1978) and 
employed a 10% polyacrylamide slab gel (14 cm X 28 cm X 1.5 mm)
containing 0.2% methylenebisacrylamide, 0.1% SDS, 0.1 % TEMED, and 1 M 
urea in 0.01 M sodium phosphate buffer, pH 12  . Polymerization was initiated 
by the addition of 5 ml of 1% ammonium persulfate per 95 ml of aciylamide 
monomer. Electrophoresis buffer consisted of 0.1 M sodium phosphate, pH
7.2, with 0.1% SDS and 0.01 M 3-mercaptoproprionic acid. Samples to be 
electrophoresed were dissociated at 100 C for 3-5 min in 1% SDS and 1% 
mercaptoethanol in 0.01 M sodium phosphate buffer. Sucrose crystals were 
added to a final concentration of 20-30% to increase the density of the sample, 
and 1 ul of 0.5% bromophenol blue in 0.02 N NaOH was utilized as the 
tracking dye. After the samples were layered onto the gel, a current of 50 
mA/gel was applied for 16-20 hr.
SDS-PAGE was employed to evaluate the quality of virus propagation 
and clarification from cell debris, to monitor the progress of protein 
purification protocols, to separate full length gp90 from its breakdown products 
for sequencing, and to assess the purity of HPLC-purified virus proteins 
(below). Proteins were either visualized by Coomassie blue staining, 
transferred to nitrocellulose for immunoblot analysis, or transferred to 
activated glass sheets for protein sequencing. Coomassie blue was diluted to 
0.25% in acetic acid: methanol: water (46:227:227, v/v/v), and destaining 
solution was prepared by mixing acetic acid, methanol, and water at 3:10:27
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Western and dot blot immunoassays.
Electrotransfer from SDS-PAGE. Following separation by SDS-PAGE, 
proteins were electrophoretically transferred to nitrocellulose membranes (0.45 
urn, binding capacity of 80 um/cm2) as previously described (Burnette, 1981; 
Salinovich and Montelaro, 1986). The membranes were soaked in transfer 
buffer consisting of 0.02 M Tris-HG, pH 8.3, and 0.15 M glycine in 20% 
methanol. The soaked membrane was placed in direct contact with the 
polyacrylamide gel containing the resolved proteins and placed in a TE series 
Transfer apparatus (Hoefer Scientific Instruments, San Francisco, Ca.) such 
that the polyacrylamide gel faced the cathode and the nitrocellulose membrane 
faced the anode. Electrotransfer was accomplished at 15 C for 16 to 18 hr at 
a constant current of 0.4 amps.
The nitrocellulose sheet containing the electrotransferred proteins was 
directly used for immunoblotting techniques, while the polyacrylamide gel was 
stained with coomassie blue to evaluate the efficiency of transfer.
ImmunQbtotting of polypeptides electrotransferred to  nitrocellulose.
The nitrocellulose membrane containing the electrotransferred virus 
polypeptides was saturated with 3% bovine serum albumin (BSA) in Tris-saline 
(0.01 M Tris-HG, pH 7.4, with 0.9% NaCl) for 30 min at 37 C to block 
nonspecific protein binding to the nitrocellulose surface. Polyclonal reference 
immune sera (Montelaro, et al., 1984) was diluted in 3% BSA and reacted with 
the membrane for 90 min at room temperature. Extensive, sequential washes
with Tris-saline and Tris-saline with 0.05% Nonidet P-40 (NP-40) facilitated 
the removal of nonspecifically bound antibody. The membrane was incubated 
with ^I-labeled  Protein A of Staphlococcus aureus (500,000 dpm/ml in 3% 
BSA) for 30 min at room temperature, and the wash procedure was repeated. 
Protein bands reactive with each of the antibodies employed were visualized by 
autoradiography employing Kodak XRP film.
Staphlococcus Protein A was radiolabeled by the chloramine-T 
procedure which has been previously described (Greenwood, et al., 1963; 
Hunter, 1978). Briefly, chloramine-T (4 mg/ml), sodium metabisulfate 
(2.5mg/ml), and sodium iodide (10 mg/ml) were prepared fresh in 0.1 M 
sodium phosphate, pH 7.4. One millicurie of [125I]-sodium iodide was added 
to 50 ug of protein A in 0.2 ml of 0.1 M phosphate, pH 7.4, on ice in a fume 
hood. The reaction was initiated by the addition of 30 ul of chloramine-T, 
allowed to react for 3 min, and terminated by the addition of 100 ul of sodium 
metabisulfate. To minimize noncovalent binding of radiolabeled iodine to 
protein A, 200 ul of unlabeled sodium iodide was added as a carrier. 
Radioiodinated protein A was separated from unbound 125I on a Sephadex G- 
25 (20-80 um) size exclusion column prepared in a 10 ml disposable pipette. 
Fractions were collected in a Gilson fraction collector, and a 5 ul aliquot of 
each fraction was assayed for reactivity in a Packard Auto-gamma counter.
The appropriate fractions were pooled, and 10 ul of 10% deoxycholate (DOC) 
was added to prevent protein aggregation. Covalently-bound [^Ij-pro tein  A
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was approximated by trichloroacetic acid precipitation of the radiolabeled, 
pooled sample and reported as acid precipitable counts.
The western blot assay was utilized as a more sensitive test of virus 
protein purity, as a measure of immune reactivity in infected horses, and as an 
indication of the titer and specificity of antibodies induced in immunized 
rabbits.
Immunoblotting of polypeptides directly applied to nitrocellulose. To 
evaluate the binding of purified monoclonal antibodies to EIAV proteins, 
glycoprotein enriched lentil-lectin fractions (Montelaro, et al., 1983) or intact 
purified virus were "dotted" directly onto a nitrocellulose sheet contained 
within a micro-sample filtration manifold (Schleicher & Schuell Inc., Keene, 
N.H.). The membrane was allowed to dry, and the immunoblot procedure was 
performed essentially as described above with the addition of one step. After 
incubation with the monoclonal antibody, the nitrocellulose sheet was washed 
and incubated with goat anti-mouse IgG (Sigma) for 90 min at a concentration 
of 5 mg/ml in Tris-saline with 3% BSA. The membrane was washed again, 
and all subsequent steps were performed as listed above.
Purification of EIAV gag and guy proteins by reverse-phase HPLC.
Since viral env glycoprotein isolation presented the major obstacle in the 
purification of lentivirus protein components, an extensive survey was made of 
HPLC ion exchange, gel filtration, and reverse-phase columns and
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chromatographic conditions to determine the general adsorption and 
desorption properties of EIAV gp90 and gp45. Glycoprotein enriched samples 
obtained from lentil-lectin affinity chromatography were initially used for this 
purpose. EIAV gp90 and gp45 were found to bind irreversibly or to be 
desorbed very poorly (less than 5% recovery) from the following binding 
matrices in the reverse-phase mode: C18, C8, C3, and cyano (CN). This avid 
binding was irreversible regardless of eluant choice (acetonitrile containing 
formic acid or ammonium acetate, 2-propanol containing formic acid or TFA, 
triethylamine with 1-propanol and /o r formic add), eluant concentration (0- 
100%), or column temperature (20-56 C). All of these columns were stainless 
steel, uBondapak, 3.9 mm x 30 cm, and obtained from Waters Chromatography 
Division (Milford, Ma.).
In contrast, EIAV glycoproteins adsorbed and desorbed efficiently on 
uBondapak phenyl columns (Waters) eluted with acetonitrile and 0.1% TFA. 
When a stainless steel column was employed, a temperature of 37 C yielded 
the best recoveries, but when a Radial-pak cartridge contained within a high 
pressure radial compression chamber (RCM, Waters Chromatography 
Division) was utilized, room temperature was suffident. Increasing the 
temperature or altering the elution solvents did not enhance protein recovery. 
Based on these observations, the radially compressed phenyl cartridge with 
acetonitrile and TFA as the eluting solvent was chosen for further 
development.
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A HPLC technique for purifying the four EIAV gag proteins (p26, pl5, 
p l l ,  and p9), and two env glycoproteins (gp90 and gp4S) in a single step from 
gradient purified virus was accomplished and has been reported (Ball, et al., 
1988). The purification procedure was determined by judiciously applying a 
variety of multistep acetonitrile gradients at ambient temperatures. Each 
gradient was evaluated for protein recovery, eluted protein homogeneity, and 
retention of antigenicity. Detailed analyses revealed that the resolving capacity 
of the phenyl functional group was remarkably sensitive to the slope of the 
acetonitrile gradient utilized; that is, very minor differences in acetonitrile 
concentration resulted in dramatic differences in protein resolution. Thus, 
variation of the acetonitrile gradient was the primary parameter altered in 
enhancing protein separation.
Viral proteins were separated on a Waters uBondapak phenyl, 8 mm x 
10 cm, Radial-pak cartridge employing the Radial Compression Module-100 
(Waters). A Varian 5000 HPLC unit consisting of two proportioning valves, a 
single-piston pump, a central microprocessor, and a manual high pressure loop 
injector was utilized for solvent delivery. Eluted proteins were detected by UV 
absorption at 280 nm with a UV-5 (Varian) fixed wavelength detector, and 
chromatograms were recorded by a Recordall Series 5000 recorder (Fisher 
Scientific).
Approximately 10 mg of purified virus in 0.01 M sodium phosphate, pH
7.2, was disrupted in 2 vol of 6 M guanidinium hydrochloride, pH 3.1,
65
immediately before injection. Multiple injections were employed and spaced at 
1 min intervals with no loss of loading efficiency or resolution. Eluted 
products were collected in 0.5 ml fractions, pooled according to the peaks 
observed, and subjected to lyophilization. Chromatography conditions and the 
elution gradient were as follows:
Flow rate: 1 ml/min
Solvent A: acetonitrile with 0.1% trifluoroacetic acid (TFA)
Solvent B: water with 0,1% TFA
Gradient: 0-60% Solvent A, 180 min, multistep linear segments,
0 to 36% Solvent A in 77 min,
36 to 40% Solvent A in 12 min, hold for 10 min,
40 to 43% Solvent A in 12 min, hold for 7 min,
43 to 45% Solvent A in 8 min, hold for 9 min,
45 to 60% Solvent A in 45 min.
The gradient was held at 40%, 43%, and 45% acetonitrile for the times 
indicated to aid in the complete elution of one protein before reaching the 
elution concentration of another. In this way, it was possible to achieve 
baseline separation of proteins which coeluted when a linear gradient of 
acetonitrile was applied.
A wash consisting of a multistep gradient of 2-propanol and water 
containing 0.1% TFA followed each separation. At a flow rate of 0.7 ml/min, 
a shallow, linear gradient to 60% 2-propanol was succeeded by a step gradient
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to 70, 80, 90. and 100% propanol. Each step of the gradient was held for a 
minimum of 10 min to insure the complete removal of bound lipids and any 
remaining viral or cellular proteins. This wash was necessary to maintain good 
protein resolution and extended column life. With routine propanol washing 
between each separation, a single phenyl cartridge was utilized for 12-15 runs 
without observable deterioration. The columns were routinely monitored by 
fractionation of a mixture of protein standards, and were stored in 70% 
acetonitrile.
Protein homogeneity was confirmed by SDS-PAGE, immunoblots with 
reference equine sera, and N-terminal protein sequencing.
Purification of HIV and SIV glycoproteins. Analogous to EIAV, other 
lentivirus glycoproteins have proven to be difficult to purify in quantities 
sufficient for use in diagnostic and/or vaccine development. Therefore, the 
utility of the HPLC procedure used for EIAV was evaulated for the absorption 
and desorption of the major env protein of HIV, gpl20. A 100 ug sample of 
gpl20 purified by immunoaffinity chromatography of infected cell culture 
supernatants (Robey, et al., 1986) was subjected to reverse-phase HPLC using 
a 3 step gradient from 0 - 60% acetonitrile with 0.1% TFA: 0 to 32% 
acetonitrile in 64 min, 32 to 40% acetonitrile in 24 min, and 40 to 60% 
acetonitrile in 30 min. Eluted fractions were subjected to SDS-PAGE and 
Western blot analyses to evaluate the efficacy of the gpl20 isolation (pooled 
AIDS patient sera was supplied by Program Resources of the National Cancer
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Institute, Frederick, Md.).
The usefulness of the newly developed HPLC protocol in lentivirus 
glycoprotein separation was further explored by examining the isolation of HIV 
gpl20 and gp41 from purified virus preparations. Intact HIV was disrupted in 
6 M guinidinium hydrochloride, injected onto the radially compressed cartridge 
(Waters, RCM-100), and a multistep gradient from 0 to 60% acetonitrile with 
0.1% TFA was applied over 160 min. Fractions containing gpl20 were 
selected based on the chromatographic properties established with the purified 
glycoprotein, and confirmed by immunoblotting of the purified protein with 
AIDS patient sera. The location of HTV gp41 was established by similar 
immunoblotting of pooled fractions eluting at greater than 46% acetonitrile.
Finally, isolation of SIV glycoproteins from purified virus preparations 
using similar elution conditions was evaluated. Gradient purified SIV was 
obtained from Dr. M. Murphey-Corb, Delta Regional Primate Center, Tulane 
University, Covington, La.
Notably, the acetonitrile gradient was the only parameter which had to 
be adjusted for optimum resolution with each virus system.
Gas phase sequencing of HPLC purified proteins.
To verify the homogeneity of HPLC isolated viral proteins and 
glycoproteins, separated proteins were subjected to protein sequencing on an 
Applied Biosystems 470-A gas-phase sequencer (Table 6). Resultant
TABLE 6. COMPARISON OF LIQUID AND GAS PHASE 
AUTOMATIC SEQUENCING










ATZ Extraction Butyl chloride
Conversion 25% TFA


















a) Polybrene is a quartenaiy ammonium salt which prevents "sample 
washout" by solvents during the sequencing protocol.
b) The coupling base and cleavage acid used in gas-phase Edman 
chemistry are delivered as vapors and are carried by a stream of inert 
(generally nitrogen).
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phenylthiohydantoin (PTH)-amino acid derivatives were identified by reverse- 
phase HPLC. The sequencing protocol utilized was sensitive to the picomole 
level, so minor contaminants could easily be detected. Soluble protein samples 
(p26, pl5, p l l ,  p9, and gp45) were directly applied to TFA treated glassfiber 
discs, whereas gp90 was electrophoretically transferred to an activated 
glassfiber sheet. In addition to direct sequence analysis, the TM protein, gp45, 
was also sequenced by electrotransfer to a polyvinylidene difluoride (PVDF) 
membrane. The two env glycoproteins were sequenced at least twice since 
there were no previous reports of their direct protein sequences.
The PVDF and GF/C  protein supports were directly inserted into the 
sequenator reaction cartridge by cutting them into 2 x 4  mm strips and evenly 
placing them into the chamber of the upper cartridge block. If polybrene was 
employed to prevent sample washout, it was diluted to 40% with HPLC water, 
applied to the membrane strips, and air dried. These support membranes did 
not require the precycle program, PRE, so the regular sample operating 
program, 03RPTH, was initiated immediately.
Etectrobtotting Qnlfl chemically activated glassfiber sheets (G F/C). 
Untreated glassfiber sheets (GF/C, Whatman Inc., Clifton, N J.) were etched 
with neat TFA for 1 hr in a covered dish as described by Aebersold, et al. 
(1986). The add was decanted and the sheets were dried overnight at room 
temperature in a fume hood. Derivatization of the add-etched glassfiber was 
accomplished by immersion in a freshly made 2% (v/v) solution of 3-
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aminopropyltriethoxysilane (AP) in 97% acetonitrile for 2 min (Figure 7). The 
sheets were then washed at least 10 times in acetonitrile, and cured at 100 C 
for 1 hr.
The electrophoretic transfer of gp90 from a 10% polyacrylamide gel to 
the derivatized glass membrane was achieved in 2 hr at a constant voltage of 
50 volts using a transblotting buffer of 0.025 M N-ethylmorpholine, pH 8.3.
The activated sheets were removed from the transblot sandwich and dried 
between two sheets of Whatman filter paper. Electrotransferred proteins were 
detected by a novel fluorescent staining technique using 3,3’- 
dipentyloxacarbocyanine iodide dissolved in methanol (1 mg/ml) and diluted 
tenfold in 0.05 M sodium bicarbonate, pH 8.2. Protein bands were visualized 
under a short wavelength ultraviolet light and excised from the activated glass 
with a sharp razor blade (Applied Biosystems User Bulletin, Issue No. 25, 
1986).
Electrotransfer la  PVDF. Small amounts of polypeptide can be 
directly spotted or electroblotted onto a PVDF (Immobilon) surface, stained 
with Coomassie blue, and directly sequenced in an automated gas-phase 
sequenator without prior chemical activation (Matsudaira, 1987).
Following SDS-PAGE, the gel was soaked in transfer buffer (0.01 M 3- 
[cyclohexylamino]-l-propanesulfonic acid, 10% methanol, pH 11.0) for 5 min 
while the PVDF membrane (0.45 wm) was rinsed in methanol. Although 
published protocols recommended electroeluting for 10-30 min at 0.5 A
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FIGURE 7. AMINOPROPYL-GLASS (AP-GLASS) CHEMISTRY OF 
ACTIVATION*
a) 3-Aminopropyltriethoxysilane was used to derivatize acid-etched glass 
fiber supports. The resulting aminopropyl-glass fiber sheets were used 
in electroblotting SDS-coated proteins at an alkaline pH. Aminopropyl 
groups (pKj, = 10.5) are known to retain their positive charge at pH 
8 in the transfer procedure, and the cured silane linkage to be stable 
to sequencing chemistry.
+NH3 - CH2 - CH2 - CH2 - Si - O - - GF/C
(Matsudaira, 1987; LeGendre and Matsudaira, 1987), preliminaiy 
electrotransfers of low molecular weight standards indicated a longer elution 
time was needed. Isolated gp45 and a lane of low molecular weight standards 
were electroeluted for SO min at 0.6 A. The membrane was rinsed for 5 min 
in deionized H20 , stained with 0.1% Coomassie blue in 10% methanol, and 
destained in 45% methanol, 10% acetic acid. The stained gp45 band was 
removed with a sharp, single-edge blade, and inserted into the sequencer 
cartridge for sequencing.
Direct application Iq glassfiber disc. Undiluted polybrene was 
applied to a TFA-treated glassfiber disc. The disc was returned to the reaction 
cartridge and a 3.3 hr precycle program (PRE) was ran before the addition of 
the sample. The lyophilized protein sample was solubilized in 50-75 u\ of 
0.1% TFA and loaded onto the precycled disc 30 ul at a time.
Automatic Gas-phase sequencing. The N-terminal sequence of each 
purified protein was determined by automated Edman degradation and HPLC 
identification of the PTH-amino acid derivatives obtained from each Edman 
cycle (Figure 8). The first step in this degradation was the selective coupling 
of the protein’s N-terminal amino acid with the Edman reagent, 
phenylisothiocyanate (PITC) in the presence of the coupling base, trimethyl 
amine. Cleavage of the PITC-amino acid from the remainder of the protein
t
was effected by the addition of TFA. Repeated cycles of coupling and 
cleavage occurred at the newly-formed N-terminus left by the previous cycle.
FIGURE 8. EDMAN CHEMISTRY
C oup ling
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The cleaved anilinothiazolinone (ATZ)-amino acid derivative was not suitable 
for HPLC identification, therefore it was converted into the more stable 
phenylthiohydantoin (PTH) derivative prior to HPLC analysis. The ATZ- 
amino adds were extracted from the supporting matrix with butyl chloride, 
transferred to a separate reaction vessel, and converted to the PTH form by 
25% aqueous TFA. All of the reagents/solvents were passed over the fixed 
protein film contained on a glassfiber disc as per programmed routine 
(Applied Biosystems User Manual).
HPLC analysis of Ih£ PTH-amino adds. The PTH-derivatized amino 
adds generated from the sequencer were analyzed in a Waters PicoTag HPLC 
system equipped with 2 high performance pumps (Waters Model 510), a 
temperature control module, a variable wavelength UV detector (Waters 
Model 481), an automatic sample injection module (WISP 710B), and a control 
system for data acquisition and reprocessing (Waters 840). The WISP limited 
volume inserts containing the derivatized amino adds were removed from the 
sequenator and placed under vacuum until dry. The amino add sample was 
resolubilized in 50 ul of 20% acetonitrile and inserted into the WISP 
autoinjector. A standard PTH mixture including 19 PTH amino acids (no 
cysteine derivative), diphenylthiourea (DPTU), and dimethylphenylthiourea 
(DMPTU) was prepared in 100% acetonitrile, stored at -20 C, and diluted 
fresh each day to a final concentration of 10 pmol/ul.
PTH derivatives of the amino adds were identified by reverse-phase
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HPLC using a C18, 3.8 mm x 15 cm, Waters Novapak column at 54 C, and a 
gradient of 0.014 M sodium acetate, pH 3.9, containing 5%  aqueous 
tetrahydrofuran (THF) (Solvent A) and acetonitrile (Solvent B). Local UV 
absorbance maximum for most PTH amino adds lies between 266 and 270 nm 
(Applied Biosystems User Bulletin Issue No. 14, 1986), hence the detection 
wavelength was set at 269 nm. This protocol was able to resolve all of the 
PTH amino adds in the standard mixture and to detect the amino adds at the 
picomole level. The standard mixture was run after every tenth residue to 
insure that the retention times remained constant (Figure 9).
Because repeated add treatment of the protein sample during Edman 
degradation gradually fragments the sample into a series of smaller peptides, 
the background level steadily increases. Thus, amino add assignments at each 
cycle were made in relation to both the background level of the amino acids 
present, and to the carryover from preceding cycles due to incomplete 
degradations. Consecutive chromatograms were compared for spedfic increase 
and decrease in peak heights, and the amino add residue was identified by a 
quantitative distinction between the level of one PTH amino add at a  given 
cycle versus the background level of that amino add at preceding and 
subsequent cycles.
Production of polyclonal antisera.
HPLC purified proteins. High titer polyclonal antisera to purified
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FIGURE 9. STANDARD PTH-AMINO ACID POOL 
SEQUENCING CHROMATOGRAM.
Chromatogram of PTH-amino acid standards depicting relative HPLC 
























EIAV proteins were produced in female, New Zealand white rabbits. The 
initial protein inoculum was emulsified in Freund’s complete adjuvant, whereas 
subsequent antigen boosts were prepared in adjuvant lacking Mycobacterium. 
Equal volumes of antigen and adjuvant were added to separate, siliconized, 
glass syringes and mixed or sonicated until the emulsification was complete. 
Typically, 100 - 500 ug o f the pure protein was diluted to 1-2 ml in 0.86% 
saline for the initial injection, while 50 - 200 ug of of antigen was used for 
boosting the immune response.
Rabbits were injected intramuscularly (once in each hip) and 
subcutaneously across the back of the neck with between 0.1 and 0.4 ml of the 
inoculum (Dr. Linda Adams, personal communication). Boosting doses of 
emulsified antigen were injected every 2 to 4 weeks.
Preimmunization and weekly postimmunization blood samples were 
acquired from each rabbit. The outermost ear vein was nicked with a sharp, 
single-edge blade, and the ear was placed under a mild vacuum (40-90 mm 
Hg) to promote bleeding (Cathy McVay, personal communication). Direct 
pressure was applied to the cut site for several minutes to insure that the 
bleeding had completely stopped and to avoid hematoma formation. A single 
heart puncture was utilized for the final bleed and euthanasia of the animal.
Chemically synthesized peptides. Synthetic peptides representing key 
regions of gp90 were employed as immunogens to induce polyclonal, anti- 
peptide sera in rabbits. In general, the same protocol listed above was
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followed. The initial peptide dose was between 8 and 10 mg if the peptide was 
not bound to a carrier protein, while a 3-5 mg dose was utilized if the peptide 
was linked to a high molecular weight carrier, such as keyhole limpet 
hemocyanain (KLH) (Sigma). Similar peptide concentrations were used as 
boosts. Adjuvant, immunization schedules, modes of injection, and bleeds were 
identical to the purified protein protocol.
Peptide linkage to KLH was promoted by the crosslinking reagent, 
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). In brief, 3 mg of MBS 
in 300 ul of dimethylformamide was added dropwise to a 1 mg/ml solution of 
KLH in 0.01 M phosphate, pH 7.4, while stirring at room temperature. The 
mixture was stirred for 30 min and subjected to size exclusion chromatography 
to separate the nonbound MBS. Sephadex G-25 (3 X 40 mm) equilibrated in
0.05 M phosphate, pH 6.01, was employed for this purpose. The crosslinked 
KLH-MBS was collected and the pH was raised above 7.0 with 10 N NaOH 
for peptide linkage. The peptide was added dropwise (10 mg in 1 ml of 0.01 
M phosphate, pH 7.4) and mixed for 3 hr at room temperature. Linked 
peptide was dialyzed against 0.1 M ammonium bicarbonate and lyophilized to 
dryness.
Computer Algorithms.
Secondary and antigenic structure predictions, and comparisons of 
envelope glycoproteins of selected retroviruses were accomplished by closely
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examining the predictive algorithms of hydrophobic and hydrophilic character, 
alpha helix and beta sheet propensity, amphipathic helical regions, and 
localized areas of accessibility and mobility. The EIAV TM protein, gp45, was 
evaluated and compared to the HIV TM model presented by Gallaher, et el. 
(1989). The SU proteins of several virus systems were examined and 
compared to EIAV gp90.
Deduced amino acid sequences of the env gene products of the 
following viruses were evaluated: the oncornavirus RSV (Schwartz, et al.,
1983), the slow leukemogenic viruses BLV (Sagata, et al., 1985) and HTLV-1 
(Seiki, et al., 1983), and the lentiviruses EIAV, cell-adapted strain (Rushlow, et 
al., 1986), visna virus, Icelandic strain 1514 (Sonigo, et al., 1985), HIV-1, LAV 
strain (Wain-Hobson, et al., 1985), and SIV, African green monkey isolate 
(Franchini, et al., 1987; Hirsch, et al., 1987). The protein sequences were 
numbeicd beginning with the initial methionine in the env open reading frame.
Hydropathy. The hydropathic character of each glycoprotein was 
analyzed using the Bionet program PEP and the communication software 
KERMIT. The method of Hopp and Woods was applied to find the point of 
greatest local hydrophilicity. Since hydrophilic sites tend to be found on the 
water-exposed surface of proteins and thus are more evident than nonpolar 
regions, hydrophilicity has been proposed as an indicator of immunogenicity 
(Hopp and Woods, 1981). Each amino acid was assigned a numerical 
hydrophilicity value (Table 7) which were repetitively averaged along the
TABLE 7. HYDROPHILICITY SCALE
USED BY HOPP AND WOODS"
Amino add s. kcal/molb Hvdrophilicity value
Arginine +3.0 +3.0
Aspartic acid +2.5 +3.0*
Glutamic acid +2.5 +3.0*
Lysine +3.0 +3.0
















a) Taken from Hopp and Woods, 1981.
b) Solvent parameter values assigned by Levitt (1976).
c) Amino acid values adjusted from the original values given by Levitt.
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length of the poloypeptide chain generating a series of local hydrophilicity 
values (Hopp and Woods, 1981). Window averaging at residue i was 
calculated across 7 residues, from i-3 through and including i+3.
Specificity of antibody binding, however, is not strictly limited to 
hydrophilic regions. Hydrophobic interactions and the exclusion of water from 
the interacting surfaces of proteins could also contribute to the energy of 
antibody binding (Berzofsky and Berkower, 1989). Therefore, the parameters 
of Kyte and Doolittle (1982) which reflect the contribution of both the 
hydrophobicity and hydrophilicity of each amino acid were also utilized. The 
hydropathy values reported by Kyte and Doolittle (Table 8) were averaged 
over a span of 7 amino acids within overlapping segments differing by one 
residue. This algorithm was employed to localize transmembrane segments, 
and to visualize the overall hydrophobic character of the protein. 
Transmembrane regions were estimated as continuous segments of 19 or more 
amino acids with an average hydrophobic value of 1.6 or greater over the 
entire region (Kyte and Doolittle, 1982).
Surface prediction foe antigenic sites. Parker, et al. (1986) presented a 
novel hydrophilicity scale derived from HPLC analysis (retention time) of 20 
model synthetic peptides, Ac-Gly-X-X-(Leu)3-(Lys)2-amide, where X was 
substituted with one of the 20 amino acids (Table 9). It was presumed that 
the retention time of a peptide directly reflected the summed hydrophobicity 
and hydrophilicity of the amino acid residues in that peptide. Two additional


















Glutamic acid -3.5 -3.9
Glutamine -3.5 -33




Taken from Kyte and Doolittle, 1982.
Table 9. HPLC Hydrophilicity Scale"
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Retention* HPLC













Arg + 0.9 +4.2
Thr +03 +5.2






Asp -2.6 + 10.0
alpha-amino -2.4 +9.7
alpha-carboxy -5.2 + 14.3
a) Extracted from Parker, et al., 1986.
b) Retention coefficients were determined from the retention times of the 
model peptides when evaluated by reverse-phase HPLC.
c) The amino acid residue with the maximum retention coefficient was 
assigned a hydrophobic value of -10, and the amino acid residue showing 
the minimum retention coefficient a hydrophilic value of +10. Remaining 
amino acids were scaled proportionally.
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parameters, accessibility and flexibility (or mobility) were added to the surface 
prediction to improve the prediction of antigenic regions. These parameters 
were chosen because of their individual high scores at predicting antigenic 
sites. Separate plots reflecting the HPLC, accessibility, and flexibility 
parameters were combined to produce a composite surface profile. The 
composite plot was reported to correlate well to known antigenic sites and X- 
ray-determined surface accessible sites. The authors recommended that sites 
with a surface profile value greater than 50% be chemically synthesized to 
produce anti-peptide antibodies capable of recognizing linear antigenic 
determinants on the native protein (Parker, et al., 1986).
Each of the glycoproteins were analyzed by the individual parameters 
(hydrophilicity, flexibility, accessibility), and a composite surface profile was 
computed and plotted. Residues with composite profile values greater than 
50% were preferentially synthesized (below). This predictive algorithm was 
acquired from the Alberta Peptide Institute, University of Alberta, Canada.
Secondary structure predictions. Prediction of secondary structure from 
deduced amino acid sequences was initially accomplished by application of the 
rules of Chou and Fasman (1974, 1978). When Chou-Fasman parameters were 
computed, the BIONET STRUCTURE program was employed, however most 
of the sequences were reported as having no obvious preference for a specific 
structure. Thus, the Chou-Fasman rules were applied by closely examining the 
contribution of each amino acid in nucleation, continuation, and breaking of a
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particular secondary structure and by altering the segment lengths which were 
averaged across the protein. Chou-Fasman potentials which were utilized are 
listed in Table 10.
In addition to Chou-Fasman, the secondary structure assignments for 
gp90 were evaluated in light of the predictive algorithms of Garnier, et al. 
(1978), Gibrat, et al. (1987), and Qian and Sejnowski (1988) using the 
SYBYL/BIOPOLYMER, PREDICT_SECONDARY program on a VAX 750 
host system. This set of algorithms was also utilized to predict the secondary 
structure, if any, of the chemically synthesized peptides. Peptide secondary 
structure plots were facilitated by the SYBYL molecular graphics software on 
an Evans and Sutherland PS-390 interactive graphics terminal.
Many fibrous proteins are constructed from parallel right-handed 
alpha-helices with amphipathic character (3.5 residues per turn with one face 
polar and the opposite face apolar) which coil around each other forming a 
left-handed supercoil known as a coiled-coil (Venable, et al., 1989). The 
interhelical contacts are often mediated by hydrophobic interactions on the 
repeating faces of the helices. The most commonly encountered repeat is a 7 
amino acid heptad (a, b, c, d, e, f and g) with hydrophobic residues at positions 
a and d, and charged and polar residues at the other positions (Kodama, et al., 
1990). A strong correlation between T cell antigenic sites and amphipathic 
helices has been reported and an optimized algorithm for the prediction of T 
cell epitopes based on the amphipathic helix model has been developed
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TABLE 10. ASSIGNMENT OF AMINO ACIDS AS FORMERS, BREAKERS, 
AND INDIFFERENT FOR HELICAL AND BETA-SHEET REGIONS IN 
PROTEINS BASED ON P , AND Pb VALUES*
Helical
residues
P . assignment* Beta
residues
assignment1
GLU 1.53 Ha MET 1.67 Hb
ALA 1.45 Ha VAL 1.65 Hb
LEU 134 Ha ILE 1.60 Hb
HIS 134 ha CYS 130 hb
MET L20 ha TYR 139 hb
GLN 1.17 ha PHE 138 hb
TRP 1.14 ha GLN 133 hb
VAL 1.14 ha LEU 132 hb
PHE 1.12 ha THR 130 hb
LYS 1.07 Ia TRP 1.19 hb
ILE 1.00 Ia ALA 0.97 Ib
ASP 0.98 ia ARG 0.90 ib
THR 032 ia GLY 031 ib
SER 0.79 ia ASP 030 ib
ARG 0.79 ia LYS 0.74 bb
CYS 0.77 ia SER 0.72 bb
ASN 0.73 ba HIS 0.71 bb
TYR 0.61 ba ASN 0.65 bb
PRO 0.59 Ba PRO 0.62 bb
GLY 0.53 Ba GLU 036 Bb
a) Chou and Fasman (1974)
b) Helical assignments: Ha, strong alpha helix former;
ha, alpha helix former;
la, weak alpha helix former;
ia, alpha indifferent;
ba, alpha helix breaker;
Ba. strong alpha helix breaker.
Ia assignments are also given to Pro and Asp when located near the N-terminal 
helix as well as Arg near the C-terminal helix.
c) R-sheet assignments: Hb, strong beta-sheet former;
hb, beta-sheet former;
lb, weak beta-sheet former;
ib, beta indifferent;
bb, beta-sheet breaker;
Bb, strong beta-sheet breaker, 
bb assignment is also given to Trp when near the C-terminal beta region.
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(Margalit, et al,, 1987). This algorithm first converts the amino acid sequence 
into a sequence of hydrophobicity values which are then divided into 
overlapping blocks. In each of the blocks, a search for periodicity in 
hydrophobicity consistent with the amphipathic helical structure is made. 
Implicit in the analysis is the capability of a specific sequence of residues to 
form an alpha helix, and only then is the propensity for an amphipathic helix 
considered. To evaluate the stability of the amphipathic helical segments, the 
length of the segment and the amphipathic character around 100 or 120 
degrees of the individual blocks are computed into an amphipathic score (AS). 
A segment that has an AS above a certain threshold is reported as 
amphipathic and stable. In this way, the prediction of a short segment of high 
intensity can be made as well as a longer segment with blocks of lower 
intensity (Margalit, e al,, 1987). The program is written in FORTRAN 77 and 
runs under the VMS operating system on a VAX 750 host system. When a 
block length of 11 is employed, the program uses a threshold AS of 4, whereas 
when a block length of 7 is evaluated, the program then uses a threshold of 8 
for the amphipathic score.
The AMPHI program was employed not only to predict T  cell epitopes, 
but to confirm the helical structure predictions and to evaluate the distribution 




Peptide bond formation is facilitated by the bifunctionality of the alpha 
amino acids and involves a condensation-dehydration reaction resulting in an 
amide bond. Amide bond formation is an energy-requiring reaction, 
consequently one of the groups contributing to the desired amide, either the 
carboxy or amino group, must be activated (Bozansky, 1984). In its simplest 
form, peptide synthesis involves 5 steps:
1. Synthesis of the carboxyl component by blocking the amino group, 
H2N-CH(Rl)-COOH — > Y-NH-CH(Rl)-COOH (Carboxyl
component)
2. Synthesis of the amino component by blocking the carboxy group, 
H2N-CH(R2)-COOH -----> H2N-CH(R2)-CO-Z (Amino component)
3. Activation of the carboxyl constituent,
Y-NH-CH(Rl)-COOH — > Y-NH-CH(Rl)-CO-X (Activated amino 
acid)
4. Peptide or amide bond formation between the activated carboxy group and 
the free amino group,
Y-NH-CH(Rl)-CO-X + H2N-CH(R2)-CO-Z — >
Y-NH-CH(R1)-CO-NH-CH(R2)-CO-Z + HX (Protected dipeptide)
5. Removal of the protecting groups (deblocking) to yield a free peptide, 
Y-NH-CH(R1)-CO-NH-CH(R2)-CO-Z — >
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H2N-CH(Rl)-CO-NH-CH(R2)COOH (Free dipeptide). 
Notably, the amino protection group Y can be preferentially removed while the 
carboxy protector Z remains, such that a third amino add can be activated and 
coupled to extend the peptide chain. The activation, coupling, and 
deprotection steps can be repeated until the desired sequence has been 
assembled (Merrifield, 1986). Although the actual reaction conditions are 
quite complex, these fundamental steps form the basis of peptide synthesis 
today. (Synthetic peptides are made from the carboxyl- to the amino-terminus 
while in vivo protein synthesis proceeds from the amino- to the carboxyl- 
terminus.)
Amino add residues such as aspartate, lysine, serine, etc. which contain 
reactive side-chain functional groups (-OH, -COOH, -SH, -NH2) must be 
protected or blocked during the various synthetic reactions. These protecting 
groups must remain intact throughout the synthesis (i.e. be stable to the 
deblocking reagent) and be easily removed in the final cleavage reaction 
(Stewart and Young, 1984).
Solid phase peptide synthesis (SPPS1. In 1963, Merrifield introduced the 
concept of solid phase chemistry whereby peptide synthesis occurred with one 
end of the peptide attached to an insoluble solid support. The solid support, 
usually a polymeric resin, covalently binds the C-terminal amino add and 
renders the peptide insoluble (Merrifield, 1963). In this way, the organic 
chemicals employed at each step can be rapidly filtered and the intermediate
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peptide can be readily washed following each synthetic reaction (Merrifield, 
1986). Many SPPS procedures have been reported in an effort to maximize 
yields and minimize side reactions and racemizations; these protocols vary 
primarily in the properties of the a) solid support, b) protecting groups, c) 
activation agents, d) deblocking reagents, and e) solvent and reaction 
conditions (Atherton, et al., 1988). A general scheme of solid phase synthesis 
is depicted in Figure 10.
The 2 most popular strategies, t-Boc and F-moc, are based on the 
alpha-amino protection group. The /erf-butyloxycarbonyl (t-Boc) group 
protects the alpha-amino group until it is removed by TFA leaving the benzyl- 
based side-chain protectors intact. These latter groups are removed at the end 
of the synthesis by anhydrous hydrofluoric acid (HF). The alternate alpha- 
amino protection group, 9-fluorenylmethyloxycarbonyl (F-moc), is removed 
under basic conditions, while the butyl-based side-chain protecting groups are 
removed with TFA (Stewart and Young, 1984). These 2 strategies are 
complimentary, whereby each peptide to be synthesized can be critically 
evaluated and the best synthesis protocol applied.
A panel of peptides covering all of gp90 (Table 11) and key regions of 
gp45 (table 12) were synthesized by solid phase strategies employing both t- 
Boc (t-butyloxycarbonyl) (Merrifield, 1963; Barany and Merrifield, 1980) and 
F-moc (fluorenylmethoxycarbonyl) (Carpino and Han, 1972) chemistries. 
Further optimization of these strategies was attempted by employing a variety
92
FIGURE 10. SCHEME OF SOUD PHASE PEPTIDE SYNTHESIS.
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The polymer support bears the reactive group X. The C-terminal amino acid has 
2 protecting groups, the labile (L) amino protector and the stable (S) side-chain 
protecting group. After the C-terminal residue is coupled to the resin, deblocking 
reagent is added to remove the labile blocking group, while the stable protection group 
remains intact. The next amino acid is coupled to the aminoacyl polymer by use of a 
suitable coupling reaction and the deblocking step repeated. The final cleavage reaction 
removes the bound peptide from the resin and the stable side-chain protecting groups.
T ab le  11. E IA V  SU Peptides
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Residue Molecular Synthesis
Peptides Numbers Weight Chemistry
l 7-26 2030.0 t-Boc, SAM n
2 22-36 1821.0 F-moc, RAMPS
3 35-53 2207.6 F-moc, RAMPS
4 50-79 3928.7 F-moc, SAM II
4A 60-68 1162.3 F-moc, RAMPS
4B 69-77 1205.5 F-moc, RAMPS
4C 50-58 1490.6 F-moc, RAMPS
5 79-105 30023) F-moc, SAM II
5A 79-94 1796.5 F-moc, RAMPS
SB 92-105 1702.9 F-moc, RAMPS
6 103-122 1916.5 t-Boc, SAM n
7V 123-140 2186.5 F-moc, RAMPS
8V 137-162 3098.7 t-Boc, SAM D
9V 159-173 1609.0 F-moc, RAMPS
10V 171-190 2300.5 F-moc, RAMPS
VI 187-216 4130.5 t-Boc, SAM H
V1D 201-209 899.0 t-Boc, SAM n
V2A 211-230 2350.7 F-moc, RAMPS
V2B 227-245 2091.5 F-moc, RAMPS
V3 241-269 3324.4 t-Boc, SAM II
V3A 241-252 1447.8 F-moc, RAMPS
V3B 254-266 1520.2 F-moc, RAMPS
V4 265-299 3921.0 F-moc, SAM n
V4A 265-284 2248.6 F-moc, RAMPS
V4B 281-299 2078.7 F-moc, RAMPS
V5 294-328 4113.0 F-moc, SAM II
V5A 294-311 1966.5 F-moc, SAM II
V5B 312-328 2279.7 F-moc, SAM II
V5C 305-316 1537.9 F-moc, RAMPS
V6 323-358 2925.7 t-Boc, SAM n
V7A 355-367 1536.7 F-moc, RAMPS
V7B 365-375 1309.3 F-moc, RAMPS
V7C 372-382 1283.4 F-moc, RAMPS
13 381-406 2995.6 t-Boc, RAMPS
11 403-427 3115.5 t-Boc, SAM n
12 424-447 2771.4 t-Boc, SAM II










FD 445-465 1935.7 t-Boc, SAM II
R31 512-524 1550.7 F-moc, RAMPS
R32 522-534 1633.6 F-moc, RAMPS
51 535-547 1630.3 t-Boc, SAM II
R33 537-544 901.1 F-moc, RAMPS
R34 545-557 1560.0 F-moc, RAMPS
95
of activation procedures including symmetric anhydrides, 
diisopropylcarbodiimide (DIPCIDI), hydroxybenzotriazole (Hobt) esters, 
pentafluorophenyl (OPfp) esters, and 3-hydroxy-4-oxo-3,4-dihydrobenzyltriazine 
(Odhbt) esters. Synthesis protocols were either perfomed automatically on a 
Biosearch SAM II automatic peptide synthesizer or manually on a DuPont 
Rapid Multiple Peptide Synthesizer (RAMPS).
F-moc manual synthesis. Manual syntheses were done on a 
commercial RAMPS apparatus consisting of a series of parallel reaction vessels 
and employed the base-labile Fmoc protection group. With this system, 90-150 
mg of 25 distinct peptides can be simultaneously synthesized providing a 
convenient means to synthesize peptide analogs or "nested" peptides for 
immunological studies (Wolfe and Wild, 1989). The protocol recommended by 
the manufacturer was generally followed although, as a precaution, no more 
than 6 peptides were concurrently synthesized (Wolfe, 1987). Additionally, 
coupling and deblocking times were altered as well as some of the activation 
chemistries to optimize the yield of full-length peptide product. Briefly, 0.1 
mM of Dupont Rapid Amide (2,3-dimethoxy-benzhydiylamine) resin was 
swollen in 50% piperidine and dimethylformamide (DMF) prior to the 
coupling of the C-terminal residue to the resin (Penke and Rivier, 1987). The 
standard coupling procedure employed 0.25 mM (2.5-fold M excess) of 
pentafluorophenol derivitized amino acids and 0.1 mM 1-hydroxy be nzotriazole 
(HOBT) in DMF. Amino acids which were not amenable to OPfP ester
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activation were activated by preformed symmetrical anhydrides (arginine), 
carbodiimide (via isourea formation) (alanine), HOBT esters (histidine and 
cysteine), or Odhbt esters (serine and threonine). OPfP and Odhbt esters were 
purchased from DuPont and were used directly. HOBT esters, symmetric 
anhydrides, and carbodiimide activated amino acids were constructed from the 
free F-moc amino acids immediately before use. These reaction mixtures 
consisted of 0.5 mM of F-moc amino acid in dichloromethane (DCM) with 
0.25 mM DIPCIDI for symmetric anhydride formation; equimolar 
concetrations (0.25 mM) of the F-moc amino acid, HOBT and DIPCIDI to 
form HOBT esters; and 0.25 mM of the F-moc amino acid dissolved in 5 parts 
DCM to 1 part DMF and 0.25 mM of DIPCIDI to achieve carbodiimide 
activation (Stewart and Young, 1984; Wolfe, 1987). The key to these alternate 
activation protocols was the ratio of protected amino acid to DIPCIDI which 
were mixed for 5 min at 0 C followed by the addition of 1 equivalent of 
HOBT relative to the protected amino acid (Wolfe and Wilk, 1989). Each 
amino acid, regardless of the method of activation, was coupled for 1 hour at 
room temperature followed by a series of washes (3 X DMF, 3 X methanol, 4 
X DMF) to effectively remove all reaction products from the resin.
Side-chain protecting groups included t-butyl for tyrosine, threonine, 
serine, glutamate, and aspartate; butyloxycarbonyl for lysine; N-(2,2,5,7,8- 
pentamethyl)chroman-6-sulfonyl (PMC), Advanced ChemTech) and 4-methoxy- 
2,3,6-trimethylbenzenesulphonyI (MTR) for arginine; trityl and t-butyl for
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cysteine; and trityl for histidine (Biosearch).
Following each coupling, removal of the Fmoc group was accomplished 
by treatment with a 1:1 solution of piperidine and DMF for 18 min, and the 
wash procedure was repeated. The alternate shrinking with methanol and 
swelling with DMF assures the removal of piperidine which would interfere 
with the next coupling reaction (Carpino and Han, 1972). After the final 
methanol rinse, the resin was air dried for 10 min under vacuum.
The completeness of both the coupling and deblocking steps were 
monitored by the Kaiser or Isatin test which detect the presence of free amino 
terminal groups (Kaiser, et al., 1970; Wolfe, 1987). The Isatin assay was used 
to monitor the completion of coupling of any amino acid to proline and the 
efficiency of Fmoc removal after the coupling of proline. Peptide bond 
formation was considered complete if the color assay indicated a coupling 
efficiency of 90% or greater. A dark color reaction after deblocking indicated 
the thoroughness of Fmoc removal. If either the coupling or deblocking 
appeared incomplete, the reaction was repeated and the efficiency of the 
reaction reevaluated. However, several problems with these qualitative assays 
have been noted and therefore, must be utilized with discretion (Fontenot, et 
al., 1990). Both the Kaiser and Isatin assays were provided in kit form from 
DuPont and were performed exactly as recommended by the manufacter.
Cleavage of the final peptide product from the resin support and 
removal of side-chain protecting groups was facilitated by TFA in the presence
of ethanedithiol (EDT). Two cleavage mixtures were utilized depending on 
the presence of arginine in the peptide sequence. Arginine-containing peptides 
were cleaved for 16 hr in a solution of 90% TFA, 4% water, 1% thioanisole, 
and 5% EDT; peptides lacking arginine were cleaved for 16 hr in a solution 
of 90% TFA, 5% water, and 5% EDT (DuPont Technical Report, RAMPS 
Update. 1987). The cleavage mixture containing the cleaved peptide was 
filtered into a polypropylene tube and the resin was rinsed several times with 
TFA to insure the complete recovery of the cleaved peptide. The volume of 
TFA was reduced to 1-2 ml under a stream of nitrogen, and the peptide was 
precipitated by the addition of cold diethyl ether and incubation in a dry ice 
bath. The ether layer containing the remaining TFA and the scavengers was 
discarded. The ether precipitation was repeated 4 times followed by 2 ethyl 
acetate:diethyl ether (1:2) extractions. Precipitated peptide was dissolved in 2- 
8 ml of water, cold diethyl ether added (15-20 ml), and the slurry placed in the 
freezer overnight. Lastly, the ether was decanted and the peptide placed under 
a stream of nitrogen to evaporate residual ether before lyophilization.
Automated F-moc synthesis. The Biosearch SAM n  automatic peptide 
synthesizer is computer driven with each step electronically regulated by the 
opening and closing of a series of valves which control the flow of reagents 
into the reaction vessel. Algorithms are easily adjusted and can accomodate 
changes in reaction times and reagent volumes. In contrast to manual 
synthesis, only 1 peptide can be synthesized at a time, but the peptide yield is
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considerably higher ranging from 500-800 mg.
One gram of a benzyloxybenzyl alcohol resin with the C-terminal amino 
acid residue attached (Fmoc-amino acid-p-benzyloxybenzyl) was employed 
which generated a carboxyl C-terminus in contrast to the C-terminal amide 
acquired from the amine resin used with the RAMPS system (Sivanandaiah 
and Gurusiddappa, 1981). Thus, the first step in the automatic Fmoc strategy 
was deprotection of the attached residue by addition of a solution of 30% 
piperidine in 1:1 toluene:DMF for 3.15 min followed by a series of washes (1:1 
DCM:DMF) to remove the excess piperidine. A standard coupling cocktail 
consisted of equimolar (0.4 M) concentrations of DIPCIDI, HOBT, and the 
protected Fmoc amino acid. Each of these were added to separate reservoirs 
and automatically added to the reaction vessel in the correct concentration.
The 2 exceptions were asparagine and glutamine which were activated by 
pentafluorophenyl esters (Atherton and Sheppard, 1985). The OPfP esters 
were prepared just prior to use and manually added to the reaction vessel. A 
separate program was written so that immediately before the addition of 
aspargine or glutamine, the reaction vessel was filled with wash solution and 
paused. Synthesis was then resumed by initiation of the "empty" process.
Once all of the solvent had drained and the "mix” step had begun, the vessel 
was carefully removed, the activated amino acid added, and the reaction vessel 
replaced. Finally, after trying several procedures, it was discovered that 
leucine required symmetric anhydride formation (2:1 leucine:DIPCIDI) in
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order to achieve peptide bond formation. All Fmoc amino adds were singly 
coupled for 1 hr except for any combination of tryptophan, valine, leudne and 
methionine; these reactions were extended to 2 hr to effect adequate coupling 
effidency (personal observation; Dr. R. Rao, personal commmunication).
Protected Fmoc amino adds were acquired from Advanced Chem Tech 
and included the following side-chain protecting groups: acetaidomethyl 
(ACM)-cysteine, MTR-arginine, trityl-histidine, BOC-lysine, and O-butyl- 
aspartate, glutamate, serine, threonine and tyrosine.
The ninhydrin (Kaiser) assay was performed on new amino acid stocks 
to insure the stablility of the Fmoc protection group and after difficult Fmoc 
linkages to evaluate the effidency of coupling. The protocol was acquired 
from Biosearch technical service (personal communication). Solution A was 
prepared by diluting 2 ml of Solution A l (40 gm of phenol in 10 ml of ethanol 
mixed with 65 mg of KCN in 100 ml of water) to 100 ml with pyridine; 
solution B was made by dissolving 2.5 gm of ninhydrin in 50 ml of methanol. 
Briefly, 50 ul of each solution was added to a small number of resin beads, 
heated for 5 min at 80 C , and the color of the solution and the beads 
compared to a protected Fmoc amino add control. If necessary, the beads 
were washed in ethanol prior to the addition of the ninhydrin solutions.
After the synthesis was complete, the resin was rinsed with methanol for 
5-8 min, transferred to a glass vial, and dried overnight under vacuum.
Cleavage of the peptide from the resin and removal of the side-chain
101
protecting groups was accomplished by placing the dry, peptide bound resin in 
a round bottom flask with a stir bar and adding 10-20 ml of 70% TFA, 25% 
DCM and 5% dimethyl sulfide (DMS). This cleavage mixture was utilized for 
the cleavage of peptide sequences lacking arginine and tryptophan, and was 
stirred for 2 hr at room temperature. If the peptide contained arginine, the 
cleavage solution was composed of 90% TFA, 3% EDT, 5% thioanisole, 2% 
anisole, and was stirred for 8 hr. Those sequences containing tryptophan but 
not arginine were cleaved for 2 hr in 70% TFA, 30% DCM and 2% indole 
(Hankila, 1988).
The detached peptide was precipitated with cold anhydrous ether and 
incubated in a dry ice bath for 30 min. The cleavage slurry was filtered 
through a fritted glass funnel such that the insoluble resin and the precipitated 
peptide were retained and the cleavage solvent was collected in a vacuum 
flask. The flask was changed and the peptide was solubilized in 10-50% acetic 
acid. Acid soluble peptide was filtered into the vacuum flask leaving the resin 
behind. Any trace of ether was removed by blowing nitrogen over the peptide 
solution prior to lyophilization.
Automated t-Boc peptide synthesis. Synthesis in the t-Boc mode was 
the first to be developed and has been thoroughly analyzed for technical 
difficulties and side reactions (Barany and Merrifield, 1978). Modified 
polystyrene resins are most often utilized and are typically sized to 100-200 
mesh with 1% crosslinking (Biosearch manual). In this study, the Merrifield
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copoly(styrene-l%-divinylbenzene) chloromethyl resin with the C-terminal 
amino acid already attached and the amine resin, 4-methylbenzhydrylamine 
(MBHA), which yields C-terminal amides were routinely employed (Merrifield, 
1963; Atherton, et al., 1975). In standard operation, the driver program 
facilitates the attachment of the C-terminal residue to the MBHA resin and 
"caps" the resin for the remainder of the synthesis (Figure 11). The synthesis 
cycle consists of deblocking, base wash, coupling and capping.
Deprotection of the t-Boc group from the alpha-amino function was 
typically effected by 45% TFA with 2.5% anisole in DCM. If tryptophan was 
part of the peptide sequence, 2.5% dimethylphosphite was added to the 
deblocking reagent; deblock in the absence of tryptophan, but in the presence 
of methionine or cysteine was prepared with 2% EDT (Biosearch manual). 
Following several DCM and DMF washes, the residual TFA and the resultant 
alpha-amine salt were neutralized with 10% diisopropylethylamine (DIPEA) in 
methylene dichloride (Figure 12). Activation of the coupling reaction was 
usually accomplished with 0.4 M DIPCIDI which was mixed in line with an 
equimolar solution of t-Boc protected amino acid. The activated amino acid 
mixture was then delivered to the reaction vessel for coupling to the free 
amino group of the resin-bound peptide. The last step in the cycle was 
capping or blocking of any unreacted alpha-amino groups by the powerful 
acylating reagent, 0.3 M acetyl imidazole (Figure 12). Acetylation of unreacted 
alpha-amino groups has been shown to be important in the prevention of
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The resin is deprotonated followed by DIPCIDI-activated coupling.
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FIGURE 12. Standard t-BOC Synthesis
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deletion peptide sequences. In addition, these truncated peptides have been 
reported to be easier to separate from the full length product than those 
missing 1 or 2 residues (Stewart and Young, 1984).
The side-chain protecting groups were benzyl esters for serine, 
threonine, glutamate, and aspartate; 2,6-dichlorobenzyl for tyrosine; 4- 
methylbenzyl for cysteine; tosyl for arginine and histidine; and 2- 
chlorobenzylcarbonyl for lysine. Protected t-Boc amino acids were purchased 
from MilliGen/Biosearch (San Rafael, Ca.) and Advanced ChemTech, Inc. 
(Louisville, Ky.).
Although double couplings were routinely employed with the t-Boc 
strategy, difficult couplings were monitored for completeness by the Kaiser 
(ninhydrin) colorometric test and a third coupling performed if necessary 
(Kaiser, et aL, 1970; Sarin, et al., 1981). Additionally, efficiency of the 
acetylation reaction was evaluated at random using the Kaiser assay.
After complete evaporation under vacuum, the dried resin was placed in 
a reaction vessel with a magnetic stir bar for cleavage by liquified hydrogen 
fluoride (HF). Anhydrous HF is a highly toxic, corrosive gas (boiling point 19 
C) which is known to promote a number of side reactions and the formation of 
carbonium ions (Erickson and Merrifield, 1973; Merrifield, 1986). Hence, the 
resin was saturated with an ion scavenger (anisole) prior to attaching the 
reaction vessel to the HF apparatus (Multiple Peptide Systems, La Jolla, Ca.) 
situated in a fume hood. This apparatus was equipped with multiple base
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traps leading to a vacuum pump; 2 threaded ports, one serving as a vent, and 
the other leading to a radial distribution manifold; and several 3-way valves 
connecting the HF cylinder, a nitrogen tank, and the reaction vessels 
(Houghton, et al., 1986; Multiple Peptide Systems Manual). The HF cylinder 
was warmed to 50 C and the N2 pressure turned up to approximately 2 PSI 
before the main valve to the HF tank was opened. The reaction vessels were 
placed in a dry ice/acetone bath sitting on a magnetic stirrer and the 3-way 
valve was adjusted to permit the gaseous HF to enter the chilled vessels and 
condense. Condensation was continued until the vessels were filled to the 
desired volume (about 15 ml total volume of anisole and HF per gm of resin). 
Before the main HF cylinder valve was turned off, the 3-way valve was 
switched from the HF to the nitrogen tank. The dry ice bath (-70 C) was 
replaced with an ice/water bath; the resin and HF was allowed to react in this 
configuration for 45-90 min while stirring (Tam, et al., 1983). To remove the 
HF quickly, the vacuum line was directly connected to an aspirator line and 
the aspirator turned to full force. Aspiration was continued until there was no 
visible evidence of acid (20-40 min) and then continued for an addition 15 min 
to remove residual HF. After complete evaporation, the vessels were detached 
from the apparatus and the resin was washed several times with ether to 
eliminate excess scavenger. The crude peptide was recovered from the spent 
resin with 10-50% acetic acid, frozen, and lyophilized.
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Peptide purification and characterization.
As the peptide grows in length, the opportunity for synthetic errors, 
undesirable modifications, and cumulative effects arising from incomplete 
reactions dramatically increases. It is therefore critical to verify the correctness 
and purity of the covalent structure, and detect/identify unwanted peptide by­
products (Fontenot, et al., 1990). Several techniques were implemented to 
separate the desired product from contaminants and to evaluate peptide 
homogeneity, including gel filtration chromatography, analytical and semi­
preparative HPLC, and mass spectrometiy.
Crude peptides were desalted on a Sephadex G-25 (Sigma) gel filtration 
column to remove organic contaminants and to partially separate peptide by­
products on the basis of molecular weight. Swollen Sephadex G-25 beads were 
poured into a glass column (3 cm X S3 cm), equilibrated with 10-20% acetic 
acid, and the void volume (Vo) determined. The peptides were dissolved in 
20-50% acetic acid at a concentration of 2-10 mg/ml, applied to the top of the 
column, and eluted with 10-20% acetic acid. Peptide components were 
detected at 215 nm using an ISCO UA-5 absorbance detector. Fractions which 
corresponded to absorbance peaks were collected manually, frozen and 
lyophilized.
HPLC purification of desalted peptides was performed using a Waters 
600E single pump, multisolvent delivery system equipped with a U6K universal 
injector and 491 variable wavelength UV detector. Eluted peptides were
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detected at 220 nm and chromatograms were recorded by a Linear 1200 series 
recorder (Cole Palmer). For analytical analysis, 5-7 mg of peptide was 
dissolved in a small volume of water with 0.1% TFA, filtered, and injected 
onto the column. A linear gradient from water with 0.1% TFA to 60% 
acetonitrile with 0.1% TFA (1.5% /  min) was applied at a flow rate of 1 
ml/min. A uBondapak C18 radially compressed cartridge (Waters Radial-pak) 
contained within a RCM-100 was utilized for the separation. Peptide 
components corresponding to eluted peak areas were collected, lyophilized, 
and submitted to the College of Basic Sciences, Louisiana State University, for 
characterization by mass spectrometiy.
Plasma desorption mass spectrometry (PDMS) provided a direct means 
of discerning peptide by-products which differ only slightly from the target 
peptide theoretical molecular weight. Mass spectrometric analyses were 
performed on a BIO-ION Nordic time-of-flight spectrometer (Uppsala,
Sweden) which utilizes ^ C f  as the ionization source and an acceleration 
voltage of 18 Kv (Cotter, 1988; Chowdhuiy and Chait, 1989). Peptide samples 
(10-20 micrograms) were applied to nitrocellulose coated foils in a 1:1 solution 
of ethanol and 0.1% TFA. The peptide solution was allowed to adsorb to the 
nitrocellulose surface for approximately 15 min, spun dry, rinsed with water to 
decrease the concentration of sodium ions, and loaded into the instrument (C. 
David, personal communication). The instrument is equipped with automatic 
valves for loading up to 8 samples concurrently and a complete data system
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which provides simultaneous acquisition and processing of the same or 
different spectra with background subtraction and mass calibration (Cotter, 
1988). Lastly, peptides with inconclusive mass data were completely sequenced 
by automatic gas-phase sequencing as previously described.
Once it was determined which HPLC fractions contained the full length 
product, the peptide was subjected to further purification by semipreparative, 
reverse-phase HPLC. A Waters uBondapak C18 stainless steel column (7.8 
mm X 30 cm) was employed with the Waters 600E system. A linear gradient 
(0.5% /  min) from 0 to 70% acetonitrile with 0.1% TFA was applied at a flow 
rate of 5 ml/min. Fifty to 75 mg of peptide was solubilized in water with 0.1% 
TFA, filtered, and injected onto the column. Eluted peptide of the correct 
theoretical molecular mass was collected in 2.5 ml fractions, pooled, and 
lyophilized to dryness.
Notably, peptides which eluted as a single peak when examined by 
analytical HPLC and contained the correct theoretical mass were not subjected 
to semipreparative HPLC purification. When the semipreparative elution 
profile did not clearly match that of the analytical profile, PDMS analysis was 
repeated to verify the full length product. Many peptides were not absolutely 
free of by-products following HPLC separation. Peptides with at least 70% 
purity were deemed acceptable for immunological testing. Those peptides 




Chemically synthesized peptides were reacted against a panel of equine 
immune sera (Table 3) and glycoprotein-specific monoclonal antibodies (Table 
5) by a standard dot blot assay, a recently reported strip-enzyme linked 
immunosorbent assay (S-ELISA) (Lo, et al., 1990), and a novel poly-L-lysine- 
E liS A  immunoassay (PLLrELISA). Equine sera taken at various times post 
infection (Table 4) were reacted against peptides 1, 4, and 6 from the 
conserved env N-terminus, peptides 8V, VI, V3, and V6 from the variable 
region, peptides 11 and 12 from the C-terminus of gp90, and peptides 51 and 
R32 from gp45 by the PLL-ELISA immunoassay.
Peptide immunoblots. Peptides were bound to nitrocellulose in the 
presence of 0.1% carrier BSA by a 12 min fixation with 0.8% glutaraldehyde in 
phosphate buffered saline (PBS) (Elder, et al., 1987). The peptide-bound 
membrane was then washed for 15 min (X 4) with Tris-glycine (0.02 M Tris- 
HC1 with 1.5% glycine) at room temperature and blocked for 30 min at 37 C 
with 3% BSA in Tris-saline (0.01 M Tris-HCl with 0.9% NaCl, pH 7.4).
Primary antibody was diluted in 3% BSA Tris-saline and incubated with the 
nitrocellulose membrane for either 1 hr (horse antisera) or 90 min 
(monoclonal antibodies). The immunoblots were washed extensively with Tris- 
saline and Tris-saline with 0.05% NP-40 as described for protein Western 
blots. Immune reactivity of the monoclonal antibodies was detected by 
incubation with anti-mouse IgG (Sigma) followed by either peroxidase
I l l
conjugated protein A or ^ I-p ro te in  A  Reactivity of immune horse sera was 
detected by incubation with anti-horse IgG (Sigma) followed by peroxidase 
conjugated protein A or anti-horse IgG peroxidase. Unconjugated secondaiy 
antibodies were diluted 1:50 • 1:150 in 3% BSA Tris-saline and reacted for 1 
hr. Peroxidase conjugated antibodies were diluted 1:100 and incubated for 90 
min. The coupled peroxidase enzyme was reacted with 4-chloro- l-napthol 
(0.015 g in 5 ml of methanol mixed with 25 ul of H20 2 in 25 ml Tris-saline) to 
expedite color development. After a short exposure to the 4-chloro-l-napthol 
substrate, nitrocellulose membranes were thoroughly rinsed with deionized 
water and visually scored as positive or negative. Immunoblot results were 
repeated a minimum of 3 times before reporting.
S-EUSA with synthetic peptides. Antibody reactivity was also evaluated 
by S-EUSA and generally followed the published protocol (Lo, et al., 1990). 
Briefly, peptides were glutaraldehyde linked to nitrocellulose exactly as 
described for immunoblots. Areas of the nitrocellulose membrane which were 
bound with peptide were then carefully cut into 1-4 mm squares and placed 
into the wells of an Immulon I 96-well microtiter plate (Dynatech). The wells 
and membrane pieces were blocked for 30 min in Blotto (5% dry milk) to 
reduce nonspecific adherence of antibody. After primary antibody binding, the 
membrane squares were washed with 0.05% Tween 20 in Tris-saline (X 3) by 
using a gentle suction to remove the wash solution. Secondary antibody (at 
saturation) was reacted for 45 min and removed by suction. Following a 30
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min incubation with protein A peroxidase, the membrane strips were washed 
and treated with substrate to reveal antibody reactivity. The ABTS (2,2’- 
azinobis[3-ethylbenzthiazoline sulfonic acid]) substrate was prepared in 0.15 M 
citric acid, pH 4.25, at a concentration of 0.11 mg/ml and incubated for 30-60 
min to assure the detection of any weak reactivities. Absorbance 
measurements were recorded at 410 nm by a MR700 automated ELISA plate 
reader (Dynatech). To avoid blocking the beam, the nitrocellulose squares 
were moved to the side of the wells before the absorbance readings were 
taken.
PLL-EUSA immunoassay. Difficulties with reproduciblity and high, 
nonspecific backgrounds using the dot blot and S-ELISA immunological 
procedures required the development of the PLL-ELISA immunoassay for 
evaluation of antibody reactivity to synthetic peptides. This unique approach 
provided an efficient means of attaching the peptide antigens to the wells of 
microtiter plates with little or no background, and was amenable to multiple 
enzyme detection sytsems, inducing peroxidase-O-phenylenediamine 
dihydrochloride (OPD), urease-urea, and avidin/biotin-OPD.
One of the problems of immunoassays utilizing antigen substrates bound 
to solid supports is the ineffedent absorbance of the relatively small peptide to 
the support resulting in the loss of antigen (subsequently reactivity) during the 
various reactions and wash procedures. Covalent coupling of peptides to the 
immunosorbent matrix is often a tedious procedure which frequently results in
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low yields of coupled peptide. Uncoated surface areas leads to nonspecific 
absorbance of IgG molecules and a high background (Nygren and Karlsson, 
1988; Hobbs, 1989). In contrast, poly-L-lysine (Mr 45-50K) readily adsorbs 
onto the plastic surface of microtiter plates and is easily linked to aldehyde 
functional groups. Various microtiter plates and coupling reagents were 
examined for optimal binding of poly-L-lysine (PLL). A  low background with 
adequate signal (high signal to noise ratio) was achieved when PLL was bound 
to the wells of Immulon I (Dynatech) 96-well microtiter plates and was 
coupled with 1% glutaraldehyde in PBS.
Selected peptides which varied in size and charge were treated with a 
number of blocking solutions and were reacted against a wide range of diluted 
immune horse sera (1:100 to 1:6400) in quadruplicate for 1 hr at room 
temperature. Following extensive testing and evaluation, a combination of 
gelatin, blotto, and glycine for blocking nonspecific reactivity with primary 
antibody dilutions of 1:250, 1:500, and 1:750 was chosen for subsequent assay 
development. To establish the highest dilution of saturating secondary 
antibody, serial dilutions of peroxidase-conjugated anti-horse IgG (1:50 to 
1:1600) were examined (Dr. R J. Siebeling, personal communication). Finally, 
the signal to noise ratio was optimized and was found to be dependent on the 
combination of the solid support, antigen coupling and blocking reagents, 
antibody dilutions, wash solution, and incubation times.
Poly-L-lysine (Sigma) was diluted to 40 ug/ml in 0.05 M sodium
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bicarbonate buffer, pH 9.6; 50 ul of this solution (10 ng) was added to each 
well and allowed to adsorb onto the surface of the wells for 1 hr at room 
temperature. The plates were washed once with PBS, treated with 1% 
glutaraldehyde in PBS for precisely 13 min, and the PBS wash was repeated. 
Test peptides were diluted to 10 ug/ml in PBS, pipetted into the polylysine 
coated wells (50 ul/well), and absorbed overnight in tightly sealed plates.
These concentrations achieved reproducible and presumably saturated coating 
of the peptide antigen. Unbound peptide was removed by washing the wells 
twice with PBS. Nonspecific adherence of antibody was blocked by treating 
each well with 200 ul of 1 M glycine for 1 hr, followed by a 1 hr incubation 
with a  1:1 solution of Blotto: 1% gelatin (Gibco) in PBS. The blocking 
reagents were discarded and the plates blotted dry. Primary antibody was 
diluted in Blotto, added in quadruplicate to the peptide-bound wells (50 
ul/well), and incubated for 1 hr. Unbound antibody was removed by washing 
X 8 with 1 M NaCl with 0.05% Tween 20 using an Ultra Wash 2 automatic 
microplate washer (Dynatech Laboratories). Biotinylated anti-horse IgG 
(Sigma) was diluted 1:400 in Blotto and reacted for 30 min; peroxidase- 
conjugated anti-horse IgG (Sigma) was diluted 1:200 and incubated for 45 min. 
These reagents were individually titered to determine the maximum working 
dilution which still obtained saturation. The wash was repeated (X 8) using 
the automatic washer and the 1 M salt wash solution.
The biotinylated secondary antibody was reacted with a solution of
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avidin DH and biotinylated horseradish peroxidase H  (AB reagent, Vector 
Laboratories, Vectastain ABC kit) before the addition of the OPD substrate to 
enhance the detection of weak reactions. AB reagent was prepared by adding 
1 drop of reagent A and 1 drop of reagent B to 5 ml of PBS with 0.1% Tween 
20, incubating for 30 min, and adding 5 more ml of PBS/ 0.1% Tween 20 for a 
final concentration of 1 drop of AB per 10 ml of solvent (Dr. M. Newman, 
personal communication). This enhancing reagent (49 ul/well) was incubated 
for 30 min and the wash step was repeated. A 1 mg/ml solution of substrate 
(O-phenylenediamine dihydrochloride, Sigma) was prepared in 0.05 M citrate 
buffer, pH 4.0, with 0.015% hydrogen peroxide. To detect bound antibody, 100 
ul of the acidic substrate was quickly added to each well and the plates placed 
in the dark for a minimum of 20 min. Color development was halted by the 
addition of 50 ul of 2.5 M sulfuric add. Finally, absorbance measurements 
were recorded at 490 nm by a MR700 automatic ELISA plate reader 
(Dynatech).
Peroxidase-conjugated secondary antibody was directly reacted with 
OPD substrate (100 ul/well). The plates were placed in the dark and 
incubated for 1 hr before the addition of 2.5 M sulfuric add to stop the 
coloumetric reaction. Again, absorbance measurements were made at 490 nm 
by an automatic plate reader.
Included in each assay was a panel of 10 "normal" horses (EIAV 
negative by Western blot). Positive reactivity was defined as 1 if the
»
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absorbance was greater than 2 X the average absorbance of the normal horse 
panel (NHP), as 2 if the absorbance was greater than 4 X the average 
absorbance of the NHP, as 3 if the absorbance was greater than 6 X the 
average absorbance of the NHP, and as 4 if the absorbance was greater than 8 
X the average absorbance of the NHP. Each reaction was repeated a 
minimum of 3 times before the results were considered reliable and reported.
Several ELISA controls were employed, including the conjugate control 
(no primary antibody) to test nonspecific binding of secondary antibody, the 
substrate control (no primary or secondary antibody) to determine the extent 
of substrate change by the antigen alone, primary antibody control (no 
secondary antibody) to test "peroxidase-like" activity in the primary antibody 
and specificity of the system, and when appropriate, an AB control (no AB 
reagent) to test the specificity of the biotinylated system (Dr. M. Newman, 
personal communication). Notably, these controls were consistently negative 
with an absorbance value at or or less than 0.01.
Monoclonal antibody binding was assayed in the same way except 
peroxidase-conjugated anti-mouse IgG was used and the incubation time was 
increased by 15 min.
CHAPTER 3 
RESULTS
Purification of EIAV ggg and env proteins by reverse-phase HPLC.
Previous studies have described the purification of EIAV gag proteins 
using either conventional gel filtration chromatography (Montelaro, et al.,
1982), or a multistep, HPLC strategy employing two or more reverse-phase 
columns (Henderson, et al., 1987). With careful manipulation of the 
acetonitrile gradient, the purification of both the gag and env proteins of EIAV 
was accomplished in a single step. Using the radially compressed phenyl 
cartridge system, the purified proteins were recovered at an efficiency of 60- 
70%. The flexible phenyl cartridge and radial compression technology resulted 
in significant improvements in separation capabilities, reproducibility, and 
protein yields when compared to the identical phenyl resin contained in a 
stainless steel column. In fact, complete resolution of EIAV gp45 was not 
possible until the compressed cartridge was critically appraised. Moreover, the 
isolated components retained their antigenicity and were suitable for a variety 
of biochemical analyses including protein sequencing. It is noteworthy that the 
purification of EIAV gp90 and gp45 represents the first successful isolation of 
a lentivirus glycoprotein from purified virus preparations.
A representative chromatogram depicting the separation of 10 mg of 
EIAV is shown in Figure 13, and SDS-PAGE analysis of the resolved protein
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Solvent A is acetonitrile with 0.1% TFA, and solvent B is water with 0.1% 
TFA. The gradient is multistep going from 0-60% solvent A in 180 min at a flow 
rate of 1 ml/min. The column is a Waters gBondapak phenyl, Radial-pak 
cartridge, RCM-100. The Indicated protein pools include: A -pll, B-p9, C-gp90, 
D-p26, E-pl5, and F-gp45.
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components is presented in Figure 14. This data demonstrates that the EIAV 
proteins all bind to the phenyl column and efficiently elute in the following 
order (and % acetonitrile): the basic ribonucleoprotein p l l  (30%), the acidic 
core protein p9 (35%), the highly glycosylated, hydrophilic envelope protein 
gp90 (40%), the major core protein p26 (43%), the fatty acylated matrix 
protein pl5 (45%), and the hydrophobic transmembrane protein gp45 (56%). 
Figure 14 indicates that under the conditions utilized, a single protein band is 
resolved in each pooled fraction.
The observed elution pattern, column resolution, and protein yields 
were highly reproducible using different preparations of EIAV and in multiple 
analysis of a single virus preparation. This reproducibility was maintained for 
15-20 runs (150-200 mg of purified virus) on a single phenyl cartridge, at which 
time the resolving capacity of the resin began to decrease. Using sample loads 
above 12 mg of EIAV protein also reduced the efficacy of protein separation. 
Finally, it was observed that removal of viral lipid by acetone precipitation 
prior to solubilization in guanidinium hydrochloride did not improve protein 
resolution in subsequent HPLC analyses.
Purification of HIV and SIV glycoproteins. Additional experiments 
examining the adsorption and desorption properties of HIV gpl20 and gp41 on 
the phenyl resin indicated that the described system should be a useful strategy 
in the purification of these viral components, either from purified virus, virus- 
infected cell extracts, or cloned antigen preparations. Immunoaffinity purified
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FIGURE 14. SDS-PAGE analysis of viral proteins resolved by 
reverse-phase HPLC.
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Protein pools (A-F) correspond to the elution peaks designated in Figure 
13. EIAV (V) and protein molecular weight standards (S) were included as 
references. Lanes A-F were purposely overloaded to reveal the presence of any 
minor contaminants.
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gpl20 from infected cell culture supernatants was found to elute at 40% 
acetonitrile, identical to the elution concentration of gp90 (Figure 15). When 
purified virus preparations were employed, gp41 eluted at 52% acetonitrile, 
similar to the 56% elution concentration of gp45 (Ball, et al.t 1988). Like the 
EIAV isolated proteins, the antigenicity of the eluted HIV glycoproteins was 
maintained as demonstrated by positive reactivity with AIDS patient sera in 
Western blots (Figure 16).
The prospect of the EIAV protocol being applicable to the purification 
of lentivirus glycoproteins in general was strengthened by subjecting purified 
SIV to HPLC analysis. Again, the surface glycoprotein was efficiently bound 
and desorbed at 40% acetonitrile (data not shown). The SIV transmembrane 
glycoprotein however did not bind the phenyl resin as tightly as gp45 and gp41 
eluting at 49% acetonitrile (data not shown). These isolated proteins were 
amenable to N-terminal sequence analysis.
Gas phase sequencing of HPLC purified proteins.
The N-terminal sequence of each purified protein was determined by 
automated Edman degradation and HPLC identification of the PTH-amino 
acid derivatives obtained from each Edman cycle. Figures 17 and 18 show the 
chromatograms of cycles 1-4, and 10 for gp90 and gp45, respectively. The 
presence of a single amino acid peak in each cycle confirms the purity of the 
protein preparations. The sequencing method utilized is sensitive to the
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Solvent A is acetonitrile with 0.1% TFA and solvent B is water with 
0.1% TFA. A 3-step gradient from 0-60% solvent A was applied over 110 min 











FIGURE 16. IMMUNOBLOT ANALYSIS OF HIV gpl20 
ELUTED FROM THE PHENYL RESIN.
HIV gpl20 (A) is indicated and corresponds to the elution peak in 
Figure 15. Immunoblotting was performed with AIDS patient sera and 
confirms that the HPLC technique does not adversely affect protein 
antigenicity. HIV (V) and protein molecular weight standards (S) were 
included as references.
FIGURE 17. HPLC PROFILE OF PTH-AMINO ACID 
DERIVATIVES OF EIAV gp90.
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N-terminal sequence analysis was performed on an automated Applied 
Biosystems 470-A gas-phase sequencer, and the resultant phcnylthiohydantoin 
(PTH)-amino acid derivatives were identified by reverse-phase HPLC. Edman 
degradation cycles 1 through 4 and cycle 10 are presented. Cycle 10 was 
















FIGURE 18. HPLC PROFILE OF PTH-AMINO ACID 
DERIVATIVES OF EIAV gp45.
Edman degradation cycles 1 through 4 and cycle 10 are shown for PTH- 
amino acid derivatives of gp45. Cycle 10 was included to demonstrate the low 
background and high repetitive yield after 10 cycles.
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picomole level, thus minor contaminants could easily be identified.
Additionally, the HPLC profiles revealed a single PTH-derivative at each cycle 
for EIAV p26, pl5, p l l ,  and p9 (data not shown); no detectable PTH-amino 
acid derivatives were obtained from plS, presumably because its N-terminus is 
fatty acylated (Henderson, et a l 1987). The first 20 N-terminal residues 
identified for each isolated gag protein are presented in Figure 19 (Panel A), 
while the env glycoproteins N-terminal sequences are shown in Figure 19 
(Panel B).
The amino acid sequence determined for gp90 and gp45 was found to 
correspond exactly with the sequences deduced from the lambda-12 proviral 
clone (Rushlow, et al., 1986), thus confirming the identity of the env gene as 
predicted by nucleotide sequencing. In addition, the direct protein sequencing 
of the isolated surface glycoproteins revealed processing events that occur 
during the production of infectious virions. An unexpected finding is that the 
N-terminal residue of gp90 is tyrosine, the seventh residue encoded by the env 
gene. The gp90 amino terminus was previously predicted to be glutamate, the 
sixteenth residue, based on the assumption that the initial IS hydrophobic or 
uncharged residues constitute a signal peptide removed during polyproteiii 
processing. The elucidation of the gp45 N-terminal residue as aspartate 
confirms the previously predicted cleavage site between the env gp90 and gp45 
components (Rushlow, et al., 1986).
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FIGURE 19 (Panel A). N-terminal sequence of EIAV sag proteins 
separated by reverse-phase HPLC.
N -  TERMINUS SEQUENCE OF HPLC PURIFIED Q a q  PROTEINS
P * N - P I Q Q K S Q H N K S V V Q E T P Q T O
P l l N - Q T G L A S P F K G G A L K G G P L K A
P I S N - f a r m l n u t  I t  b l o c k t d ,  u n t b l t  t o  t t q u t n c * .
P 2 6 N - P 1 MIDGAG NRNF R PL TP R G W
The first 20 N-terminal amino acids were readily identified for each 
purified protein and correspond precisely to previously reported sequences.
FIGURE 19 (Panel B). N-terminal sequence of env proteins 
recovered from HPLC separation of EIAV.
N -  TERMINUS SEQUENCE OF HPLC PURIFIED env PROTEINS
GP 4 5
GP 9 0 N *  YGGIPGGISTPITQQ S EK
The first 18 N-terminal amino acids of gp90 and the first 20 N-terminal 
amino acids of gp45 were readily identified. These reported sequences were in 
exact agreement with the deduced amino acid sequence.
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Immunological analyses of HPLC purified EIAV proteins.
EIAV gp90, gp45, and p26 constitute the predominant viral immunogens 
during infection and are the basis for diagnostic and vaccine procedures.
Hence, it was important to ascertain the reactivity of these purified proteins in 
several pertinent immunoassays. The immunoblot shown in Figure 20 
demonstrates that purified gp90, gp45, and p26 retain their reactivity with 
equine reference serum; in fact, the levels of reactivity are similar to those 
observed in immunoblots of the purified virus (Figure 20, lane V). In addition, 
the purified proteins reacted effectively in diagnostic agar gel immunodiffusion 
(AGID), enzyme-linked immunosorbent assay (ELISA), and in direct or 
competitive radioimmunoassay (RIA). Taken together, these observations 
indicate that the HPLC purification technique does not adversely affect protein 
antigenicity and thus, can be used to produce antigens needed for diagnostic or 
subunit vaccine protocols.
Each of the isolated proteins was used as an immunogen to induce high 
titer polyclonal antisera in New Zealand white rabbits (data not shown). 
Following the described immunization protocol, specific antibodies were 
produced. These antisera provided a valuable reagent in several procedures. 
Antibodies directed against gp90 and gp45 were used to identify and confirm 
the presence of EIAV env protein fragments expressed in E. coli (Payne, et al., 
1989; Chong, et al., 1990); anti-p26 was utilized to detect the gag polypeptide 
precursor, Pr55*°*, and other intermediate cleavage products in detergent-
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FIGURE 20. IMMUNOBLOT ANALYSIS OF HPLC ISOLATED 
EIAV PROTEINS.
V A B  C D  E F
%  i
Immunoblot analysis of HPLC isolated EIAV proteins (A-F) depicted in 
Figure 14 and corresponding to the elution peaks in Figure 13. Comparison with 
purified EIAV (V) demonstrates the retention of antigenicity and confirms the 
identity of the eluted viral proteins.
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soluble lysates of virus-infected cells (Hussain, et al., 1988); and lastly, rabbit 
antibodies provided known positive controls in the development of various 
immunoassays.
Structural model of gp45.
The EIAV TM protein was closely examined with respect to the 
common structural features proposed for the N-terminal amino acids of 
retrovirus TM proteins (Gallaher, et al., 1989) including: 1) a hydrophobic 
fusion domain following the conserved cleavage site RXK/RR in the SU 
protein, 2) a region rich in serine and threonine residues following the N- 
terminal hydrophobic region, 3) an extended, ascending, amphipathic helix 
which leads to the apex of the molecule containing an immunodominant 
epitope, 4) at the apex, 2-3 conserved vicinal cysteines beginning at position 
81-90, 5) a conserved N-linked glycosylation site contained in an extended 
alpha helix closely following the vicinal cysteines, 7) a second hydrophobic 
region, beginning at position 122-152 and extending 19-27 amino acids which 
traverses the lipid membrane, and 9) several conserved reverse turns, one 
preceding the extended alpha-helix, one near the disulfide linked cysteines at 
the apex, a tryptophan-containing turn immediately preceding the 
transmembrane domain, and a sharp turn just as the protein emerges from the 
lipid bilayer into the cell cytosol.
The 2 key hydrophobic sequences, the fusion and membrane-spanning
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domains, were readily identified by subjecting the primary sequence of gp45 to 
the hydropathy parameters of Hopp and Woods (1981) and Kyte and Doolittle 
(1982). The Kyte and Doolittle prediction profile clearly depicted the N- 
terminal fusion and the membrane-spanning hydrophobic regions with averaged 
hydrophobicity values of 1.97 and 2.17, respectively. The Hopp and Woods 
parameters calculated the region of greatest hydrophilicity (hence predicted 
antigenicity) to be centered at residue 80 (Glutamine) with a value of 1.3167. 
The minimum value was localized to residue 187 (Leucine) which lies in the 
transmembrane domain. Scrutiny of the gp45 sequence revealed that 4 out of 
the 10 residues following the fusion domain (FD) were either serine or 
threonine, and 2 vicinal cysteines were localized to positions 91 and 99, well 
within the limitations established by the Gallaher TM model.
Listed in Table 13 are the averaged potentials (Pg, Pt) across gp45 
based on the values presented by Chou and Fasman (1974) (Table 10). The 
numbering begins with the amino-terminal aspartate of gp45. Correlating with 
the Gallaher TM model, there is an extended helical region succeeding the 
hydrophobic, fusion domain leading to the apical cysteines. The amphipathic 
character of this alpha-helix was confirmed by the AMPHI program displaying 
an amphipathic score of 9.9. At the apex of the protein, a strong turn was 
predicted just where appropriate to allow for internal disulfide bond formation 
between the vicinal cysteines (residues 103-106). Notably, there is a  conserved 
glycosylation site at position 106 (Asn-Met-Ser) residing in this turn.
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TABLE 13. SECONDARY STRUCTURE PREDICTION 

































































Examination of the turn potentials in Table 13 reveals that each of the 
conserved turns described in the TM structural model is predicted in the EIAV 
sequence: the turn preceding the amphipathic helix (residues 46-49, NSTL), 
the apex turn (residues 103-106, HPWN), the tryptophan-containing turn prior 
to the polypeptide entering the lipid bilayer (residues 167-170, IGNW), and the 
strong turn which occurs after the protein emerges from the lipid membrane 
(residues 194-197, SSPK).
A linear structural model of the amino-terminus of gp45 representing 
the culmination of the results of a variety of predictive algorithms and found to 
be in complete agreement with the reported HTV TM model is portrayed in 
Figure 21. The principal features of the model are the fusion peptide, the 
ascending, amphipathic helix, and the immunodominant apical region. 
Functionally, these regions appear to play important roles in the lentivirus life 
cycle. Comparison with the influenza model suggests that the virus envelope 
and the cell membrane fuse to release the virion core into the cytoplasm. The 
hydrophobic N-terminal peptide of influenza HA2 is thought to mediate this 
fusion event (Coffin, 1990). Experimental evidence has shown that HIV 
introduces its core into the cytoplasm of CD4+ lymphocytes by direct fusion of 
the virus membrane with the plasma membrane of the cell in a pH- 
independent manner (Stein, et al., 1987). In addition, site-directed mutagenesis 
of the TM fusion domain blocked infectivity and the cell-fusion ability of the 
virus, that is, the mutated virions were biologically inactive (McCune, et al.,
FIGURE 21. STRUCTURAL MODEL OF THE TM 
GLYCOPROTEIN OF EIAV.
137
The linear sequence of the N-terminus of gp45 is displayed in a planar 
projection of the proposed structure derived from computer modeling and 
based on the model presented by Gallaher, et al.. 1989. Alpha-helices are 
depicted as modified helical nets with recurring 3 and 4 amino acid residues 
per turn connected by single lines. Hydrophobic residues are indicated as 
solid circles, charged/polar amino acids as open circles, and neutral residues 
as incompletely filled circles. Hie proposed intramolecular disulfide bond 
connecting the vicinal cysteines is indicated by a double line; potential N- 
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1988). Thus, it is reasonable to assume that like other enveloped mammalian 
viruses, the conserved fusogenic domain is critical to lentivirus infectivity.
Precedence for the existence of oligomeric forms of the surface 
glycoproteins of enveloped viruses has been established (Einfeld and Hunter,
1988). The influenza HA2 and vesicular stomatitis virus G glycoproteins have 
been shown to exist as trimers (Kreis and Lodish, 1986; Copeland, et al., 1988). 
In addition, trimeric and tetrameric forms of the env glycoproteins of MuLV, 
MMTV, RSV, and HIV have been reported (Pinter, et al., 1989). This 
oligomerization could be facilitated by the conserved, extended, amphipathic 
helix. Delwart and Mosialos (1990) proposed that a "leucine-zipper" motif in 
this helical region would prompt the oligomerization of the TM glycoproteins 
through the formation of a coiled-coil. A coiled-coil helix is energetically 
favorable allowing side-chain "meshing" without much helical distortion. The 
side-chain interactions stabilize the helical regions forming a left-handed 
superhelix with a heptapeptide structural repeating unit (Schulz and Schirmer, 
1979). The same heptad repeat of apolar residues is characteristic of 
amphipathic helices. Thus, the conserved ascending helix could oligomerize 
the env protein via a coiled-coil interaction and impart an elongated character 
to the molecule. This model is further supported by the fact that the influenza 
virus HA2 protein forms a three-stranded coiled-coil structural trimer (Cohen 
and Parry, 1986).
The final significant constant in the proposed model is the
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immunodominant domain, so designated because of the vast immunochemical 
evidence (Gnann, Jr., et al., 1987; Wang, et al., 1986; Ball and Montelaro, 
unpublished results) in spite of the overt absence of this region in computer 
generated antigenicity profiles. Evaluation of the composite surface profile of 
gp45 (Figure 22) discloses that regions of greatest accessibility, flexibility and 
hydrophilicity based on amino acid sequence alone are localized between 
residues 205 and 315. The apical region was not calculated to be antigenic or 
surface accessible by the parameters utilized by this algorithm.
The remainder of the TM protein is thought to be intracellular and 
widely disparate, accounting for the significant differences in molecular weights 
amongst the TM proteins of the different retrovirus families. However, a 
common theme for an intracellular domain of the lentivirus TM glycoproteins 
may also exist. Venable, et al, (1989) noted that 2 segments in the C-terminus 
of HTV gp41 possessed unusually high hydrophobic moments (despite the large 
number of charged groups) and a strong tendency to form amphipathic helices 
(residues 772-790 and 828-848). Energy minimization and molecular dynamics 
calculations generated paired structural segments arranged in an antiparallel 
conformation and stabilized by complimentary charges which could form 
interior salt links (Figure 23). The authors proposed that such a structure 
could aggregate to form membrane-spanning channels which could disrupt the 
membrane integrity and contribute to the cytopathic effects of the gpl20-gp41 
complex. Further examination of the AMPHI calculation of the gp45 sequence
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FIGURE 22. COMPOSITE SURFACE PLOT OF EIAV gp45
The primaiy amino acid sequence of the EIAV TM protein was 
subjected to the algorithms of Parker, et al. (1986). Individual parameters of 
hydrophilicity, flexibility and accessibility were combined to generate a 
composite profile reflecting surface accessible, antigenic sites.
Sequences with a combined surface value greater than 50% are 
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revealed 2 C-terminal segments with high amphipathic scores, residues 770-786 
(AS=8.8) and residues 834-854 (AS=57.0). Alignment of the EIAV sequences 
analogous to the HIV segments revealed that similar interior salt linkages 
could be formed (Figure 23). Similar amphipathic scores and potential salt 
linkages were localized in the C-terminal sequences of visna and SIV TM 
proteins (data not shown). Thus, the structural similarity of the lentivirus TM 
proteins can be extended to include an intracellular domain despite the lack of 
amino acid sequence identity.
Miller, et al. (1990) reported the presence of an arginine-rich 
amphipathic helical segment at the carboxyl end of lentivirus TM proteins 
which are structurally similar to the cytolytic, defensive peptides produced by 
certain insects and amphibians (Gibson, et al., 1986). The authors noted that 
the lytic structural organization of these peptides were not present in the 
oncovirus TM proteins and proposed that this structural variation could 
account for the known differences in their cytopathology. Given that natural 
cytolytic peptides form peptide multimers and the C-terminal amphipathic 
segments are predicted to form salt bridges, it seems reasonable that lentivirus 
TM multimers could form, insert into the lipid bilayer forming a channel or 
pore, and disrupt the membrane structure.
In addition to forming a membrane-channel, dimerization by ionic or 
hydrophobic bonding of the helical regions may be involved in env processing. 
Rey, et al. (1990) showed that the TM proteins of SIV and HIV-2 existed as a
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homodimer in infected cells during transport and in the mature virion. It has 
also been documented that dimerization of the vesicular stomatitis virus TM 
protein is necessary for transport to the Golgi apparatus from the rough 
endoplasmic reticulum (Kreis and Lodish, 1986). Thus the intracellular helices 
of the TM proteins could be responsible for the dimerization and subsequent 
processing of env glycoproteins.
Although the assignment of function to a given region of the TM 
polypeptide is hypothetical, it is intriguing to speculate on a mechanism 
whereby the extracellular amphipathic properties induce a coiled-coil trimeric 
motif which buries apolar segments such as the fusion domain. Following 
receptor binding, perturbation of the coiled structure would assist in a 
conformation change of the envelope heterodimer exposing the N-terminal 
hydrophobic fusogenic peptide resulting in membrane fusion and virus 
infectivity. In this way, both terminal regions would contribute to 
cytopathology. The amino-terminus has been shown to be responsible for 
syndtia formation and the carboxy-terminus could expedite cell lysis. Key 
amphipathic helical regions at both termini are potentially capable of env 
oligomerization and processing.
S tructu ral model of retrovirus SU glycoproteins.
Primary amino add sequences of the SU glycoproteins of RSV, BLV, 
HTLV-I, SIV, HTV and EIAV were subjected to a battery of predictive
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computer algorithms in an effort to deduce common structural motifs. Each 
protein was analyzed individually by hydropathy, secondary structure and 
surface potential parameters. Structural features were derived for each protein 
and were found compatible with Chou-Fasman potentials for beta-sheet (Pb), 
alpha-helix (Pfl) and reverse turns (P,).
The inferred structures were carefully examined by dividing each 
glycoprotein into 3 general areas (N-terminal, central and C-terminal regions) 
so that differences in the number of residues would not be a limiting factor in 
discovering conserved structural characteristics. Comparison of the overall 
organization in each of the 3 areas revealed a number of common properties 
(Table 14) despite the remarkable variation in size and the lack of significant 
sequence similarity.
The N-terminal sequences of each retroviral glycoprotein contain a 
predicted alpha-helix closely associated with a strong reverse turn and a 
conserved N-linked glycosylation site (Asn-X-Ser/Thr). Additionally, a cysteine 
residue occurs within the first 25 N-terminal amino adds (excluding the signal 
sequences) which suggests that the amino-terminal region is involved in a 
disulfide linkage. Within the N-terminal domain, there is also a unique region 
of multiple, high turn potentials which in turn is followed by a  conserved N- 
linked glycosylation site and a proposed alpha-helix. These features were 
consistent for each SU sequence analyzed.
The central region of the glycoproteins is distinguished tty a highly
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TABLE 14. PREDICTED STRUCTURAL PROPERTIES COMMON 
TO RETROVIRAL SU PROTEINS.
N-TERMINAL REGION:
1. Conserved N-terminal alpha-helix associated with a conserved turn with a 
high P, and N-linked glycosylation site.
2. Cysteine residue within the first 25 amino adds.
3. Region of high turn density followed by a conserved N-linked glycosylation 
site and alpha-helix.
CENTRAL REGION:
1. Heavily charged/polar segment assodated with an amphipathic helix and
containing at least 1 cysteine residue.
2. Conserved turn following the charged segment.
3. Proline-rich "kinked" area.
4. Conserved central beta sheet.
5. Sequence which "loops out" from the core of the predicted protein
structure.
C-TERMINAL REGION:
1. Region of clustered N-linked glycosylation sites assodated with a 
conserved amphipathic helix.
2. Strong turn, alpha helix, and glycosylation site preceding the cleavage 
signal.
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charged segment varying between 23 (HTLV-I) and 60 (Visna) residues; the 
percentage of charged /  polar residues within this segment varies between 52% 
(RSV) and 78% (SIV)- This charged segment is closely associated with an 
amphipathic helix (amphipathic score greater than 8.0), includes at least one 
cysteine residue, and is followed by a reverse turn. The next readily 
identifiable marker is an area rich in proline residues resulting in a random, 
"kinkedH secondary structure. Finally, the central region is characterized by a 
pronounced beta-sheet near a "looped" domain which contains the distinctive 
V3 loop of HIV (Matsushita, et al., 1988).
The carboxyl-terminal region is differentiated by a clustering of 
potential N-linked glycosylation sites. Notably, carbohydrate analysis of HTV 
gpl20 revealed that all 24 potential glycosylation sites are occupied (T.
Gregory, unpublished results). It is reasonable to presume that this is a 
common feature, especially amongst the lentivirus SU proteins. Serological 
cross-reactivity between HIV gpl20 and EIAV immune equine sera was 
reported to be attributed to the oligosaccharide rather than the peptide 
components of the viral glycoproteins indicating the similarities in the 
carbohydrate components (Montelaro, et a/., 1988). The clustered glycosylation 
sites are invariably associated with a predicted amphipathic helix. Lastly, 
immediately preceding the conserved cleavage signal, each viral glycoprotein is 
marked by a potential reverse turn, alpha-helix, and a N-linked glycosylation 
site.
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Calculated Chou-Fasman potentials reflecting the conserved structural 
properties specified above are tabulated in Table 15. Although some of the 
and Pj, values appear quite close or reversed, when other factors are taken into 
account, the propensity for helix formation is significantly increased. For 
example, the Chou-Fasman prediction method assigns high beta potentials to 
hydrophobic residues regardless of the periodic occurrence of hydrophobic 
residues characteristic of amphipathic helices. Additionally, once an alpha- 
helix is nucleated, the likelihood of that helix abruptly yielding to the presence 
of a short segment with beta-sheet potential is very low especially in the 
absence of a helix breaker tetramer (Chou and Fasman, 1978, Gallaher, et al.,
1989). Also shown in Table 15 are the P, values of the proposed conserved 
turns. The elevated Pf values (1.40 - 1.52) reflect the strong propensity for a 
conserved turn in the N-terminal region. C-terminal turn potentials and those 
associated with the central beta-sheet vary between 1.11-1.40 and 1.27-1.48, 
respectively. These potential turn values are also convincing.
listed  in Table 16 are the lentivirus (panel A) and oncovirus (panel B) 
SU segments with calculated amphipathic scores above 12.0. The amphipathic 
segments are indicated by their residue numbers and listed according to the 
midpoint positions of the predicted 11 residue blocks. Hence, the amphipathic 
sites extend for an additional 5 residues to each side of the indicated midpoint 
blocks (Margalit, et al., 1987). These sequences were weighted heavily as 
alpha-helices and indicate areas of possible T-cell epitopes and/or coiled-coil
TABLE 15. CALCULATED CHOU FASMAN POTENTIALS OF THE SU GLYCOPROTEINS*












1.13 1.09 1.13 1.07 1.15 1.17
0.84 1.06 1.01 0.96 0.98 1.01
1.50 1.52 132 132 1.40 1.4
1.11 1.14 1.16 1.16 1.10 1.02
1.09 1.02 1.00 0.91 0.95 1.07
223-233 244-266 206-218 313-322 138-151 138-1
1.04 0.96 0.88 0 3 9 1.03 0.99
1.18 123 1.14 1.03 1.19 1.12
1.32 1 2 8 127 1.48 138 134
1.16 1.11 1.05 1.09 1.00 1.17
1.00 1.13 0 3 8 0.69 1.05 1.13
1.11 1.40 12 6 122 123 134
a) Conserved structural properties correspond to Table O;
b) SU proteins numbered from the gny initiator methionine.
c) Conserved reverse turn following the central beta sheet.
d) Conserved alpha helix and reverse turn preceding the cleavage signal.
TABLE 16, PANEL A.
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TABLE 16, PANEL B.
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The SU glycoproteins recognize and interact with the host cell-surface 
receptor to initiate the virus replication cycle (Coffin, 1990). Reflecting the 
disparity in host cell specificity, the distinct SU proteins of the different viruses 
share limited amino acid sequence identity. Given that these envelope 
proteins have the same function and little sequence homology, it was not 
surprising to find extraordinary similarities in their biochemical properties 
(Table 17). As illustrated in Table 17, the SU glycoproteins display similar 
patterns of amino acid content, potential N-linked glycosylation sites, and 
predicted secondary structure. Further examination of the data reveal some 
differentiation between the lentivirus and oncovirus SU proteins.
The total number of amino add residues varies between 301 (BLV) and 
656 (Visna) in the viral proteins examined. In general, the peptide component 
of the lentivirus proteins (445-656 amino adds) is larger than that of the 
oncovirus proteins (301-405 amino adds). Only EIAV gp90 lacks a defined 
signal sequence (above). N-linked glycosylation sites appear to average around 
3.5 per 100 residues with a definite clustering in the C-terminal region. HIV 
and RSV have 5 potential N-linked glycosylation sites over a span of 20 and 24 
C-terminal amino adds; while EIAV, SIV, Visna and BLV have 3 predicted 
N-linked glycosylation sites in a limited C-terminal region of 13, 18, 7 and 20 
amino adds, respectively.
Hydroxylated amino add content varies between 12.6 and 20.9 percent,
Table 17. Biochemical Properties of Retroviral SU Proteins
LENTIVIRINAE ONCOVIRINAE
EIAV HIV SIV VISNA RSV BLV h t l v;
Total Number of Amino 
Acid Residues 445 516 527 656 405 301 312
Size of Signal Peptide 23? 30 22 100 64 33 20
Residues Analyzed 438 486 505 556 341 268 290
N-Linked Glycosylation 
Sites/100 Residues 2.7 4.9 4.0 4.3 4.1 3.0 1.4
% Serine and Threonine 12.9 16.9 17.8 12.6 19.1 14.2 20.9
% Proline 4.4 4.5 4.6 4.5 6.5 10.0 12.7
% Acidic Residues 9.7 8.2 10.7 9.9 5.9 6.7 4.5
% Basic Residues 11.5 12.1 13.1 15.5 9.4 10.1 8.6
% Cysteine 4.4 3.7 4.2 4.0 4.1 3.0 4.8
% Alpha Helix 35.2 37.2 38.8 43.9 34.3 37.3 35.8
% Beta Sheet 21.4 16.7 19.2 12.6 28.2 25.4 28.7
% Randon Coil 16.0 18.9 16.6 17.6 16.4 17.5 20.8
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while the number of cysteines per 100 residues is between 3.0 and 4.8 (Table 
17). Examination of the charged residue content reveals that the lentivirus SU 
proteins are more highly charged with 203%  - 25.4% charged residues 
compared to the 13.1% - 16.8% charged residues found in the oncovirus SU 
sequences. This disparity in charge is reflected in the composite surface plot 
in which the parameters of hydrophilicity, accessibility and flexibility are 
combined (Parker, et al.t 1986) (Figure 24, Panels A and B). The composite 
surface profiles predict that EIAV gp90 and HIV gpl20 have 8 antigenic sites 
each (surface value greater than 50%), while the SU glycoproteins of HTLV-I 
and BLV have only 2 (HTLV-1) or 3 (BLV) predicted antigenic or surface 
sites. Finally, the proposed structural similarities of the SU glycoproteins are 
supported by the overall alpha-helix, beta-sheet, reverse turn and random coil 
propensities (Table 17). Structural models, with each amino acid identified, is 
projected for EIAV gp90, HIV gpl20 and BLV gp51 in Figure 25, panels A-C. 
The general features of the proposed model can be readily identified in these 
graphical representations. The modeling of HIV gpl20 was dramatically 
simplified by the recent report of T. Gregory (unpublished results) which 
experimentally assigned all cysteine-cysteine disulfide linkages. These known 
linkages are included in Figure 25.
Prediction of chemically synthesized peptides secondary structure.
Immunological responses to discrete regions of the EIAV env 
glycoproteins were examined by utilizing a panel of chemically synthesized
FIGURE 24. COM POSITE SURFACE PRO FILES OF THE SU  
PRO TEINS OF EIAV & HIV (PANEL A) AND BLV & HTLV-I 
(PANEL B ).
The surface composite plots reflect the calculated surface accessible 
regions for each viral glycoprotein. Surface values greater than 50% indicate 
potential antigenic sites.
Panel A includes the composite profiles obtained for the lentivirus SU 
proteins, EIAV gp90 and HIV gpl20, which contain 8 predicted surface or 
antigenic regions. Representative surface plots of the oncovirus SU proteins are 
shown in panel B with only 2 (HTLV-I) or 3 (BLV) predicted antigenic domains.
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FIGURE 25. STRUCTURAL MODELS OF EIAV gp90 (PANEL A), 
HIV gp!20 (PANEL B) AND BLV gp51 (PANEL C).
The linear sequences are shown in a planar projection of the proposed 
structures derived by combining numerous computer algorithms. As with the 
gp45 model, hydrophobic residues are depicted as solid circles, charged amino 
acids as open circles, and neutral amino acid residues as partially filled circles. 
Potential N-linked glycosylation sites are shown as stick figures and random 
regions as loosely coiled extended chains.
Disulfide linkages are indicated for HIV gpl20 as reported by Gregoiy, 
unpublished results.
The proposed conserved features of the model which correspond to the 
characteristics enumerated in the text are:
a) the N-terminal alpha-helix, reverse turn and potential N-linked 
glycosylation site, b) N-terminal region of high turn density followed by a 
conserved N-linked glycosylation site and proposed alpha-helix, c) the central 
charged segment associated with an amphipathic helix, d) the proline-rich 
"kinked" sequence, e) the central beta-sheet and "looped” domain, f) the C- 
terminal region of clustered N-linked glycosylation sites, and g) the proposed 








glycoproteins were examined by utilizing a panel of chemically synthesized 
peptides. The ability of antibodies raised against intact folded proteins to 
interact with short disordered peptides and vice versa has raised a major 
theoretical concern in protein chemistry (Wilson, et al., 1985). Synthetic 
peptides as antigen have been shown to bind antibodies generated to the 
primary amino acid sequence of the cognate protein (Wilson, et al., 1984).
The probability of these peptide antigens displaying a stable conformation 
similar to that in the nascent protein is low. However, it has been 
documented that some peptides fold into distinct structural entities, even in 
aqueous buffers (Dyson, et al., 1988). The evidence for these structured forms 
has come primarily from proton nuclear magnetic resonance (NMR) studies on 
solutions of peptides (Dyson, et al., 1987). NMR analysis of a peptide from 
the influenza HA1 chain (residues 98-106) revealed a distinct conformational 
preference for a reverse turn in water solution, and NMR analysis of a peptide 
spanning an antigenic domain of herpes simplex virus glycoprotein D revealed 
an alpha-helical turn and a short helical structure in equilibrium with random 
coil (Dyson, et al., 1988). Additionally, Lark, et al. (1989) found that 2 
synthetic peptides from sperm whale myoglobin (residues 132-146 and 102-118) 
which activate T-cell clones in vitro fold as amphipathic alpha-helices in the 
structure-promoting environment of 50% trifluoroethanol and at interfacial 
environments such as water and air. However, there was very little indication 
by NMR or circular dichroism (CD) that these peptides fold in aqueous
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solutions at low concentration (Lark, et al., 1989). Despite numerous 
examples, small peptides typically lack stable folding in an aqueous 
environment, and only those peptides with a strong structural propensity 
demonstrate an ordered structure when placed in the right environment 
(Shoemaker, et al., 1985).
Given that particular synthetic peptides have been shown to maintain an 
ordered secondary structure resembling that of the native protein, synthetic 
peptide sequences representing EIAV gp90 were analyzed on a VAX 750 host 
system using SYBYL/BIOPOLYMER, PREDICTSECONDARY algorithms. 
The 3 predictive methods of information theoiy (IT), neural network (NN) and 
Bayes statistics (BS) were utilized. Information theoiy is similar to the Chou- 
Fasman prediction method in that it is grounded on statistical data, assigning a 
probability or potential value to each amino acid or pair of amino acids 
corresponding to the X-ray data of the database utilized (Gilbrat, et al., 1987). 
In contrast, neural network is an empirical predictive algorithm which assigns 
each residue to 1 of 5 conformational states based on the influences of both 
short-range and medium-range interactions. These conformational states are 
defined in terms of the backbone dihedral angles in hopes of generating the 
starting conformation for subsequent energy minimization (Gamier, et al.,
1978). Finally, the Bayes statistics algorithm expands the neural network 
parameters to include residues separated by up to 8 amino acids, and a larger 
and more recent database of crystallized proteins (SYBYL manual; Qian and
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Sejnowski, 1988).
Table 18 lists the percentages of alpha-helix, beta-sheet and random coil 
acquired from each predictive method for the various synthetic peptides. All 
three algorithms were employed, and the results analyzed to obtain an 
indication of possible structure based on different parameters. As shown in 
Table 18 most of the peptide calculations indicateded primarily random coil 
conformations. Although predictive algorithms frequently default to coil 
assignments when a clear distinction cannot be made, it is reasonable to 
presume that a high percentage of coiled sequences are contained in short 
peptides. Notably, the predictave calculations utilized did project a stable 
conformation for some of the peptide sequences.
Graphical representations of the predicted structures of selected 
peptides are illustrated in Figures 26-28. As shown in Figure 26, distinct 
structural motifs are obtained depending on the algorithm used in the 
calculation. Peptide 2, a 15-mer, is predicted to be 66.7% alpha-helical by the 
IT parameters and an extended coil by the NN parameters. In the complete 
protein, the sequence which corresponds to peptide 2 is predicted to be an 
alpha-helix. The proposed structure of peptide 1 is shown in Figure 27, top 
panel. Although the NN algorithm proposes that peptide 1 is 100% random 
with no preferred structure, the 2 proline residues "kink" the chain in such a 
way that it almost appears as a closed circle, thus preventing the extended, 
linear organization typically seen with random sequences. In contrast, the IT
Table 18. PEPTIDE SECONDARY STRUCTURE COMPARISON 166 
% Alpha % Beta &Coil
Pep NN BS IT_________ NN BS IT_________ NN BS IT
I 0.0 0.0 0.0 0.0 5.0 20.0 100.0 95.0 80.0
2 0.0 0.0 66.7 0.0 0.0 0.0 100.0 100.0 333
3 15.8 15.8 47.4 0.0 0.0 53 843 84.2 47.4
4 60.7 643 71.4 0.0 0.0 0.0 393 35.7 28.6
5A 0.0 0.0 0.0 373 0.0 50.0 623 100.0 50.0
SB 0.0 0.0 0.0 0.0 0.0 42.9 100.0 100.0 57.1
6 0.0 0.0 0.0 15.0 5.0 55.0 85.0 95.0 45.0
7V 0.0 0.0 0.0 0.0 0.0 0.0 100.0 100.0 100.0
8V 38.5 303 533 0.0 33 0.0 613 65.4 46.2
9V 0.0 0.0 20.0 333 20.0 133 66.7 80.0 66.7
10V 35.0 0.0 25.0 0.0 5.0 20.0 65.0 95.0 55.0
11 0.0 0.0 24.0 0.0 4.0 12.0 100.0 96.0 64.0
12 0.0 0.0 203 16.7 83 16.7 833 91.7 623
13 0.0 11.5 0.0 383 7.7 73.0 613 803 26.9
VI 21.4 143 10.7 21.4 25.0 21.4 57.1 60.7 67.9
V2A 0.0 0.0 50.0 10.0 5.0 20.0 90.0 95.0 30.0
V2B 0.0 0.0 22.0 0.0 0.0 5.6 100.0 100.0 723
V3 6.9 133 173 6.9 0.0 37.9 863 863 443
V4 8.3 13.9 22.0 11.1 5.6 36.1 80.6 80.6 41.7
V5A 0.0 0.0 22.0 11.1 5.6 50.0 88.9 94.4 273
VSB 5.6 0.0 0.0 11.1 0.0 55.6 833 100.0 44.4
V6 0.0 0.0 0.0 423 193 463 57.7 803 533
V7 0.0 3.6 0.0 393 28.6 46.4 60.7 673 53.6
NN = Neural Network BS = Bayes Statistics IT = Information Theory
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FIGURE 26. PRO PO SED SECONDARY STRUCTURE OF  
PEPTIDE 2
Secondaiy structure plots of the peptide sequence 
SEKSKCEENTMFQPY predicted by the information theoiy (top panel) and 
neural network (bottom panel) parameters. Line drawings were facilitated by 
the Evans and Sutherland PS-390 interactive graphics terminal.
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FIGURE 27. PEPTIDE 1 AND PEPTIDE 12 PROPOSED 
SECONDARY STRUCTURE BY NEURAL NET AND 
INFORMATION THEORY ALGORITHMS
Top Panel: Proposed structure of peptide 1 (amino-terminus of gp90, 
residues 7-26, YGGI£GGIST£ITQQSEKSK) as determined by neural network 
(left) (100% random coil) and information theory (right) (20% beta).
Bottom Panel: Proposed structure of peptide 12 (carboxyl-terminus of 
gp90, residues 424-447, ETWKLVKTSGVI£L£ISSEANTGL) as determined by 
NN (left) (16.7% beta) and IT (20.8% alpha-helix, 16.7% beta).
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FIGURE 28. PROPOSED SECONDARY STRUCTURE OF 
PEPTIDES 4 AND Vd.
Peptide 4 (top panel)(KEARDQEMNLKEESKEEKRRNDWWKIGF) 
was consistently predicted to be alpha-helical by the SYBYL/BIOPOLYMER 
PREDICT_SECONDARY algorithms. Shown is a graphical representation of 
the proposed alpha structure based on the parameters of neural network.
Peptide V* (bottom panel) (TGIYQVEIFYTCTFTNITSCNSKEII) was 
predicted to be a combination of beta-sheet and random coil by all 3 of the 
SYBYL predictive parameters.
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algorithm calculated peptide 1 to contain a reverse turn at its C-terminus and 
a central beta region (20%). This proposed ordered structure resulted in an 
extended peptide chain with the effect of the proline residues less prominent. 
Interestingly, a similar pattern is seen with peptide 12 (Figure 27, bottom 
panel). Given that these 2 peptides represent the carboxyl and amino termini 
of gp90, and are immunodominant (discussed below), it is possible that the 
prolines alternately "kink" the peptide in different directions in solution 
yielding a sequence with increased flexibility or mobility which is known to 
enhance antigenicity (Tainer, et al., 1984). The sequence of peptides 1 and 12 
are both predicted to be alpha-helical with amphipathic character in the parent 
SU protein based on the algorithms used to develop the SU structural model. 
Lastly, displayed in Figure 28 are peptides 4 (top panel) and V6 (bottom 
panel) which are consistently predicted to be alpha-helical (peptide 4) and a 
combination of beta-sheet and random coil (peptide V6) by all 3 algorithms. 
These assignments agree with the assignments of the same regions in the SU 
structural model of the intact protein.
It is uncertain if it is necessary for synthetic peptides to assume a 
conformation similar to that present in the native structure to accurately reflect 
the immunogenicity of the region. However, to correlate antigenic regions 
with a specific structure, the conformation of the antigen employed must be 
considered. If peptides indeed assume no secondary structure in solution, then 
antibody binding would only reflect recognition of the linear sequence. If
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instead there is an equilibrium between randomness and ordered structure with 
the short peptides, then antibody binding may reflect a conformational 
preference. In this case antibody binding may contribute to the structure of 
the peptide mimicking the native conformation of the intact immunogen. By 
utilizing 3 distinct algorithms which utilize different predictive parameters, 
perhaps an indication of peptide ordered structure versus randomness can be 
obtained and correlated to observed antigenicity.
Peptide Synthesis.
SU and TM peptides were synthesized automatically and manually by t- 
Boc and F-moc chemistries, cleaved from the resin support, and subjected to 
purification by gel filtration and reverse-phase HPLC. Determination of the 
purified peptide molecular weight was accomplished by PDMS which was 
reported to be accurate from 0.007% - 0.080% of the theoretical molecular 
weight values (Fontenot, et al., 1990). Using this protocol, a  range of peptide 
homogeneity was obtained. Synthesis efficiency can be grouped according to 
the peptide HPLC and PDMS results as follows: 1) the major product 
appeared as a single, homogeneous peak by analytical HPLC and corresponded 
to the desired molecular weight as determined by PDMS, 2) the major 
product coeluted with minor contaminants, 3) the major product coeluted 
with significant by-products and required further purification, 4) the desired 
product was not contained in fractions corresponding to the major HPLC peak,
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but present in fractions corresponding to a minor HPLC peak, 5) the desired 
peptide product was not obtained and the synthesis was repeated. Commonly 
encountered contaminants included double additions of certain amino acids (in 
particular glycine, alanine, arginine and phenylalanine), deletion sequences 
and peptides with retained side-chain protecting groups.
Representative HPLC chromatograms and PDMS spectra of successful 
and problematic peptide syntheses is shown in Figure 29 (manual F-moc 
synthesis) and 30 (automatic t-Boc synthesis). Included in Figure 29 are 2 
peptide syntheses (peptide V5C and R31) whose products display a single 
elution peak by HPLC and the correct theoretical mass by PDMS (top and 
center panel), and an example where the desired peptide product (peptide 2) 
did not elute in fractions corresponding to the major HPLC absorbance peak 
(bottom panel). In addition, PDMS analysis of this HPLC purified peptide 
(peptide 2) revealed a contaminating deletion sequence corresponding to the 
theoretical molecular weight of the desired product minus 87.1 daltons (bottom 
panel). Given that the residue weight of serine is 87.08 daltons (appendix II) 
and there are 2 serine residues within the sequence of peptide 2, it is 
reasonable to assume that the deletion sequence is lacking a serine residue. 
Figure 30 displays 2 problematic syntheses (center and bottom panel) and a 
successful synthesis (top panel) performed on the SAM II automatic 
synthesizer. The top panel depicts the data obtained on peptide V5A and 
reveals a  near homogenous peak by HPLC and minor contaminants by PDMS.
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FIGURE 29. HPLC AND PDMS ANALYSES OF 
REPRESENTATIVE SYNTHETIC PEPTIDE PRODUCTS 
SYNTHESIZED BY F-MOC CHEMICAL STRATEGIES.
Peptides were manually synthesized by the F-moc strategy and 
subjected to reverse phase HPLC to evaluate purity and PDMS to evaluate the 
correctness of the product. Chromatographic conditions and mass 
spectroscopy parameters are enumerated in the materials and methods.
Shown are HPLC chromatograms (right panels) and PDMS spectra (left 
panels) of peptides V5C (top), R31 (center) and 2 (bottom).
[M] signifies the theoretical molecular weight of the desired peptide 
product.
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FIGURE 30. HPLC AND PDMS ANALYSES OF 
REPRESENTATIVE SYNTHETIC PEPTIDE PRODUCTS 
SYNTHESIZED BY T-BOC CHEMICAL STRATEGIES.
Peptides were automatically synthesized on a Biosearch SAM II 
automatic peptide synthesizer by the t-Boc chemical strategy. Peptide 
products were subjected to reverse phase HPLC to evaluate purity and PDMS 
to evaluate the accuracy of the sequence obtained Shown are HPLC 
chromatograms (right panels) and PDMS spectra (left panels) of peptides VSA 
(top), V5B (center) and V4 (bottom). These peptides were chosen to illustrate 
the various problems encountered during the chemical synthesis of 
polypeptides.
[M] signifies the theoretical molecular weight of the desired peptide 
product.
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The data included in the center panel on peptide VSB also revealed a near 
homogeneous peak by HPLC indicating the relative purity of the peptide 
product, however the PDMS spectra disclosed that the major product is 72 
daltons over the theoretical mass of the desired peptide. Alanine has a 
residue weight of 71.08 daltons (appendix n), is a residue contained within the 
V5B sequence, and has been shown to double couple with standard synthesis 
protocols (Fontenot, et al., 1990). Thus, the major peptide product probably 
has an extra alanine residue. Lastly, the bottom panel in Figure 30 displays 
one of the more difficult problems in peptide purification, separation of very 
closely related sequences. Although the HPLC chromatogram depicts a 
shoulder and an unsymmetrical peak, the PDMS spectra uncovered numerous 
contaminating peaks with a predominant incorrect mass.
Humoral immune response to EIAV TM and SU peptides.
EIAV immune sera from both experimentally and naturally infected 
animals bind isolated gp90 and gp45 which indicates the presence of conserved 
glycoprotein epitopes among uncharacterized viruses. Previous studies 
employing recombinant fusion proteins have broadly defined EIAV envelope 
fragments which are recognized by immune equine sera during the course of a 
persistent infection (Payne, et al,, 1989). To extend this study and provide a 
more precise identification of antigenic sites, peptides representing key regions 
of gp45 and all of gp90 were chemically synthesized and reacted against the
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same panel of equine sera. Additional serological analyses were performed 
with serial equine sera to obtain a detailed characterization of the humoral 
immune response during the early stages of infection with an avirulent and 
virulent virus strain (Table 4). Monoclonal antibodies were utilized to localize 
distinct glycoprotein epitopes.
Immune reactivity to kev peptides of the TM protein. gp45. A  91 
amino acid recombinant protein (residues 492-582) was reported to be strongly 
reactive with sera from both experimentally and naturally infected animals 
(Payne, et al., 1989). Significantly, this reactive env fragment overlaps with the 
predicted immunodominant domain in the proposed TM structural model. 
Immunodominant epitopes have been localized near the conserved vicinal 
cysteines in HIV-1, HTV-2 and SIVmac (Gnann, et al., 1987b; Norrby, et al., 
1989). More recently it has been demonstrated that the carboxyl half of EIAV 
gp45 reveals only negligible antigenicity with equine immune sera (Chong, et 
al., 1990). Hence, overlapping peptides from the N-terminal apical region of 
gp45 were synthesized and reacted with equine immune sera in peptide 
immunoassays. The peptides utilized in these assays are outlined in Figure 31. 
As indicated in Figure 31, peptides R33 and 51 are localized at the apex and 
differ by the presence (peptide 51) or absence (peptide R33) of the vicinal 
cysteines (in addition to other residues). Peptides R31 and R32 correspond to 
the noted L2 region in HTV which has been reported to be immunodominant 
in several isolates (Ratner, et al., 1985; Wang, et al., 1986; Norby, et al.,
FIGURE 31. PROPOSED MODEL OF THE 
EXTRACYTOPLASMIC DOMAIN OF gp45 WITH SYNTHETIC 
PEPTIDES OUTLINED.
The proposed structural model of gp45 is projected as previously 
described. Synthetic peptides which were reacted against equine immune sera 
are indicated.
Peptide R33 depicts the monoclonal antibody epitope, gp45-A. 
Serological reactivity data defined peptides R32 and 51 as the 
immunodominant domain. Peptide R32 represents an equine epitope.









1989b). The peptide designated FD corresponds to the hydrophobic fusion 
domain (Gallaher, 1987) and was reacted against EIAV immune sera to 
confirm its extracellular location. By computer analyses alone, the lentiviral 
fusion peptide has been predicted to span the lipid membrane (Modrow, et al., 
1987). The Gallaher TM model, however, proposes that the fusion peptide is 
outside the lipid bilayer where it can freely interact with the host cell 
(Gallaher, et al., 1989).
Immune reactivity of these selected TM peptides against the standard 
equine immune sera panel is illustrated in Table 19. Notably, all of the sera 
tested reacted with peptide R32 which also displayed the strongest relative 
reactivity of all the TM peptides examined. Peptide R31 which is located 
immediately downstream of peptide R32 at the end of the extended, 
amphipathic alpha-helix (Figure 31) only reacts with 55% of the immune sera 
tested. Perhaps the amphipathic character of peptide R31 represents a T-cell 
helper epitope which enhances the humoral immune response to peptide R32. 
Peptide 51 which is upstream of R32 and inclusive of the vicinal cysteines 
reacts with 90% of the horse sera while peptide R33 only reacts with 45% of 
the immune sera. Thus, it appears that antibody binding is enhanced by the 
presence of additional residues outside of the disulfide bonded loop.
Except for the 2 immunodominant peptides, R32 and 51, experimentally 
infected horses (E1-E5) had very little, if any, reactivity to the TM peptides 
assayed (Table 19). Horse E5 reacted weakly with peptides R31, R33 and R34
Table 19. Reactivity of Immune Horse Sera with Selected
Peptides of EIAV gp45
Horse
Sera













E l 0 0 4 2 0 0
E2 0 0 3 3 0 0
E3 0 0 4 3 0 0
E4 1 0 2 1 0 0
E5 1 1 4 4 1 1
N6 0 0 4 0 0 0
N7 1 4 4 3 1 1
N8 2 4 4 2 1 2
N9 1 4 4 1 1 3
N10 0 0 4 0 0 0
N il 1 0 4 2 0 1
N12 1 3 4 2 1 1
N13 1 0 4 4 1 3
N14 1 4 4 2 1 1
N15 3 3 4 4 1 2
N16 0 2 4 1 0 0
N17 1 2 2 1 1 1
N18 1 0 3 1 0 1
N19 2 1 4 3 0 0
N20 3 3 1 3 1 1
% Pos 70 55 100 90 45 60
a) Corresponding residue numbers, beginning with the initiator methionine of env (Rushlow 
et al.. 1986).
b) A selected panel of synthetic peptides representing the specific segments of gp45. 
Antibody binding was evaluated by peptide-ELISA andis expressed in relative terms
of reactivity.
0 = No antibody binding to peptide detected.
1 = Absorbance greater than 2 times the average absorbance of a panel of normal horse
sera (NHS).
2 = Absorbance greater than 4 times the average NHS.
3 = Absorbance greater than 6 times the average NHS.
4 = Absorbance greater than 8 times the average NHS.
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while there was no antibody binding detected with E1-E4. Yet all 5 of the 
experimentally infected horses reacted strongly to peptide R32. Hence, 
peptide R32 may prove useful as a diagnostic reagent.
Epitope mapping of gp45. A single, non-neutralizing monoclonal 
antibody defining epitope gp45-A was reacted with each of the TM peptides. 
Positive reactivity was obtained with both peptides 51 and R33. These results 
are in agreement with a previous study which localized epitope gp45-A 
between the fusion and transmembrane domains (Payne, et al.t 1989). Given 
that the sequence of peptide R33 is contained within that of peptide 51, the 
minimal epitope sequence is represented by R33. Thus, epitope gp45 A has 
been localized to 7 amino acid residues at the TM apex with the sequence 
ILE-GLU-ARG-THR-HIS-VAL-PHE. Notably, peptide R33 which defines the 
minimal monoclonal epitope, gp45-A, only reacted with 45% of the horse sera 
tested. The apical horse epitope defined by peptide 51 is obviously similar but 
not identical to the mouse epitope.
Immune reactivity 12 fii£ £12 peptides. A panel of overlapping peptides 
representing the EIAV SU protein, gp90, were synthesized and reacted against 
the standard equine serum panel. A linear sequence of gp90 with the location 
of each peptide depicted is shown in Figure 32. There are 10 peptides from 
the conserved amino and carboxyl regions (peptides 1, 2, 3, 4, 5A, 5B, 6, 13, 11 
and 12); and 13 peptides from the variable region (peptides 7V, 8V, 9V, 10V, 
VI, V2A, V2B, V3, V4A, V4B, V5A, V5B and V6). Additional, smaller
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FIGURE 32. UNEAR SEQUENCE OF THE SU PEPTIDES.
The primary amino acid sequence of gp90 is displayed in a linear 
fashion with the SU synthetic peptides delineated by overlapping bars. The 
shading of the bars is alternated to clarify the overlapping residues.
Peptides 1 - 6  correspond to the conserved amino-terminal domain; 
peptides 7V - V7 represent prototype sequences of the variable domain; and 
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peptides were synthesized to localize monoclonal antibody epitopes (peptides 
4A, 4B, 4C, V1D and VSC) and were not reacted against the immune horse 
sera.
Examination of the reactivity of the immune sera with recombinant 
fusion proteins originating from conserved and variable regions of the env gene 
revealed an immunodominant, conserved C-terminal region in gp90 (Payne, et 
al., 1989). This recombinant protein was 75 amino acids in length and reacted 
strongly with sera from both experimentally and naturally infected animals. In 
contrast, a conserved, N-terminal recombinant protein (117 amino acids in 
length) had variable reactivity with equine immune sera (Payne, et cd.y 1989).
Listed in Table 20 are the relative reactivities obtained against the 
conserved SU peptides from both the amino and carboxyl termini. In 
agreement with the recombinant protein data, the C-terminal peptide (peptide 
12) reacted veiy strongly (100% at a relative reactivity of 4) with sera from 
both naturally and experimentally infected animals. This reactivity dropped to 
85% with peptide 11 which overlaps peptide 12 by 4 amino acids (Figure 32). 
Thus, the SU immunodominant, C-terminal horse epitope has been localized to 
20 amino acids and displays the strongest relative reactivity of all the peptides 
tested to date, including those of the TM protein. In contrast to the fusion 
protein data, the amino-terminal peptide (peptide 1) reacted with all of the 
sera analyzed. The relative reactivity was somewhat weak with an average of 
1.7. Immune reactivity immediately fell to 60% with peptide 2 which overlaps
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Table 20. PLL-ELISA Results with Synthetic Peptides 
from the Conserved Regions of gp90
N-terminus C-tenninus
Sera 1 2 3 4 5A 5B 6 13 11
E l 1 3 2 3 2 1 1 1 4
E2 1 2 0 3 2 1 0 0 4
E3 2 1 0 1 1 1 0 0 3
E4 1 0 0 1 0 0 1 1 0
E5 2 3 0 3 2 2 3 1 4
N6 1 0 0 0 2 3 0 0 1
N7 2 4 0 1 0 1 1 1 3
N8 3 1 1 2 1 2 2 1 2
N9 3 0 0 1 1 1 1 1 3
N10 2 0 0 0 1 1 0 0 0
N il 1 1 0 1 0 2 1 0
N12 1 1 0 1 1 1 3 1 1
N13 2 0 0 0 1 1 1 1 1
N14 2 1 0 1 1 1 1 1 2
N15 4 2 0 1 2 1 2 2
N16 1 0 0 1 1 1 0 0 3
N17 1 1 0 1 1 1 1 0 3
N18 1 0 0 0 0 0 0 1
N19 1 0 0 1 1 1 1 0 1
N20 2 1 0 1 1 1 1 1 2




peptide 1 by 5 amino acids. So a comparably weaker N-terminal horse epitope 
has been identified and localized to the first 15 amino-terminal residues.
It is possible that the N-terminal epitope was not apparent with the 
expressed fusion protein because of the relatively weak binding activity of the 
N-terminal residues corresponding to the epitope. Western blot immunoassays 
were employed to analyze immune reactivity to the recombinant proteins as 
opposed to the more sensitive ELISA assay utilized with the synthetic peptides. 
Peptides 2, 3, 4, 5 and 6 are also included in the E. coli expressed, amino- 
terminal protein. These peptide sequences did not exhibit 100% reactivity with 
the immune horse sera and possibly contributed to a folding motif which "hid" 
the dominant epitope. The pattern of antibody reactivity to peptides derived 
from the variable region of gp90 was different from the reported antibody 
binding to 2 recombinant proteins covering 200 amino acids of the variable 
sequence (83%). All sera from experimentally infected horses showed positive 
reactivity with the 2 expressed proteins, while sera from naturally infected 
animals reacted variably (33-40%) with the same 2 polypeptides (Payne, et al., 
1989). PLL-ELISA results with synthetic peptides corresponding to the 
variable sequence of gp90 as antigen are shown in Table 21.
In contrast to the recombinant fusion protein data, sera from 
experimentally infected animals displayed an overall lower reactivity than sera 
from naturally infected horses (Table 21). However, all of the experimentally 
























PLL-ELISA Results with Peptides from 
the Variable Region of gp90
Peptides
8V 9V 10V VI V2A V2B V3 V4A V4B V5A V5B V<
4 0 0 4 0 0 0 0 0 0 1 0
2 0 0 4 1 0 0 0 0 0 0 0
3 0 0 4 0 0 0 0 0 0 0 0
2 0 0 1 0 0 1 1 1 0 1 0
4 0 0 4 0 1 1 1 1 1 2 0
0 0 0 0 0 0 0 0 0 0 0 0
4 0 1 1 1 1 1 1 1 0 4 0
3 0 1 1 1 2 3 2 2 1 2 2
4 0 0 0 1 1 2 2 2 1 1 0
0 0 0 0 0 0 1 1 0 0
1 0 0 3 1 0 1 1 1 1 1 1
2 0 0 1 1 1 1 2 2 1 1 1
0 0 0 0 0 3 I 1 1 0 1
1 0 0 2 1 1 2 2 2 1 1 2
1 0 0 2 1 1 3 3 2 1 3 1
0 0 1 0 0 2 1 1 4 1
1 0 0 1 1 2 3 1 1 1 I 2
0 0 1 0 0 1 1 2 1 1
1 0 0 0 0 0 4 1 2 1 1 0
1 0 0 3 0 2 4 2 2 1 2 1
80 0 10 75 45 45 75 80 80 60 80 50
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naturally infected sera. No antibody reactivity was detected to peptide 9V with 
any of the sera tested, and only 10% of the sera bound peptide 10V. Possibly 
these segments are not exposed in the native protein structure or perhaps the 
prototype sequence is not recognized by the immune sera. The extensive 
amino acid sequence variation in this region of gp90 could preclude notable 
serological cross reactivity.
The remaining peptides representing the SU variable region show a 
weak, scattered reactivity pattern. Peptides 8V, V4A and V4B had the largest 
percent of antibody binding with peptide 8V exhibiting the highest relative 
reactivity.
In conclusion, immunoassays with variable peptides utilized as antigen 
provide an enhanced resolution of the previously defined conserved and 
variable domains within the EIAV env gene (Payne, et al., 1987).
Examination of the progression of the immune response in 
experimentally infected animals. Ponies were experimentally infected with 
either the avirulent prototype strain of EIAV (horses 78, 712, 714) or the 
virulent "6493" variant which was derived from prototype virus (horses 71, 74, 
76). Daily temperatures and approximately weekly bleeds were acquired to 
carefully monitor the immune response as the infection progressed. A 
graphical representation of the temperature patterns is shown in Figure 33 
(horses inoculated with prototype) and Figure 34 (horses inoculated with 
variant "6493"). A  febrile episode is defined as a temperature of 39.5 C (103.1
FIGURE 33. TEMPERATURE RECORD OF PONIES 
EXPERIMENTALLY INFECTED WITH PROTOTYPE EIAV.
Three equine were experimentally infected with the cell-adapted 
Wyoming strain (prototype) of EIAV. Rectal temperatures were monitored 
daily post infection and are graphically depicted. All sustained temperature 









































FIGURE 34. TEMPERATURE RECORD O F PO N IES  
EXPERIMENTALLY INFECTED WITH A VIRULENT VARIANT 
O F EIAV.
Three ponies were experimentally infected with the "6493" variant strain 
of prototype EIAV. Rectal temperatures were recorded daily. A graphical 
representation of the temperature log is shown. All sustained temperatures (2 
or more days) of 103.1 F (dashed line) were considered febrile episodes.
These infected animals displayed 2 (top panel) and 3 (center and 
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F) for 2 or more days (Dr. C J. Issel, personal communication). Of the 
prototype infected horses, only horse 78 demonstrated a single febrile episode 
(67-69 dpi). In contrast, all 3 of the 6493 infected horses displayed 2-3 febrile 
episodes by 49 dpi. Horse 71 had 2 episodes, 17-21 dpi and 41-44 dpi, while 
horses 74 and 76 each had 3 febrile incidents. Notably, horse 76 had a febrile 
episode which lasted for 10 days (15-24 dpi); none of the other horses had a 
sustained temperature for greater than 4 days (information acquired from the 
stable’s daily logs, Department of Veterinary Science, Louisiana State 
University).
Despite the lack of defined febrile incidents in prototype infected 
horses, all 3 of these horses seroconverted (positive by AGID) on day 17 post 
inoculation, and virus was recovered by 10 dpi. However, by day 17 post 
inoculation, virus was no longer recovered from horse 714. All 3 of the ponies 
infected with the variant virus seroconverted on day 21 post inoculation, and 
virus was recovered on 17 dpi (Dr. C. Issel, personal communication).
Table 22 (Panels A-C) and Table 23 (Panels A-C) summarize the 
relative reactivity of the chronological serum samples to a selected panel of 
synthetic peptides. Sera from prototype infected animals did not bind peptides 
V3 or V6, while there was strong reactivity to peptides 4 and 12 by day 17 post 
inoculation which remained strong in all 3 horses (Table 22). In addition, 
peptides VI and 51 gave positive absorbance values by 17 dpi with horse sera 
78; peptides VI and 11 displayed positive reactivity by day 14 with horse sera
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Conserved Variable Conserved gp45
DPI 1 4 6 8V VI V3 V6 11 12 51 R32
8 0 0 0 0 0 0 0 0 0 0 0
17 0 1 1 0 0 0 0 0 4 3 3
24 0 4 1 0 1 0 0 0 4 3 3
42 0 2 0 0 3 0 0 0 4 2 1
49 1 3 0 1 3 0 0 0 4 2 0
55 1 4 0 1 2 0 0 0 4 3 0
62 1 4 0 1 2 0 0 0 4 3 0
69 3 4 0 1 2 0 0 0 4 2 0
77 4 4 0 2 4 0 0 1 4 2 0
84 4 4 0 2 3 0 0 2 4 2 1
119 4 4 0 2 3 0 0 2 4 2 1
a) Experimentally infected with Prototype EIAV; a virulent of EIAV
b) dpi = days post inoculation
0 = no antibody binding detected
1 = absorabnce greater tha 2x the average absorbance of a panel of normal horse
sera (NHS)
2 = Absorbance greater than 4x the average NHS
3 = Abosrbance greater than 6x the average NHS
4 = Absorbance greater than 8x the average NHS
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Conserved Variable Conserved gp45
DPI 1 4 6 8V VI V3 V6 11 12 51 R32
8 0 0 0 1 0 0 0 0 0 0 0
14 0 2 0 0 2 0 0 0 3 0 2
21 0 4 1 1 2 0 0 1 4 0 2
24 0 4 1 3 2 0 0 1 4 1 2
38 1 4 1 1 2 0 0 3 4 1 1
42 0 3 2 1 0 0 1 4 0 0
45 0 4 1 3 2 0 0 2 4 0 1
49 1 4 1 3 2 0 0 3 4 0 1
55 1 4 1 2 2 0 0 4 4 0 1
65 1 3 1 2 2 0 0 3 4 1 0
70 1 3 1 2 2 0 0 3 4 1 1
77 1 3 1 2 2 0 0 3 4 1 1
119 1 4 1 3 3 0 0 4 4 1 1
140 1 4 0 3 4 0 0 4 4 1 1
a) Experimentally infected with Prototype EIAV; avirulent
b) dpi = days post inoculation
0 = no antibody binding detected
1 = absorabnce greater tha 2x the average absorbance of a panel of normal horse
sera (NHS)
2 = Absorbance greater than 4x the average NHS
3 = Abosrbance greater than 6x the average NHS
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Conserved Variable Conserved gp45
DPI 1 4 6 8V VI V3 V6 11 12 51 R32
7 0 0 0 0 0 0 0 0 0 0 0
17 1 3 3 0 0 0 0 0 4 1 3
24 2 4 2 1 0 0 0 0 4 1 3
42 2 4 1 1 0 0 0 0 4 2 1
49 2 4 1 1 0 0 0 0 3 2 1
56 2 4 1 1 0 0 0 0 3 1 1
70 2 2 0 1 0 0 0 0 2 1 1
77 2 2 0 0 0 0 0 0 2 1 0
83 2 1 0 0 0 0 0 0 2 1 0
91 2 1 0 0 0 0 0 0 2 1 0
146 3 1 0 0 0 0 0 0 1 1 0
a) Experimentally infected with Prototype EIAV; avirulent
b) dpi = days post inoculation
0 = no antibody binding detected
1 = absorabnce greater tha 2x the average absorbance of a panel of normal horse
sera (NHS)
2 = Absorbance greater than 4x the average NHS
3 = Abosrbance greater than 6x the average NHS
4 = Absorbance greater than 8x the average NHS
202




Conserved Variable Conserved gp45
DPI 1 4 6 8V VI V3 V6 11 12 51 R32
8 0 0 0 0 0 0 0 1 0 0 0
17 0 0 0 0 0 0 0 0 0 0 1
24 0 4 4 4 4 0 1 4 4 4 4
35 4 4 4 4 2 0 0 4 4 1 4
42 4 4 2 4 2 0 0 4 4 1 4
49 4 4 4 4 4 0 0 4 4 4 4
55 4 4 3 4 4 0 0 4 4 4 4
62 4 4 3 4 4 0 0 4 4 4 4
70 4 4 2 4 4 0 0 4 4 4 4
77 4 4 3 4 4 0 0 4 4 3 4
84 4 4 2 4 4 0 0 4 4 2 4
91 4 4 2 4 4 0 0 4 4 1 2
119 4 4 2 4 4 0 0 4 4 1 2
147 4 4 1 3 4 0 0 4 4 1 2
a) Experimentally infected with the virulent 6493 variant of EIAV
b) dpi = days post inoculation
0 = no antibody binding detected
1 = absorabnce greater tha 2x the average absorbance of a panel of normal horse
sera (NHS)
2 = Absorbance greater than 4x the average NHS
3 = Abosrbance greater than 6x the average NHS
203




Conserved Variable Conserved gp45
DPI 1 4 6 8V VI V3 V6 11 12 51 r :
8 0 2 0 0 0 0 0 0 0 0 0
10 0 2 0 0 0 0 1 0 0 0 0
14 0 2 0 0 0 0 0 0 0 0 0
17 0 2 0 0 0 0 0 1 0 0 1
21 0 4 1 4 1 0 0 4 4 2 4
24 0 4 4 4 1 0 0 4 4 3 4
35 1 4 2 4 2 0 1 4 4 2 4
38 1 4 1 4 2 0 0 4 4 2 4
42 1 4 1 4 3 0 0 4 4 3 4
45 1 4 1 4 4 0 0 4 4 4 4
49 1 4 2 4 1 1 4 4 4 4
55 2 4 2 4 4 0 1 4 4 4 4
62 3 4 2 4 4 1 1 4 4 4 4
70 4 4 2 4 1 1 4 4 4 4
77 4 4 2 4 4 1 0 4 4 4 4
84 4 4 2 4 4 0 0 4 4 4 4
91 4 4 1 4 4 0 0 4 4 4 4
119 4 4 1 3 4 0 0 4 4 4 4
140 4 4 1 3 4 0 0 4 4 4 4
143 4 4 1 2 4 0 0 4 4 4 4
a) Experimentally infected with the virulent 6493 variant of EIAV
b) dpi = days post inoculation
0 = no antibody binding detected
1 = absorabnce greater tha 2x the average absorbance of a panel of normal horse
sera (NHS)
2 = Absorbance greater than 4x the average NHS
3 = Abosrbance greater than 6x the average NHS
4 = Absorbance greater than 8x the average NHS
204




Conserved Variable Conserved gp45
DPI 1 4 6 8V VI V3 V6 11 12 51
8 0 0 1 0 0 0 0 0 0 0
10 0 1 2 0 0 0 0 0 0 0
14 0 0 1 0 0 0 0 0 0 0
17 0 0 1 0 0 0 0 0 0 1
21 0 0 4 3 1 0 0 0 2 3
24 0 2 2 4 3 0 0 4 4 3
28 0 4 3 4 3 0 0 4 4 4
35 0 4 2 4 2 0 0 4 4 4
42 0 4 2 4 1 0 0 4 4 4
45 0 4 1 4 1 0 0 4 4 4
49 1 4 4 2 3 0 0 4 4 4
55 2 4 2 2 3 0 0 3 4 4
65 1 4 1 2 3 0 0 3 4 4
77 1 4 2 1 4 0 0 2 4 4
84 1 4 1 1 4 0 0 2 4 4
91 4 4 2 4 4 0 0 4 4 4
91 1 4 1 1 4 0 0 2 4 4
105 1 4 1 0 4 0 0 1 4 4
119 1 4 1 0 4 0 1 1 4 4
140 0 4 1 0 4 0 0 1 4 4
153 0 4 1 1 4 0 0 0 4 4
0
0
a) Experimentally infected with the virulent 6493 variant of EIAV
b) dpi = days post inoculation
0 * no antibody binding detected
1 = absorabnce greater tha 2x the average absorbance of a panel of normal horse
sera (NHS)
2 ~ Absorbance greater than 4x the average NHS
3 = Abosrbance greater than 6x the average NHS
4 = Absorbance greater than 8x the average NHS
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712; and peptide 1 bound horse sera 714 by day 17 post inoculation. These 
peptides reacted with relatively strong binding which was maintained over time. 
Finally, some peptides displayed variable binding with certain antisera, i.e., the 
peptide would test positive with sera from 17 dpi, negative with sera from 49 
dpi and then positive again with sera from 84 dpi (Panel A, peptide R32).
Two explanations for this variable reactivity have been proposed. The first 
hypothesis is that the antibody has been bound (or cleared) by binding to virus 
or viral proteins which are circulating in the infected host serum during a 
period of intense antigenemia as seen with SIV in serial serum samples 
(Zhang, et al., 1988). The second theory is that the antibody titer fluctuates 
over time, reflecting the cyclic nature of the infection. Only by further 
experimentation can these hypotheses be proven or dispelled.
Sera from "6493" infected animals tested with an overall higher 
reactivity and with a higher sustained titer. Peptides 4, VI, 12, 51 and R32 
displayed positive reactivity by day 24 post inoculation and remained strongly 
positive (relative reactivity of 4) for all 3 horses (Table 23). Horse sera 74 
reacted with peptide 4 by 8 dpi and sera from horse 76 gave a positive reaction 
with peptide 6 by 8 dpi, significantly before seroconversion was detected by 
AGED (21 dpi). Very strong antibody binding was also observed with horse 
sera 71 and 74 when analyzed against peptides 1, 8 and 11. Similar to the 
prototype infected horses, variable reactivity over time was noted with the 6493 
infected horse sera.
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Taken together, peptides 4 and 12 were detected early by both 
prototype and variant infected equine sera. These peptides consistently 
remained positive and gave high relative absorbance readings with each sera. 
As a diagnostic reagent, these peptides are reasonable candidates.
Epitope mapping of gp90. The production and characterization of six 
gp90 monoclonal antibodies have been described previously (Hussain, et al.,
1987). Five monoclonal antibodies representing gp90 epitopes A-D and F 
were tested for binding with env recombinant proteins by Western blot assays 
(Payne, et al., 1989). This data indicated that MAbs which define epitopes B, 
C, D and F bind with sequences in the variable region of gp90 while the MAb 
which defines epitope A reacts with a sequence in the N-terminal conserved 
domain. Based on these results, MAbs were appropriately tested against either 
variable region peptides or N-terminal conserved peptides. Initially, the 
antibody reactivity pattern was as follows: MAb defining epitope A reacted 
with peptide 4 in the amino-terminal region, MAb representing epitope B 
bound peptide V2, MAb specifying epitope C (neutralizing) was localized to 
peptide V4, MAb which defines epitope D (neutralizing) reacted with peptide 
VI and lastly, MAb which represents epitope F bound peptide V5.
Significantly, in agreement with the fusion protein data, 4 out of the 5 
monoclonal antibodies analyzed, including the 2 neutralizing antibodies, were 
localized to the variable region of gp90.
To further localize the mouse epitopes to minimal sequences,
overlapping peptides were synthesized covering the sequences of each of the 
previously determined reactive peptides (peptides 4, VI, V2, V4 and V5). The 
monoclonal antibodies were then reanalyzed with these smaller peptides. 
Antibody reactivity defined the epitopes to 9-12 amino add residues as defined 
in Table 24. Thus, each monoclonal epitope has now been localized to near 
minimal sequences. Both neutralizing antibodies map to the variable region of 
gp90 as well as 2 of the nonneutralizing monoclonal antibodies. The single, 
conserved epitope maps to the N-terminal region of gp90 (peptide 4) which 
bound 80% of the immune equine sera tested.
TABLE 24. EIAV SU MONOCLONAL ANTIBODY EPITOPES
Euitoue Residue Numbers Amino Acid Seauence
gp90 A 5 0 -5 8 KEARDQEMN
gp90B 229 - 238 NINIDTWIP
gp90 Cjyp 270 - 280 PPFFLVQEKGI
gp90 201 - 209 NTAEYWGFK
gp90 F 305 - 316 RGDYTACNVR.
CHAPTER 4 
DISCUSSION
Development of a lentivirus glycoprotein purification technique.
The HPLC parameters and results presented here demonstrate that 
reverse-phase HPLC using compressed phenyl cartridges eluted judiciously with 
an acetonitrile gradient can effect the purification of the viral proteins and 
glycoproteins of EIAV from purified virus in a single step. The procedure is 
straightforward and efficient in producing proteins suitable for biochemical and 
immunological procedures. The purity and identity of each of the proteins 
isolated in this single step has been verified by SDS-PAGE, immunoblot, and 
N-terminal sequence analyses. Additional experiments examining the 
adsorption and desorption properties of HTV gpl20 and gp41 on the phenyl 
resin indicate that the described system should be a functional strategy in the 
purification of these viral components, either from purified virus, virus-infected 
cell extracts, or cloned antigen preparations. Furthermore, this purification 
protocol has been successfully employed in the isolation of other lentivirus SU 
glycoproteins from purified virus, including visna virus gpl35 (Dr. J. Clements, 
personal communication), and SIV gpllO (data not shown). In this regard, the 
SU and TM proteins of each of the respective lentiviruses elute from the 
phenyl bound resin at about 40% and 56% acetonitrile, respectively. These 
similarities in chromatographic elution properties reflect a  similarity in
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hydrophobicity and support the proposed conserved structural features of these 
envelope proteins.
The purification technique outlined offers a number of advantages over 
previously reported HPLC procedures for purifying retrovirus proteins 
(Henderson, et al., 1987). The phenyl matrix efficiently adsorbs and desorbs 
proteins of widely varying hydrophobicity which eliminates the need for 
multiple columns, additional organic solvent elutions and elevated column 
temperatures. The rapidity and mildness of the chromatographic conditions 
also facilitate maximum recovery of native protein properties, including 
antigenicity and immunogenicity. Based on these observations, it appears that 
the phenyl resin may be a more versatile matrix for protein isolations than 
previously recognized, especially for purifying hydrophobic, membrane 
associated glycoproteins. The success of the phenyl bound phase evidently 
cannot be attributed only to its degree of hydrophobicity, since resins of similar 
(CN, C8) or less (C3) hydrophobicity irreversibly bound EIAV and HIV 
glycoproteins.
The purification of EIAV gp90 and gp45 constitutes the first successful 
isolation of the env glycoproteins from any lentivirus system from purified 
virus, despite extensive efforts. Availability of an efficient purification 
technique for the EIAV gag protein, p26, in addition to the SU and TM 
proteins provides valuable reagents for the development of diagnostic and 
vaccine protocols for this economically important virus infection.
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Gas phase sequencing of HPLC purified proteins.
Protein sequencing of isolated gp90 and gp45 verified the amino acid 
sequences deduced previously from the env gene nucleotide sequence 
(Rushlow, et al., 1986) and confirmed the predicted proteolytic cleavage site 
between the 2 glycoproteins. In addition, direct sequencing of the purified env 
products helped to resolve conflicting nucleotide sequence analyses for the 
EIAV genome (Ball, et al., 1988). An unanticipated result was the finding that 
the amino-terminal residue of gp90 is only 7 residues downstream of the 
initiating methionine.
It has generally been assumed that the signal peptides of lentiviruses 
can be identified from nucleotide sequence data and that these signal 
sequences are removed completely during processing of the envelope 
polyprotein to mature viral proteins. However, a number of signal peptides 
are retained in a variety of secreted or membrane associated proteins 
(Wickner and Lodish, 1985). In HTV, the entire 30 amino acid signal peptide 
is removed during processing of gpl60 to gpl20 and gp41 as confirmed by 
amino acid sequencing (Allan, et al., 1985). The first 25 to 35 amino acids of 
SIV gpllO are hydrophobic, but the signal sequence lacks the hydrophilic 
residues which usually precedes the hydrophobic amino acids (Fukasawa, et al.,
1988). In contrast, the putative signal sequence in visna virus is a stretch of 25 
hydrophobic amino adds that is preceded by 78 hydrophilic residues. Analysis 
of the N-terminal amino add sequences of these respective envelope proteins
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would help to determine if complete or partial signal peptide sequence 
removal is the usual route of lentivirus env protein processing.
In EIAV, the amino-terminus is conserved among serologically distinct 
virus isolates (Payne, et aL, 1987). In fact, a  horse epitope has now been 
identified at the known amino-terminus (peptide 1). Thus, it can be assumed 
that this segment of gp90 which represents the putative signal sequence is 
conserved and accessible in its native form. Examination of the amino acid 
sequence in this region reveals that it does not share all of the conserved 
structural features of a signal peptide: a) a charged amino-terminal region, 
usually with a net positive charge, b) a central core of hydrophobic residues 
and c) a C-terminal polar region which contains the signal peptidase cleavage 
site (Randall and Hardy, 1989; Briggs and Gierasch, 1986). As reported, the 
length of the N-terminal charged region is quite variable ranging from 2 to 8 
or more amino acids. The hydrophobic core varying between 7-20 amino acids 
is described as the most distinctive feature of the leader sequence with most 
signal peptides having 10-15 hydrophobic residues. Finally, the carboxyl polar 
region ranges from 4-10 amino acids with the cleavage site being defined by 
the last 3 residues of this region (Briggs and Gierasch, 1986). Taken together, 
signal sequences range in length from 13-36 amino acid residues. Considering 
the EIAV sequence, the 6 amino adds which are removed during processing 
are not suffident to serve as a signal peptide and lack the characteristic 
charged residues. Hence, it is assumed that most of the leader sequence is
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retained and not cleaved by the signal peptidase. Further examination of the 
N-terminal amino acids of E1AV discloses a clustering of hydrophobic residues 
followed by a charged domain, however the only residue preceding the 
hydrophobic core is tyrosine. Perhaps the hydroxyl group of tyrosine is 
sufficiently polar given the large variation in length and tremendous variation 
in sequence of known signal sequences (Randall and Hardy, 1989).
The first 6 amino acids from the initiating methionine are very 
hydrophobic, so even if these residues play a role in the leader sequence 
before they are removed, there are still no N-terminal charged residues. The 
hydropathy parameters of Hopp and Woods (1981) calculate the first 13 
residues from the N-terminal tyrosine as hydrophobic, followed by a 
hydrophilic region of 10 amino acids. A similar pattern was predicted by the 
parameters of Kyte and Doolittle (1982) except that the hydrophobic segment 
included 2 additional residues and the hydrophilic region was extended to 15 
amino acids. This pattern is well within the limits established for the 
hydrophobic core and the carboxyl charged segment of signal sequences. So 
perhaps, like SIV, the E1AV signal lacks the N-terminal charged domain but 
contains the distinctive and conserved hydrophobic core followed by a region 
of dense charge.
The TM structural model and immune reactivity of gp45.
A  proposed structural model of the TM glycoprotein of EIAV has been
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described which concurs with the reported structural features of retrovirus TM 
proteins (Gallaher et al., 1989) including the hydrophobic fusion domain, an 
extended amphipathic helix, vicinal cysteines followed by a conserved N-linked 
glycosylation site, an immunodominant region, and several conserved reverse 
turns (Figure 21). This model parallels the known structural characteristics of 
the membrane-spanning protein of influenza virus, HA2. The HA2 fusion 
domain has been localized to its hydrophobic amino terminus immediately 
following the REKR cleavage site (Richardson, et al., 1980). An extended 54 
amino acid alpha-helix which has been determined to be highly fibrous 
precedes a region containing vicinal cysteines (Daniel, et al., 1985). The HA2 
structure was resolved by X-ray crystallography at a resolution of 3 angstroms 
and was reported to have an "unusual loop-like topology" that begins at the 
membrane and extends for 135 angstroms distally before folding back to enter 
the membrane (Wilson, et al., 1981). Finally, the HA glycoprotein heterodimer 
(HA1 and HA2) exists as a trimer built of triple-stranded coiled coil alpha- 
helices which extend for 76 angstroms from the membrane and a globular 
region composed of anti-parallel beta-sheet conformations that contain the 
receptor binding site (Air and Laver, 1986).
With the HA2 protein structure confirmed and the premise that 
functionally homologous proteins would have similar structural properties, it 
seemed reasonable to develop a working model of the EIAV TM protein 
based on known functional properties and computer algorithms despite its
215
speculative nature. Experimental data and physical characterization will 
eventually verify or disprove its validity.
Fusion domain. Examination of the EIAV N-terminal fusion sequence 
by peptide immunoassays with equine immune sera disclosed that 70% of the 
sera binds the synthetic fusion peptide (Table 19). The extracellular location 
of the fusion peptide is supported by this high percentage of reactivity with 
infected horse sera. Additional evidence that the amino-terminus of gp45 is 
extracellular comes from the known structure of the well-characterized 
influenza HA2 protein. The 3-dimensional structure of HA2 shows that it only 
crosses the membrane once, that the amino-terminal residues are buried in the 
envelope molecule after cleavage (Air and Laver, 1986) and only after a gross 
conformational change is the N-terminus exposed (Skehel, et al., 1982). The 
fusion function of this domain has been confirmed in HIV by mutational 
analyses of gp41 that prevent HIV-induced fusion (Kowalski, et al., 1987). 
Additional evidence has been presented which demonstrates that HIV enters 
susceptible cells by direct fusion of the virus envelope with the plasmalemma 
in a pH-independent reaction (Stein, et al., 1987). Thus, it is probable that 
one mechanism of EIAV entrance into an uninfected cell is via fusion of the 
viral and cellular membranes which is directed by the hydrophobic N-terminal 
fusion peptide.
C-terminal sequences. Lentivirus TM proteins differ from that of other 
retroviruses in the presence of additional sequences at their carboxyl termini
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(Ratner, et al., 198S; Gallaher, et al., 1989). The carboxyl sequence of HIV 
gp41 consists of a hydrophilic region (residues 724-745) succeeded by a region 
of alternating hydrophilic and hydrophobic character (residues 745-856) 
(Kowalski, et al., 1987). Moreover, a similar pattern is present in the EIAV 
gp45 carboxyl domain. Hopp and Woods parameters indicate an extended 
hydrophilic region (residues 658-787) and AMPHI calculations disclose a 
region of alternating polar character (residues 707-734, 770-786, 812-829, and 
834-854). It has been suggested that these amphipathic helices interact in such 
a way to form stable salt linkages which could contribute to lentivirus 
cytopathology by forming a membrane-spanning channel (Venable, et al., 1989)
The carboxyl terminal sequences of gp45 were expressed as recombinant 
proteins and displayed weak reactivity with equine immune sera (Chong, et al., 
1990) and consequently poor correlation with predicted antigenic sites (Figure 
22). The composite surface plot which indicates surface accessible sites based 
on sequence alone revealed 6 regions with greater than 50% surface value 
localized between residues 655 and 765 in the carboxyl-terminal region of 
gp45. Serological data with expressed proteins as antigen disclosed an average 
of 55% reactivity with equine immune sera, 4 of which had no reactivity with 
any of the C-terminal fusion polypeptides (Chong, et al., 1990). This data 
presents a dramatic contrast to the strong immune reactivity in horse sera 
detected against the N-terminal sequences of the TM protein.
Polyclonal antisera to HPLC-purified gp45 was produced in rabbits and
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strongly reacted with all of the carboxyl fusion proteins. Thus, in its isolated 
form, gp45 reactivity correlates to its predicted antigenicity. This contradiction 
in reactivity with membrane-bound and isolated protein indicates that most of 
the predicted antigenic sites are sequestered from the host immune system 
during the course of a persistent EIAV infection. Consistent with the 
proposed structural model and reduced immune recognition by equine immune 
sera, the hydrophilic carboxyl region of gp45 is likely to be localized to the 
cytoplasmic side of the cell membrane. Obviously the apparent, although 
weak, immune reactivity observed with the C-terminal recombinant proteins 
may be due to the release of gp45 from the membrane during cell lysis, or 
perhaps to a unique conformation of the TM protein in the mature virus 
particle which renders the C-terminus more accessible than previously 
recognized, or to antigen processing by antigen presenting cells.
The extended alpha-helix. One of the most distinctive features of the 
TM model is the extended amphipathic helix. An extended alpha-helical fiber 
has been identified in HA2 of influenza virus, the peplomeric protein of 
coronaviruses, and the hemagglutinin of reovirus (Wilson, et al., 1981; de 
Groot, et al.> 1987; Bassel-Duby, et al.y 1985). Retrovirus env glycoproteins 
have been reported to exist as multimers based on sedimentation gradient 
centrifugation analyses (Einfeld and Hunter, 1988) and chemical crosslinking 
data (Schawaller, et al., 1989). These multmeric forms are possibly induced by 
hydrophobic bonding along the alpha-helical fiber to form coiled-coil
218
structures, such that mutations along the helical backbone may disrupt the 
organization of the virion and its antigenicity. For example, a HIV mutant in 
this region (Ala 582 to Thr) abolishes antibody neutralization of HTV at distant 
epitopes (Reitz, et al., 1988). Presumably this loss of neutralization is due to 
conformational changes in the heterodimer.
Antigenic sites recognized by T-cells have been postulated to be 
amphipathic helices with one face predominantly polar and the opposite face 
predominantly apolar (Spouge, et al., 1987). It was also reported that both the 
hydrophilic and hydrophobic sides may be critical for T-cell activation with the 
polar face interacting with the T-cell receptor while the apolar face interacts 
with the antigen presenting cell (Margalit, et al., 1987). Instead of binding 
proteins with their native structure intact, T-cells are stimulated by short 
peptide fragments of the immunogen (Streicher, et al., 1984). A structural 
model for the recognition of peptides has been developed and indicates that 
class II histocompatibility proteins specifically bind peptide antigens (Rothbard 
and Taylor, 1988). Thus, the extended helical region of gp45 with amphipathic 
character could encompass several T-cell epitopes. This is important given 
that T-cell activation has been shown to be critical for clearance of many viral 
infections (Schrier, et al., 1988). Accordingly, an optimal vaccine should 
stimulate both T- and B-cell responses.
Immunodominant domain. Between 1986 and 1989, several groups 
independently reported the presence of a single, highly immunodominant
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region in the conserved N-terminal region of the TM protein of HIV (Norrby, 
et al., 1989; Schrier, et al., 1988; Narvanen, et al., 1988; Wang, et al., 1986; 
Gnann, et al,, 1987b; Johnson, et al., 1988). These reports employed synthetic 
peptides representing gp41 residues 582-613 in different combinations and 
lengths, and revealed a reactivity of 99% - 100% with the immune sera tested. 
This region is analogous to EIAV gp45 residues 522-547 represented by 
peptides R32 and 51 (Figure 31).
Norrby, et al. (1989) discovered a restricted dependence on individual 
amino acids with HIV-1 positive sera in the immunodominant region of gp41. 
By employing a set of deletion peptides and/or glycine substitutions 
representing gp41 residues 582-604 fAVERYLKDOQLLGlWGCSGKLICl. a 
dominant HIV antigenic site was localized between 597Gly and 602Leu which 
contains one of the vicinal cysteines (Norrby, et al., 1989). The authors 
identified a second antigenic site in the C-terminal half of the peptide. 
Ultimately, the data emphasized the critical role of 599Ser and 601Lys between 
the 2 cysteines in the first immunoreactive site, and residues 586Tyr and 589Asp 
in the second site. Significantly, the immunodominant region of EIAV has 
been localized to a similar sequence and relative location in gp45. Peptide 51 
which contains both of the vicinal cysteines (IGCBERTHVF£HTG) reacted 
with 90% of the equine immune sera. However, peptide R33 which includes 
the residues flanked by the vicinal cysteines (IERTHVF) only reacted with 
45% of the sera analyzed. Apparently, the amino acids contributing to the
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dominant TM epitope are included in the sequence of peptide 51 and not 
peptide R33. Examination of the residues which are present in peptide 51 and 
absent in peptide R33 revealed an N-terminal De-Gly-Cys and a C-terminal 
Cys-His-Thr-Gly. Comparison with the immunodominant HIV sequence 
indicated that the additional reactive residues of peptide 51 are most likely the 
N-terminal He-Gly-Cys. The glycine is in exact agreement with the glycine 
immediately preceding the first cysteine in HTV gp41 (597GIy). In addition, 
preceding the glycine in gp41 is the hydrophobic residue, tryptophan, which is 
analogous to the hydrophobic isoleucine preceding the glycine in gp45. It is 
likely that an extension of peptide R33 to include the N-terminal trimer (Ile- 
Gly-Cys) which is analogous to the immunodominant HIV sequence would 
generate an antigen as immunoreactive as peptide 51 with equine immune 
sera. Thus, it appears that at least one of the cysteines plays a role in 
antibody binding in the natural host.
In contrast to the equine antibody binding sequence, the mouse 
monoclonal antibody which defines epitope gp45 A efficiently binds peptide 
R33. Thus, it appears that neither cysteine is required for monoclonal 
antibody binding even though one of the vicinal cysteines is needed for 
maximum equine antibody binding activity. It is likely that both cysteines are 
necessary for antigen presentation in both the horse and the mouse. Disulfide 
linkage between the 2 cysteines results in a loop conformation causing the 
relatively hydrophobic residues flanked by the cysteines to protrude from the
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molecule. Such a protrusion would make that sequence quite accessible. This 
model is supported by additional studies in which the sulfhydryl groups were 
blocked by carboxymethylation and the binding assays were repeated. The loss 
of the cysteine functional groups did not influence monoclonal antibody 
binding, but significantly reduced equine immune reactivity (Ball and 
Montelaro, unpublished results). The effect of carboxymethylation on antigen 
presentation was not determined, but would be an interesting question to 
pursue.
The second antigenic site localized by Norrby, et al. (1989) is analogous 
to the gp45 sequence corresponding to peptide R32 which reacted with 100% 
of the immune equine sera. The critical residues elucidated in HIV were 
586Tyr and 589Asp (above) which are located 9 residues downstream from the 
first vicinal cysteine. The relatively polar tyrosine and the acidic aspartate are 
separated by a polar (Glu) and apolar residue (Leu). Further inspection of 
the residues composing peptide R32 discloses a similar pattern. Ten residues 
downstream from the first vicinal cysteine and 3 residues apart are the polar 
and acidic residues, glutamine and glutamate, which are separated by arginine 
(polar) and glutamine residues.
Notably, HIV-1, HIV-2 and SIVmH/, antibody-positive sera exhibit similar 
reactivity with synthetic peptides from the same region of the TM protein. In 
contrast to the 1-2 natural host epitopes represented in these peptides, 5 
unique monoclonal antibodies delineated 5 distinct mouse epitopes (Norrby, et
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al., 1989). Obviously, the native, folded and glycosylated TM protein only 
exposes 1 or 2 antigenic sites in this selected region while an isolated, 
unglycosylated and probably unfolded polypeptide discloses several linear 
antigenic determinants.
It remains to be explained how most lentivirus infected animals identify 
such a narrow target in this relatively hydrophobic variable sequence. Possibly, 
a disulfide linkage between the conserved vicinal cysteines presents a 
conserved, exposed conformation across the lentivirus TM proteins. Or 
perhaps this site accommodates a collection of immunogenic epitopes which 
binds a variety of different antibodies. This hypothesis is supported by the 
finding of a  varying dependence of different HIV-1 positive sera on additional 
rircumferrential amino acids outside the critical residues for antibody binding 
(Norrby, et al., 1989) and perhaps explains the variable reactivity with the 
EIAV TM peptides 51 and R33. This is an object of further studies.
Schrier, et al. (1988) examined T-cell proliferation responses to a 12 
amino acid peptide of HIV gp41 (residues 598-609) encompassing the 
immunodominant epitope and both vicinal cysteines. Although greater than 
99% of the samples tested demonstrate antibody to this peptide, only 24% of 
the samples stimulate an in vitro lymphocyte proliferative response to the 
peptide. Additionally, the authors uncovered both IgG and IgM antibodies 
early after primary infection against the dominant gp41 epitope. The IgG 
antibody response was found to be T-cell dependent in mice, while the IgM
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response was found to be T-cell independent In HIV-1 infected individuals, a 
transient IgM response was detected early in the course of infection, while the 
IgG response was sustained (Schrier, et al., 1988). Perhaps by utilizing 
conjugated anti-IgG as secondary antibody in peptide immunoassays, an early 
equine IgM response went undetected. It would be interesting to examine the 
IgM response in horse sera soon after a primary EIAV infection, especially to 
this immunodominant region of gp45.
Synthetic peptides have been shown to generate neutralizing antibody 
responses in laboratory animals (Chanh, et al., 1986). Significantly, rabbit 
antibody directed against the dominant, N-terminal epitope of gp41 contained 
HIV-1 neutralizing activity in vitro (Schrier, et al., 1988). This strongly suggests 
that peptide 51 (analogous to the HIV 12-mer used to produce neutralizing 
antibody in rabbits) could generate rabbit antisera which neutralizes EIAV in 
vitro. Given the conservation of gp45 across several EIAV isolates (Payne, et 
al., 1987), a neutralizing antibody directed at this region may be capable of 
neutralizing a variety of EIAV isolates and thus, may be an engaging vaccine 
candidate.
Finally, the 100% reactivity obtained with peptide R32 agrees with the 
serological data of Wang, et al. (1986) who reported 100% reactivity with a 
HIV peptide (residues 586-606) from the analogous TM region.
Immunosuppressive peptide. Immunosuppression often accompanies 
retrovirus infections. A highly conserved and immunosuppressive sequence has
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been identified in the TM proteins pl5E of the murine and feline leukemia 
viruses, and p21 of the human leukemia viruses, HTLV-1 and HTLV-2 
(Cianciolo, et cd.t 1984). Amino acid sequence homology of the 
immunosuppressive peptide was reported to be 73% between these various 
leukemia TM proteins (Cianciolo, et al., 1984). Inhibition of immune function 
by HIV in vivo has been duplicated in vitro where noninfectious HTV inhibited 
mitogen- and antigen-driven proliferation of T cells and differentiation of B 
cells (Pahwa, et al., 1985). Analogous to the TM proteins pl5E  and gp21, the 
HIV TM protein was found to possess immunomodulatory activity and has 
been localized to residues 581-597 (Ruegg, et a l 1989). This peptide segment 
displays 47% sequence homology over 17 amino acids with the previously 
reported retrovirus immunosuppressive sequence and directly inhibits 
lymphoproliferation in vitro (Ruegg, et cd., 1989). The HIV inhibitory region 
overlaps with the immunodominant B-cell epitope described above. Also 
mentioned above was the data presented by Schrier, et al. (1988) which 
demonstrated in the mouse that the IgG response to gp41 residues 584-609 was 
T-cell dependent. Hence, the immunosuppressive sequence overlaps with a 
strong B-cell and T-cell helper epitope. The immunological significance of this 
TM segment is not completely known, however, Klasse, et al. (1988) reported 
that positive antibody reactivity to the immunosuppressive peptide was strongly 
associated with the absence of HIV-related disease. This correlation has also 
been suggested in the murine leukemia model where anti-pl5E antibodies
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appeared to prevent the immunosuppressive effects of pl5E  (Thiel, et al.,
1987). These data present a delicate balance between the suppressive and 
immunogenic activities localized to the N-terminal region of HIV gp41 and a 
potential candidate for immunoprophylactic and therapeutic intervention.
Close examination of the HIV immunosuppressive peptide sequence 
(LQARILAVERYLKDOQL) and comparison to the N-terminal sequence of 
EIAV gp45 disclosed that peptide R31 could represent a putative 
immunosuppressive peptide in EIAV. Peptide 31 (LQTHADVQLLDERQ) is 
located in the same relative position as the HIV immunosuppressive segment 
and overlaps with a strong B-cell determinant (peptide R32). In addition, 
peptide R31 is located at the C-terminus of the extended amphipathic helix 
(Figure 31) and therefore, could potentially overlap with a T-cell helper 
epitope. Finally, 3 of the 16 amino acid residues are exactly the same as the 
HIV immunosuppressive sequence and an additional 4 residues are conserved 
in hydropathic properties. Serological analyses of peptide R31 in peptide 
immunoassays revealed 55% reactivity with equine immune sera with only one 
of the experimentally infected horses giving a positive reaction (Table 19).
The potential immunosuppression activity of this peptide has not been 
examined, but would be an intrigueing study and would provide valuable 
information concerning a relevant component of EIA disease progression.
The SU structural model and immune reactivity of gp90.
SU antigens have been the object of intense investigations since they
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mediate infection of host cells and serve as the primary target of the host 
immune response (Montelaro and Bolognesi, 1978). Antigenic variation 
displayed by lentivirus SU proteins is an effective strategy used to escape the 
current immune status of the host Emergence of antigenically distinct virus 
strains in EIAV persistent infections has been well documented and can 
explain both the recurrent nature of EIA and the complete failure of classical 
vaccination protocols. Crucial to comprehending the complex immunologic 
processes at work in the EIAV infected animal is a detailed study of the 
immunogenic regions of the SU glycoprotein and the effect of sequence 
variation on these immunogenic properties. Thus, identification and 
localization of distinct EIAV epitopes which react with both experimentally 
and naturally infected horses is critical to developing and evaluating potential 
vaccine strategies. Overlapping peptides were chemically synthesized and 
reacted with a panel of equine immune sera, monoclonal antibodies and 
immune horse sera monitored over time. In addition, a detailed retrovirus SU 
structural model has been proposed.
HIV receptor. Several studies have implicated the CD4 surface antigen 
as a component of the host cell receptor for HIV (Dalgleish, et al., 1984; 
Klatzmann, et al., 1984; McDougal, et al., 1986). These initial reports were 
based on the ability of various CD4 monoclonal antibodies to block viral 
infection of CD4-positive cell lines, and on the demonstration of a specific 
complex formed between gp!20 and the CD4 surface antigen. Confirmation of
CD4 as the HIV receptor was presented by Maddon, et al. (1986) where cell 
lines nonpermissive for HIV infection became permissive following transfection 
and expression of the CD4 cDNA sequence. HIV gpl20 binds CD4 at a site 
spatially related to that recognized by the OKT4A monoclonal antibody, and 
both purified gpl20 and OKT4 Mab are able to interfere with virus infectivity 
(Matthews, et al., 1987). Finally, Lasky, et al. (1987) determined the amino 
acid residues of gpl20 that interact with the CD4 receptor by identifying 2 
gpl20-specific monoclonal antibodies which inhibit binding to CD4. Epitopes 
corresponding to these Mabs were mapped to a relatively conserved C-terminal 
region of gpl20 (residues 427-469). Mutation analyses of this region resulted 
in diminished CD4 binding and almost a complete loss of binding when 
residues 440-451 were deleted (Lasky, et al., 1987),
Lentivirus binding domain. Examination of the HTV binding domain 
with respect to the SU structural algorithms disclosed that the putative binding 
region had an amphipathic score of 38.9 and a potential reverse turn at each 
end. By inspecting the other lentivirus SU sequences, a common structural 
and sequence pattern developed (Table 25). Although it was anticipated that 
the CD4 binding site of gpl20 would be highly conserved, the reported HIV 
binding domain displays only partial conservation (Lasky, et al., 1987).
However, the disulfide-bonded cysteines resulting in a distinct loop 
conformation (T. Gregory, unpublished results), the high thermal stability of 
gpl20 (McDougal, et al., 1986), and the elevated amphipathic score suggests a
TABLE 25. COMMON PATTERN OF THE PUTATIVE 
LENTIVIRUS BINDING DOMAIN.
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1. High calculated amphipathic score.
2. High reverse turn potential at each end of the binding segment.
3. Cysteine residue at each end of the segment near the reverse turn.
4. A conserved tryptophan residue near the center of the "looped" domain.
5. A minimum of 2 positive charges.
6. Conserved valine followed by either lysine or arginine.
7. Segment flanked by proline, often a double proline in the C-terminal 
region of the domain.
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highly stable conformation despite the variation of sequence in this region. It 
is possible that other highly conserved regions of gpl20 play a role in 
maintaining the appropriate tertiary structure for receptor binding or play a 
role in virus entry distinct from CD4 binding (Lasky, et al., 1987). Shown in 
Figure 35 are the proposed lentivirus SU binding domains which are analogous 
to the CD4 binding region of HIV.
SIV and HIV-2 also appear to infect CD4-positive cells by interacting 
with the CD4 antigen (Hirsch, et al., 1987; Guyader, et al., 1987). The putative 
binding domain of these viruses display a remarkable sequence homology to 
the variable HIV binding sequence (Figure 35). Viral tropism for cells of the 
lymphoid and monocyte/macrophage lineage is believed to result from this 
specific interaction between the SU glycoprotein and the CD4 cell-surface 
antigen. The equine and ovine receptors are unknown, however it is 
reasonable to speculate that an immune cell antigen similar to CD4 would be 
a significant component for these viral receptors.
Infectivity model. A model enumerating the combined action of gpl20 
and gp41 in infecting susceptible host cells has been proposed (Kowalski, et al., 
1987). The interaction of gpl20 with the CD4 antigen results in a 
conformational change in gpl20 which allows the N-terminus of gp41 to 
penetrate the membrane of the host cell. Once the gap between the 
membranes has been spanned by the TM protein, direct membrane fusion 
occurs and the contents of the virus particle are released into the cytoplasm of
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FIGURE 35. PROPOSED LENTIVIRUS BINDING DOMAIN 
ANALOGOUS TO THE HIV BINDING SEQUENCE
Shown on the first line is the gpl20 binding domain as proposed by 
Lasky, et al. (1987) with an amphipathic score (AS) of 38.9. Hie isoleucine 
residue depicted under the phenylalanine reflects the prevalence of lie in this 
position in the different HIV isolates.
The lentivirus sequence, residue numbers and AS of analogous 
regions are depicted. Bold and underlined residues indicate an exact match 
with the HIV sequence, while residues which are bold only reflect a conserved 
functional change.
As expected, the EIAV and visna virus sequences are the most 
divergent, however the sequence pattern and structural properties are 
conserved.
FIGURE 35. PROPOSED LENTIVIRUS BINDING DOMAIN
HIVa AS = 38.9 (AA 416 • 442)
TURN-(3 aa)-L P C R I  K [Q  F I N M W Q E V  (G) K ] A M Y A P P-(6 aa)-C-TURN
I T
SIV AS = 85.5 (AA 423 - 456)
TURN- V E C H I R  Q I I H T 5 V H K Y  £  £  N V J L P  P-TURN-(4 aa)-£
14 OUT OF 23 AA ARE IDENTICAL; 17 OUT OF 23 CONSERVED.
HIV-2 AS = 34.4 (AA 405 - 416)
T U R N -(3aa)-A E £H I£  D I I E  T J £ H K  YG R U Y X L £ E*(6aa)-£-TURN
15 OUT OF 22 AA ARE IDENTICAL; 18 OUT OF 22 CONSERVED; 5 MORE AGREE WITH SIV.
EIAV AS = 25.5 (AA 233 - 243)
£  -P-2 aa-TURN-11 aa-I P JC G C - f i E T J V  A R V K  R C P (12 aa) £-(2 aa)- £  E-TURN
VISNA AS = 34.9 (AA 405 - 416)
E S W N £ S Q  N W T G H - f f i H - V F R  X 1^8 aa-£-TURN-3 aa-£
TURN
a) LAV isolate, from Lasky, et al., 1987.
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the host cell.
This model implies that antibodies that bind the N-terminus of gp41 or 
the C-terminal binding region of gpl20 could neutralize virus infectivity. 
Nonetheless, only weak neutralizing activity has been reported for these 
regions (Chanh, et al., 1986). EIAV SU antibody reactivity to the proposed 
binding sequence represented by peptide V3 is similar to the immunoreactivity 
seen with the fusion peptide, i.e., 75% of equine immune sera tested positive. 
Neutralizing activity of antibodies specific to peptide V3 and the fusion peptide 
have not been examined in neutralization assays. Moreover, it does not seem 
likely that peptide segments which react with 70-75% of equine immune sera 
would embody a neutralizing epitope unless the antibodies are produced late 
in infection. Inspection of the immunoassay data of serial sera from 
experimentally inoculated horses which were closely monitored early after 
infection (from 1 day to 119-153 days post inoculation) reveals that this may be 
the case. Five of the 6 horses displayed no reactivity with peptide V3 in the 
time span examined, while the single exception (horse 74) demonstrated weak, 
intermittent reactivity. It therefore appears that antibodies directed to the 
putative binding domain are not present early in infection, but obviously are 
generated later, perhaps following several cycles of virus replication. Given 
that most EIAV infected horses eventually bring virus replication under 
immunological control, perhaps these peptides need to be investigated further 
as potential neutralization epitopes and vaccine candidates.
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Env induced cvtopathologv. HTV exhibits a specific cytotoxicity for cells 
expressing high levels of the CD4 molecule such that syncitia and concomitant 
cell death is induced in T4+ cell lines but not in a B-lymphocyte cell line 
(Sodroski, et al., 1986). Syncitium formation is dependent on the specific 
interaction of envelope-expressing cells with neighboring cells which bear the 
CD4 antigen. Mutation analyses have revealed that both the binding function 
of the SU protein and the fusion function of the TM protein are required for 
syncitium formation (Kowalski, et al., 1987). Thus, any antibody which 
prevents virus entrance would also inhibit glycoprotein-induced syncitia.
EIAV SU model: Correlation to equine immune reactivity. A  proposed 
structural model was presented for lentivirus SU proteins with a number of 
conserved features (Table 14). In an effort to correlate immunogenicity and 
structure, the structural propensity of each peptide region was examined and 
compared to the corresponding immune reactivity.
N-terminal conserved domain. The conserved SU segment 
corresponding to peptides 1 and 2 coincides with the proposed N-terminal 
alpha-helix which is predicted to be followed by a reverse turn with a high turn 
potential in the SU structural model (Table 17). Peptide 1 (residues 7-26) 
displays a strong amphipathic helix potential (amphipathic score of 29.3) and 
100% reactivity with the standard panel of immune horse sera. Peptide 2 
(residues 22-36) which is also proposed to be helical but without amphipathic 
character only reacts with 60% of the equine sera tested. This suggests that an
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amphipathic propensity may aid in inducing a strong humoral immune response 
in the host. A distinct immunoreactive peptide sequence was recently 
identified in the first constant region (C l) of HIV gpl20 and localized to 
residues 55-65 (Tijin, et al., 1989). Thus, an N-terminal dominant epitope may 
be common to lentivirus sequences.
Extensive serological and biochemical investigations have indicated that 
the periodic nature of EIA reflects the rapid mutations which occur in the env 
gene giving rise to antigenically distinct surface glycoproteins (Salinovich, et al., 
1986; Payne, et al., 1987b). It was reported that parallel infections of 2 
Shetland ponies yielded structurally unique isolates which appeared to arise 
from a random and noncumulative process (Payne, et al., 1987b). Each EIAV 
isolate recovered from these ponies contained a unique subset of variant 
peptides indicating that a large spectrum of variants could be generated in an 
infected animal. Yet, the N-terminus of gp90 remains conserved implying that 
this region of the variable SU protein may perform some critical function in 
the life cycle of the virus. The observed high immune reactivity of the N- 
terminal residues with immune horse sera also indicates the conserved nature 
of this segment in a variety of viral isolates. Rabbit polyclonal antisera was 
produced against the immunodominant peptide 1 and assayed for 
neutralization activity. These antibodies did not prevent virus infection or 
reduce infectivity in a standard in vitro neutralization assay (data not shown; J. 
McManus, personal communication).
The next peptide contained in the N-terminal conserved domain is 
peptide 3 (residues 35-53). This sequence includes the conserved N-terminal 
cysteine and potential N-linked glycosylation site (Asn-Asp-Ser). Unlike the 
high reactivity observed with the other conserved peptides, peptide 3 only 
reacts with 10% of the equine immune sera. Perhaps glycosylation makes this 
region inaccessible or possibly the cysteine is involved in a disulfide linkage 
forcing these residues to be localized near the neck of a looped domain. Of 
course, the sequence of peptide 3 just may not be immunogenic in the horse. 
Peptide 4 (residues 50-79) contains the only conserved SU monoclonal 
antibody epitope (gp90 A) which has been localized to its amino-terminus. 
Peptide 4 displays positive reactivity with 80% of the immune serum panel and 
a stronger relative reactivity with experimentally infected sera (Table 20). This 
pattern is consistent with the experimentally infected serial sera which 
presented a strong, sustained reactivity to peptide 4 regardless of the virus 
inoculum. Structurally, peptide 4 is predicted to be primarily alpha-helical 
with a reverse turn at its C-terminus. Finally, it is difficult to precisely 
correlate equine immune reactivity to the mouse epitope considering peptide 4 
is 30 amino adds in length and epitope gp90 A maps to the N-terminal 9 
residues. In a broader sense, this N-terminal region of 30 amino adds has 
generated both equine (infected with intact virus) and mouse (immunized with 
isolated glycoprotein) antibodies despite the variation of antigen presentation 
and host spedes. It would be instructive to examine the horse immune
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reactivity to the monoclonal antibody determinant at the amino acid level.
The observed differences between natural and experimental immune 
sera reactivity with peptides 1, 6, V3, V6 and R33 could be a reflection of the 
differences in the mode of antigen presentation, or levels of virus replication, 
or duration of antibody responses to a particular segment of gp90. Sera from 
experimentally infected animals were acquired within the first year of infection, 
but the infection date of most naturally infected animals is uncertain (Table 3). 
For example, serum samples from infected Florida horses (N11-N15) were 
acquired anywhere from 2 to 14 years after the serum first tested positive for 
EIAV by AGID.
Peptides 5A (residues 79-94) and 5B (residues 92-105) react with 80- 
85% of the equine immune sera with most sera displaying a relatively weak 
reactivity around 1 (Table 20). This segment of gp90 is predicted to form 2 
beta-sheet structures separated by a reverse turn and ending with a random 
coil. The last N-terminal conserved peptide is peptide 6 (residues 103-122) 
which continues the random and beta-sheet structural motif and demonstrates 
a somewhat lower reactivity (70%) with the immune sera panel. Immune 
reactivity of peptide 6, however, shows a clear distinction between the horses 
infected with avirulent prototype virus and the virulent variant 6493 (Tables 22 
and 23). Sera from horse 71, 74 and 76 which were experimentally infected 
with variant EIAV initially responded relatively strongly to peptide 6, but this 
reactivity decreased with time. For example, sera from horse 71 shows a
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relative absorbance of 4 on day 24 post inoculation which drops to a  relative 
absorbance of 3 on 55 dpi and then 2 on day 84 post inoculation. Finally, by 
day 147 the relative reactivity is 1. A similar pattern was observed in horse 74 
and 76. In contrast, sera from horse 78, 712 and 714 which were 
experimentally infected with prototype virus show little or no reactivity with 
peptide 6 indicating the low levels of virus replication.
gp90 variable domain. The env genes of 4 serologically distinct EIAV 
isolates recovered from a single experimentally infected pony were sequenced 
and found to contain a clustering of base substitutions within a defined region. 
This region was designated the variable domain (Payne, et al., 1987).
Variations in the EIAV genome and glycoproteins do not appear to be 
cumulative; all biochemical studies to date have indicated that the evolution of 
EIAV variants is a random process and variable sequences cannot be predicted 
(Payne, et al., 1987 and 1987b). Variant strains appear to arise from random 
point mutations generated during virus replication and result in a variety of 
integrated proviruses, any one of which may embody the next predominant 
virus strain (Payne, et al., 1987b). In contrast, sequential isolates of visna virus 
displayed cumulative changes in parallel infected animals, while HIV isolates, 
like EIAV, failed to display cumulative changes over time (Clements, et al., 
1982; Hahn, et al., 1986). In this regard, the noncumulative alterations of HIV 
has been interpreted to imply parallel evolution of variants in the infected 
individual (Hahn, et al., 1986). The variant sequences of the 4 EIAV
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sequential isolates were examined by computer algorithms for constructing 
evolutionary trees (Dr. E. Zimmer, unpublished results). These data also 
indicated that the sequential isolates were not derived from the predominant 
infecting virus strain, but evolved simultaneously (Dr. E. Zimmer, K. Hamby, 
personal communication).
The first synthetic peptide corresponding to the gp90 variable domain is 
peptide 7V (residues 123-140) which also corresponds to the region of high 
turn density proposed in the SU conformational model. The residues of 
peptide 7V are predicted to fold as reverse turns separated by alpha-helices.
In addition, this region of gp90 has a calculated amphipathic score of 45.1.
Yet only 45% of the equine immune sera exhibit antibody binding to this 
peptide sequence, perhaps reflecting the variable character of the domain.
The SU structural model proposes that a conserved glycosylation site and 
alpha-helix follow the region of high charge density. Peptide 8V (residues 137- 
162) fulfills both of those predictions beginning with a potential N-linked 
glycosylation site (Asn-Arg-Ser) as part of a reverse turn followed by a 
potential alpha-helix with strong alpha potential (Pfl). ELISA absorbance data 
with peptide 8V reveals 80% reactivity with equine immune sera despite the 
reported alterations in sequence of this segment of gp90 (Payne, et al., 1987). 
Notably, analogous to HIV, there are short segments with conserved sequence 
identity within the variable domain (Starcich, et al.f 1988). The protein 
segment corresponding to peptide 8V has 4 variable residues at positions 144,
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147,149 and 162 (Payne, et al., 1987), thus amino add residues 150-161 appear 
conserved. Conceivably, the observed immune reactivity is directed to this 
conserved segment. Immune reactivity displayed with early serum samples 
following experimental infection, however, was quite variable ranging from a 
sustained relative reactivity of 4 in sera from horse 71 and 74 to essentially no 
reactivity in sera from horse 714.
Peptide 9V (residues 159-173) which overlaps peptide 8V by 4 amino 
adds is predicted to continue the alpha-helix which was nucleated in peptide 
8V and to end in a reverse turn. Peptide 9V is the only SU peptide that 
demonstrates no reactivity with the immune serum panel and peptide 10V 
(residues 171-190) only reacted with 10% of the serum samples. These 
nonreactive peptides contain 1 (peptide 9V) or 2 (peptide 10V) conserved 
cysteine residues which can potentially form disulfide linkages. If the 
conserved cysteine residues in gp90 form disulfide linkages in a manner similar 
to that of HTV gpl20 (T. Gregory, unpublished results), the cysteines contained 
in peptides 9V and 10V would not bond with each other but with cysteine 
residues located further downstream. The projected structural model portrays 
this segment as hidden in the overall conformation of the protein. In addition, 
a potential N-linked glycosylation site is included in the sequence of peptide 
10V. It is noteworthy that this segment of the variable domain (residues 159- 
190) only has 3 variable residues with an extended region (residues 163-182) of 
conservation (Payne, et al., 1987). Hence, the absence of antibody binding to
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these peptides is probably not due to sequence variation, but rather a result of 
the native conformation of the intact protein.
The next variable peptide, peptide VI (residues 187-216), reacts with 
75% of the equine immune sera, displays reactivity with serial sera from 5 of 
the 6 horses which were monitored early in infection, contains a neutralizing 
monoclonal epitope and a calculated amphipathic score of 26.6. This is indeed 
a critical segment of the EIAV SU glycoprotein and appears to be functionally 
similar to the distinct V3 loop of HIV (below) (Javaherian, et al., 1989). 
Immune serum reactivity rises from 10% with peptide 10V to 75% with 
peptide VI despite their linear relationship. Serum samples from the 
experimentally infected animals portray a stronger relative reactivity with 
peptide VI than those from natural infections (Table 21). In agreement with 
this data, serial sera from 5 of the 6 experimentally infected ponies display 
relatively strong reactivities with peptide VI. This variable segment of gp90 is 
predicted to fold into an amphipathic alpha-helix and encompass the charged 
region of the SU structural model. As presented in Table 14, the proposed 
charged domain is predicted to be associated with an amphipathic helix and 
contain a cysteine residue. Residue 213 of peptide VI is cysteine. The 
neutralizing monoclonal antibody which defines epitope gp90 D bound a 
central portion of peptide VI represented by peptide Vld (residues 201-209).
So this variable sequence is not only dominant in the natural host, but also 
immunogenic in the mouse.
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Finally, the gp90 D neutralizing epitope was shown to be type-specific. 
Synthetic peptides with alternate peptide VI amino acid sequences (as deduced 
from nucleotide sequence analyses) were synthesized and analyzed in 
immunobinding assays (Ball and Montelaro, unpublished results). These 
variant sequence peptides did not bind the monoclonal antibody (data not 
shown). This data demonstrates that neutralizing antibody binding is lost with 
sequential variant virus strains and supports the model of chronic E1AV 
(Figure 4).
The relatively low immune reactivity (45%) of peptide V2A (residues 
211-230) with equine sera was not surprising given the random structure, 
potential glycosylation site, and sequence variability. Peptide V2B (residues 
227- 245) is predicted to fold into a beta-sheet structure forming the central 
beta region of the SU conformational model. Parallel to the immune reactivity 
with peptide V2A, only 45% of the immune serum panel reacts with peptide 
V2B. Nevertheless, the nonneutralizing monoclonal antibody defining epitope 
gp90 B maps to residues 229-238 of peptide V2B. Hence, this Mab epitope 
does not coincide with a dominant equine determinant.
Peptide V3 (residues 241-269) does not appear to be recognized early 
by the host immune system since there was essentially no positive reactivity 
detected with the early serial sera from the experimentally infected ponies. As 
mentioned earlier, peptide V3 is structurally analogous to the proposed 
lentivirus binding domain and the absence of early antibody followed by the
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presence of late antibody (75% reactivity) could be indicative of a neutralizing 
function which aids in bringing virus replication under immunological control 
by blocking virus entry into uninfected cells. Significantly, the neutralizing 
monoclonal antibody epitope gp90 C was localized to peptide V4A 
immediately downstream from peptide V3 and is inclusive of the 2 proline 
residues of the putative binding domain. Alternatively, peptide V3 may 
preferentially react with naturally infected horse sera, especially given the very 
low reactivity of sera from experimentally infected animals compared to the 
strong reactivity of sera from natural infections. Structurally, everything from 
reverse turns to random coils is predicted in this protein segment, including an 
alpha-helix and beta-sheet. The C-terminal region of peptide V3 together with 
the N-terminal region of peptide V4A, display the proline-rich "kinked" area 
described in the structural SU model.
Both peptide V4A (residues 265-299) and V4B (residues 281-299) 
exhibit positive reactivity with 80% of the immune sera panel, but like peptide 
V3, the V4 peptides exhibit weak relative immune reactivity with sera from 
experimental infections.
Peptides V5A (residues 294-311) and V5B (residues 312-328) present a 
variety of structurally different segments which have an overall loop topology 
that is predicted to extend (or loop) distally from the core of the SU protein. 
Both V5 peptides demonstrate a higher immune reactivity with sera from 
natural infections and an overall reactivity of 80% (V5A) and 60% (V5B).
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Monoclonal antibody epitope gp90 F has been localized to peptide V5C 
(residues 305-317) which overlaps a limited region of both peptide V5A and 
V5B. Once again, the mouse Mab epitope appears to coincide with a 
dominant equine determinant and these antigenic determinants have been 
mapped to the variable domain. Peptide V5C is predicted to fold as a reverse 
turn followed by a beta-sheet. This is the second Mab epitope localized to a 
proposed beta region. The other 3 Mab epitopes, including the 2 neutralizing 
determinants, mapped to potential alpha-helical segments.
Peptide V6 (residues 323-358) is the last variable peptide which was 
examined with the equine immune sera. Although peptide V6 demonstrates an 
overall reactivity of 50% with the immune serum panel, there was no detected 
reactivity with sera from experimentally infected animals. Additionally, there 
was no reactivity with the serial serum samples from experimentally infected 
ponies. So peptide V6, analogous to peptides V3, V4 and V5, displays a 
preferential reactivity with sera from natural infections.
C-terminal conserved domain of gp9Q, The conserved carboxyl domain 
of gp90 contains a conserved immunodominant horse epitope originally 
described by Payne, et al. (1989) using recombinant env-encoded protein 
fragments. The C-terminus of HIV gpl20 also contains a conserved, 
immunodominant antigenic determinant that is strongly reactive with 
nonneutralizing antibody (Palker, et al., 1987).
Three peptides encompassing the conserved C-terminal sequence were
244
synthesized and reacted in peptide immunoassays with the standard equine 
immune serum panel. Peptide 13 (residues 381-406) reacts weakly with 60% 
of the immune horse sera. Immune reactivity increases to 85% with peptide 
11 (residues 403-427) as the sequence approaches the carboxyl-terminus. Sera 
from the experimentally infected ponies which were monitored early in 
infection portray variable reactivity with relatively stronger reactions with serial 
serum samples from horses infected with virulent virus. The peptide 11 
sequence contains 3 potential N-linked glycosylation sites and represents the 
predicted region of clustered glycosylation sites. As proposed in the SU 
model, the C-terminal residues of peptide 11 initiate a potential amphipathic 
helix (amphipathic score of 19.7) which extends into the sequence of the C- 
terminal peptide, peptide 12 (residues 424-447).
Peptide 12 encompasses the C-terminal residues of gp90 and reacts with 
100% of the equine sera regardless of the mode of infection. This strong 
reactivity is consistent in sera from natural and experimental infections, 
independent of the virus inoculum. Not only does peptide 12 react with the 
highest relative reactivity, the antibody response is detected early after 
infection and the titer is maintained. So the dominant C-terminal epitope is 
located at the very carboxyl-terminus of the SU protein and immune reactivity 
decreases as the peptide segments move further downstream into the core of 
the SU molecule. In addition to peptides 1 (N-terminus of gp90) and R32 (N- 
terminal region of gp45), peptide 12 is an extremely promising diagnostic
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antigen.
Notably, the secondaiy structure of the peptide 12 segment is predicted 
to be an amphipathic alpha-helix. It is interesting that amphipathic helices are 
predicted for both the immunodominant amino- and carboxyl-termini. Other 
proposed amphipathic segments include peptides 7V with 45% reactivity, VI 
with 75% reactivity, V2B with 45% reactivity and V3A with 75% reactivity. 
Although horse sera reactivity is not outstanding with all of these amphipathic 
regions, 2 of the Mab epitopes (gp90 and B) have been mapped to these 
alpha-helical segments.
Synthetic peptides, structure and antibody binding.
Given that antibody binding was assayed with chemically synthesized 
peptides of unknown conformation as antigen, it becomes increasingly difficult 
to attribute immune reactivity to a specific structure. However, it has been 
confirmed that structure does play a role in antigen-antibody interactions 
(Davies, et al., 1988; Geyson, et al., 1987). This finding raises the question of 
how short peptides, which probably lack a fixed conformation, can nevertheless 
bind antibodies generated against the more ordered and constrained sequences 
in intact proteins. Models which assume that polyclonal antisera are 
collections of antibodies with specificities to many conformations of the 
peptide immunogen do not satisfactorily answer this question (Wilson, et al., 
1985). The answer seems to be based on the defined conformations adopted
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by the peptide in solution, on the properties of the antigenic sequence in the 
protein and the binding sites in the antibody (Wilson, et al., 1985). X-ray 
analyses of antigen-antibody complexes revealed a high degree of 
complementarity between the 2 interacting surfaces (Davies, et al., 1988). This 
complementarity was demonstrated by an almost complete exclusion of water 
from the interface and was found to reflect a combination of charge 
complimentarity, hydrogen bonding, Van der Waals forces and hydrophobic 
interactions (Davies, et al., 1988; Roitt, et al., 1985). These forces require a 
close approach of the interacting groups such that the shape of the antigen 
must "fit" the antibody combining site. In this way, several non-covalent bonds 
can form simultaneously providing sufficient binding energy to resist 
thermodynamic disruption of the bond (Roitt, et al., 1985). Thus, the antigen 
molecule appears to be contained in a cleft formed by the antibody combining 
site (Roitt, et al,, 1985).
Analysis by x-ray diffraction of a complex between influenza virus 
neuraminidase and antibody displayed features inconsistent with such an 
inflexible "lock and key" structural motif, but found that the structure of the 
antigen changed upon antibody binding to "fit" the combining site (Colman, et 
al., 1987). Lastly, Wilson, et al. (1987) compared the immunogenic and 
antigenic determinants of a synthetic peptide to the corresponding antigenic 
determinants in the parent protein. This data indicated that antibodies can 
bind to a structure different from that of the native antigen and/or possibly the
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native protein displays conformational mobility (variation) at least in local 
regions. Whether or not antibodies induce conformational changes in the 
antigen or whether they bind to minor conformations present in the protein in 
solution has not been resolved (Wilson, et al., 1987). Clearly, successful 
antibody binding in ELISA assays with peptide antigens indicates that under 
the conditions employed the peptide can attain conformations favorable for an 
antigen-antibody union. However, a considerable molar excess (loM o4) of 
peptide over native protein is generally required to detect any binding between 
the peptide and antibody, and the affinity constant of the antibody for the 
peptide is generally several orders of magnitude lower than for the protein 
(Regenmortel, 1987).
SU glycoprotein similarities in EIAV and HIV.
Significant structural and functional similarities between the env 
glycoproteins of EIAV and HIV have been previously noted despite the lack of 
substantial sequence homology (Rushlow, et al., 1986; Gallaher, et al., 1989). 
The present characterization of immunogenic segments of gp90 continues to 
reveal structural and functionally homologous regions between the envelope 
glycoproteins of the 2 lentiviruses. In both EIAV and HIV, neutralizing 
epitopes have been localized to SU variable sequences resulting in a type- 
specific immune response (Ho, et al., 1988; Matsushita, et al., 1988). Both 
viruses also contain highly conserved, immunodominant epitopes in the N-
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terminal sequences of their TM proteins and in the C-terminus of their SU 
glycoproteins (Palker, et al., 1988; Chang, et al., 1985). Synthetic peptides 
derived from the N-terminal TM sequences of HIV-1 and HIV-2 have been 
useful as diagnostic antigens (Gnann, et al., 1987a; Wang, et al., 1986) and may 
provide a similar function in the diagnosis of EIAV.
The HIV V3 loop. Several researchers taking independent approaches 
have identified an immunodominant, type-specific neutralizing epitope located 
in a hypervariable region of gpl20 between 2 cysteine residues (302 and 337) 
which are connected by a disulfide bond (Skinner, et al., 1988; Palker, et al., 
1989; Javaherian, et al., 1989). This disulfide linkage delineates the variable 
V3 loop sequence which has evoked neutralizing antibodies in goats, rabbits, 
chimpanzees and mice (Palker, et al., 1989; Goudsmit et al., 1988). Thus, this 
region of gpl20 is obviously a dominant antigenic determinant for the 
development of high-titer, isolate-specific neutralizing antibodies against HIV- 
1. Although the exact function of this region is unknown, genetic studies have 
indicated that it may be involved with the association of gpl20 with gp41 
(Kowalski, et al., 1987). Chimpanzees experimentally infected with HIV 
develop neutralizing antibodies to the V3 epitope which inhibit syncitia 
formation (Goudsmit, et al., 1988). Palker, et al. (1989) reported that the same 
region (residues 303-321) can also evoke T cell proliferation.
H ie V3 determinant was localized to a 24 amino acid peptide called 
RP135. Antibodies directed to the RP135 peptide neutralized cell-free virus
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and prevented fusion of virus-infected cells with uninfected cells bearing the 
CD4 antigen (Matsushita, et al., 1988). However, these neutralizing antibodies 
did not prevent the binding of gpl20 to CD4 (Skinner, et al., 1988). Finally, to 
define the neutralizing domain within RP135 overlapping hybrid peptides 
(containing sequences from 2 different HIV isolates) were synthesized which 
spanned the RP135 segment In this way, the dominant neutralizing epitope 
was localized to 8 amino acids at the apex of the loop which contains the 
relatively conserved central Gly-Pro-GIy residues (QRGPGRAF) (Javaherian, 
et al., 1989). T. Matthews (1990) identified residues critical to Mab binding 
by altering the V3 sequence and discovered that the neutralizing Mab 
recognizes residues to the left of the central proline at the top of the loop; but 
proline was not required for antibody binding in the MN isolate of HIV 
(unpublished results). In addition to a neutralizing epitope and a T-cell helper 
epitope, a CTL (cytotoxic T-lymphocyte) epitope was identified as part of the 
V3 loop on the right side of the central Gly-Pro-GIy trimer (Berzofsky, 
unpublished results).
A functionally homologous region in EIAV can be identified in the 
sequence of peptide VI. The neutralizing monoclonal epitope gp90 D which is 
type-specific has been mapped to a segment of peptide VI (V ld) and 
sequences downstream of the neutralizing epitope are predicted to fold as an 
amphipathic helix which indicates the presence of a potential helper T-cell 
epitope. Finally, utilizing the Rothbard and Taylor (1988) method of
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predicting cytotoxic T-cell epitopes, a  potential CTL epitope was also identified 
in this region. Located at residues 209-212 is the characteristic linear pattern 
of a charged residue (Lys) followed by 2 hydrophobic residues (Trp-Leu) and a 
polar or charged residue (Glu). It was reported that in all cases where the 
minimal sequence recognized by a T-cell clone was known, this residue pattern 
has been intact (Rothbard and Taylor, 1988). Thus, peptide VI is functionally 
similar to the HIV V3 loop containing a B-cell neutralizing epitope, and 
potential T-cell helper and CTL determinants.
CHAPTERS 
CONCLUSIONS
This study has resulted in the development of a novel lentivirus protein 
purification protocol; direct sequencing of purified EIAV env glycoproteins; 
and identification and localization of key unglycosylated, continuous 
monoclonal and equine antigenic sites by employing synthetic peptide 
strategies. Candidate synthetic peptides for vaccine and diagnostic use have 
been identified. These results can be summarized as follows:
1) Purification of gp90 and gp45 marks the first successful isolation 
of envelope glycoproteins from any lentivirus system from purified virus.
Direct amino acid sequencing of the purified proteins complimented previous 
studies on the characterization of EIAV protein components.
2) The N-terminal region of the TM protein of EIAV contains a 
conserved immunodominant domain to which a monoclonal antibody epitope 
and 2 dominant equine antigenic determinants have been mapped. These 
determinants are represented by peptides R33, 51 and R32. Peptide R32 has 
been identified as a potentential diagnostic antigen while peptide 51 may prove 
useful as a vaccine candidate.
3) The serological and structural analyses of gp45 support the 
previously reported structural model of retrovirus TM glycoproteins.
4) Two peptides corresponding to the amino- (peptide 1) and
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carboxyl-(peptide 12) termini of gp90 have been identified as immunodominant 
determinants in naturally and experimentally infected animals. These peptides 
represent respectable candidates for diagnostic antigens.
5) SU monoclonal antibody epitopes have been localized to 9-12 
amino acids. Two of these depict neutralizing epitopes and hence, are 
potential vaccine candidates.
6) A detailed retrovirus SU structural model has been proposed and 
supported by experimental data that is currently available.
7) The progression of the immune response in EIAV infected 
horses was analyzed with a selected panel of synthetic peptides to learn more 
about the immune response in a chronic infection. This study confirmed the 
previously delineated variable and conserved domains and identified peptide 12 
as a relevant diagnostic antigen.
8) The similarities between discrete regions of EIAV and HIV env 
glycoproteins with respect to structure, function and antigenicity have been 
examined. These studies have documented the significance of EIAV as an 
animal model for analyzing host immune responses in persistent infections and 
for appraising plausible HIV vaccine protocols.
Although the identification of monoclonal antibody epitopes is useful, it 
does not present a complete picture of glycoprotein antigenicity during a 
persistent infection. To obtain a more complete picture, dominant antigenic 
determinants of the natural host have been identified. Shown in Figure 36 is
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FIGURE 36. LINEAR REPRESENTATION OF EIAV SU
EPITOPES.
The prlmaiy amino add  sequence of gp90 is depicted with mouse 
monoclonal and equine immunodominant (70% or greater reactivity with 
equine sera) antibody epitopes indicated. The sequence of the monoclonal 
antibody epitopes are shown in bold face type while the amino acid residues 
corresponding to equine epitopes are boxed. Peptides 1 and 12 reacte with all 
equine immune sera tested to date.
Monoclonal antibodies corresponding to epitopes C and D are 
neutralizing in standard in vitro neutralization assays and overlap equine 
immune reactive sequences in the variable domain (underlined). The 
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the linear amino acid sequence of EIAV gp90 depicting both monoclonal 
(bold) and dominant equine (boxed) humoral epitopes. Several antigenic 
peptides (recognized by 70% and greater of equine immune sera) have been 
mapped to both the conserved and variable domains. The variable region is 
underlined and the darkened underline offsets a hypervariable segment 
contained in the variable domain. Notably, no equine epitopes were localized 
to the hypervariable region. Three of the 5 monoclonal antibody epitopes (A, 
C and D) coincide with an equine antigenic determinant. It is interesting that 
the horse and mouse recognize homologous regions of the SU glycoprotein, 
especially since the mouse was immunized with isolated protein. It is also 
noteworthy that the 2 neutralizing Mab epitopes (C and D) map to variable 
antigenic segments that are also recognized by the horse. In addition, the 
neutralizing Mab epitope gp90 D has been shown to be type-specific 
supporting the concept that antigenic variants can arise by their ability to 
escape neutralization during a persistent infection. Monoclonal antibody 
epitope F  has been localized to the hypervariable region.
There appears to be a clustering of immunogenic sites at the conserved 
termini of gp90 and in the central region of the variable domain. It is not 
clear if the antigenic sites which have been localized in the variable domain 
reflect antibody binding to the conserved residues in this region. Previous 
reports have indicated a highly variable immune response to the variable 
domain (Payne, et al., 1989). Perhaps by analyzing the variable region with
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comparably short, overlapping peptides, relative reactivities directed against the 
conserved residues could be distinguished and antigenic sites which were not 
previously recognized could be discerned.
Although there are probably several noncontinuous epitopes which 
have not been distinguished, linear conserved and variable antigenic 
determinants have been established throughout the sequence of gp90. In 
contrast, significant TM epitopes appear to be localized to the amino-terminal 
half of the protein. This general pattern of antigenicity probably reflects the 
overall accessibility of gp90 compared to the limited exposure of gp45.
This report has also examined the early humoral immune response to 
experimental EIAV infections and how that response evolves over a limited 
time span of 5 months. There was a clear difference in antibody responses 
between animals infected with a virulent versus an avirulent virus strain.
Those horses infected with the virulent virus generally had much stronger 
antibody titers probably reflecting the more vigorous virus replication and 
higher levels of viremia. Nonetheless, those horses infected with the avirulent 
prototype virus still developed antibodies, albeit at lower titers, to the various 
regions of the envelope glycoproteins. Thus, low levels of virus replication are 
sufficient to stimulate an adequate B-cell response.
Lastly, there was an overall lower reactivity to peptides corresponding to 
variable sequences in these early infections, probably reflecting the limited 
time of the study and supporting the concept of antibody broadening. Variable
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segments which were reactive with 80% of the standard immune serum panel 
were not reactive with these early serial serum samples. Obviously, in 
response to the sequential production of antigenically distinct variants during a 
persistent EIAV infection, the immune system gradually evolves to include 
antibodies to the variable domain.
Figure 36 depicts a detailed immunological analysis of the EIAV SU 
protein reflecting the accumulation of reactive antibodies in naturally and 
experimentally infected horse sera. Despite the rapid production of EIAV 
antigenic variants that are capable of escaping established humoral and cellular 
immune responses, most EIAV infected animals bring virus replication under 
control and remain inapparently infected (Hussain, et al., 1987). Hence, it is 
clear that the evolution of immune responses can achieve a life-long 
management of EIAV replication despite the array of lentivirus persistence 
mechanisms. The ability to produce a protective immune response against a 
lentivirus infection confers hope that a similar response can be generated by a 
vaccine which would protect naive horses against infection by EIAV and that 
the knowledge acquired from these studies can be extended to other lentivirus 
infections.
The goal of the present study was to characterize the antigenic 
determinants of EIAV env glycoproteins in an effort to begin the task of 
elucidating and characterizing the critical immune responses that mediate 
protection in persistently infected horses. It has become apparent that
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immunodominant epitopes may not be the key to achieving a protective 
response and neutralizing antibodies are mostly type-specific (Montelaro, et al., 
1989). Thus, nonneutralizing antibody directed at minor epitopes may play a 
larger role than previously realized and should not be excluded from further 
studies. Finally, the critical role of cellular immune responses to the envelope 
glycoproteins must be evaluated before a complete picture of a protective 
response will emerge.
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APPENDIX I 
List of Abbreviations
AGID agar gel immunodiffusion
AS amphipathic score
ATZ anilinothiazolinone
BIV bovine immunodeficiency virus
BLV bovine leukemia virus
BOC butyloxycarbonyl
BS Bayes statistics
BSA bovine serum albumin















EUSA enzyme linked immunosorbent assay








KLH keyhole limpet hemocyanin




MMTV mouse mammary tumor virus





ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate-buffered saline





RSV Rous sarcoma virus
SDS sodium dodecyl sulfate








Amino Acid Codes and Residue Weights
Three Letter Single Letter
Amino Acid Code Code “ Residue Weight1
Alanine Ala A 71.08
Arginine Arg R 156.20
Asparagine Asn N 114.11
Aspartic Acid Asp D 115.09
Cysteine Cys C 103.14
Glutamic Acid Glu E 129.12
Glutamine Gin Q 128.14
Glycine Gly G 57.06
Histidine His H 137.15
Isoleucine lie I 113.17
Leucine Leu L 113.17
Lysine Lys K 128.18
Methionine Met M 131.21
Phenylalanine Phe F 147.18
Proline Pro P 97.12
Serine Ser S 87.08
Threonine Thr T 101.11
Tryptophan Trp VV 186.21
Tyrosine Tyr Y 163.18
Valine Val V 99.14
a) Molecular weight of the amino acids minus that of water in daltons.
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